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1 ǀ INTRODUCTION 
1.1. General introduction 
1.1.1. General remarks on nucleosides, nucleotides and their analogues 
Nucleosides, nucleotides and their analogues have always attracted a significant interest owing to their 
crucial implication in several biological processes.1 These molecules, that can be synthesized in vivo either 
by the de novo or the salvage pathways, act as intracellular mediators, coenzymes and energy carriers 
(cAMP, ATP, NAD(P)H, …). Needless to say, the most important role of natural nucleosides and nucleotides 
is the constitution of nucleic acids (DNA and RNA) which convey all the necessary information for cell life. 
From the chemist’s viewpoint, a boost in nucleic acid chemistry was registered in the 1950-1960s. A great 
synthetic effort has led to a huge number of modified nucleosides designed with the goal to impair nucleic 
acid synthesis in specific pathological conditions. 
Most nucleoside analogues are used against viral infections (e.g. HIV2) or specific cancers1, 3 (Figure 1.1). 
Upon in vivo activation by phosphorylation, either nucleosides are incorporated in the viral/cellular nucleic 
acid or they inhibit specific enzymes of nucleic acid biosynthesis. They may indeed act as antimetabolites to 
arrest DNA and/or RNA replication (e.g. inhibitors of reverse transcriptase, chain terminators, …).4 Drugs 
such as Capecitabine and Azacitidine (antitumors) or Abacavir, Tenofovir Disoproxil, Adefovir, Adefovir 
Dipivoxil, Emtricitabine and Entecavir (antivirals) are only some examples of nucleoside-based molecules 
approved by the FDA (Food and Drug Administration) in the last twenty years. Some nucleoside and 
nucleotide analogues have also been used as immunosuppressive drugs, phosphodiesterase inhibitors, 
epigenetic modulators and neuroprotective agent. 5  Moreover, natural purine ribonucleoside 5’-
monophosphates are employed as building blocks for the preparation of oligonucleotides as well as food 
additives and flavor enhancers. In particular, the disodium salts of guanylic and inosinic acid (disodium 
guanylate, Na2GMP, and inosinate, Na2IMP) are known for their ability to enhance the taste intensity of 
monosodium glutamate and play a crucial role in the perception of the so-called umami taste (“fifth 
taste”).6 
Many nucleoside and nucleotide analogues contain simple chemical modifications if compared to their 
natural counterparts (e.g. Capecitabine, Zidovudine, Puromycin…), while others are remarkably different 
from them (e.g. Adefovir, Tenofovir, Abacavir, Neplanocin A…). 
Nucleoside chemistry still represents a very active research area, as the effectiveness of such analogues in 
blocking viral infections and treating solid tumors has further encouraged synthetic attempts to achieve 
new structurally-related molecules. The prodrug Sofosbuvir, marketed as Sovaldi® from 2013, is a 
paradigmatic example of this trend. In combination with other drugs (e.g. Ribavirin7 and Daclatasvir, 
Ledipasvir or Simeprevir8), it is used in the treatment of hepatitis C as an alternative to currently rooted 
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peginterferon-combined therapies.9 However, considerable concerns and debates have been raised due its 
high cost. 
 
Figure 1.1. Examples of biologically active nucleoside analogues 
1.1.2. 6-Substituted purine nucleosides 
Among modified nucleosides, ribo-, 2’-deoxyribo- and arabinonucleosides containing purine bases 
substituted in 6-position (Figure 1.2) are characterized by different biological activities: 
 cytotoxicity and cytostaticity: 6-aryl-, 6-ethylaryl- and 6-benzyl-, 6-hydroxymethyl-, 6-fluoromethyl-, 
6-difluoromethyl-, 6-trifluoromethyl- and a number of 6-amino- and 6-alkoxypurine nucleosides10; 
 antiviral activity: nucleosides bearing 5-membered heterocycles in position 6 (anti-hepatitis C)11; 
 antitumor effect: 6-alkyl, 6-amino-, 6-thio-, 6-oxo- and 6-chloropurine nucleosides.12 A few of them, 
in combination with proper enzymes such as purine nucleoside phosphorylases (PNPs) have been 
tested as substrates in the so-called “suicide gene therapy” for the treatment of solid tumors.13 
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Figure 1.2. General structure of 6-substituted ribo-, 2’-deoxyribo- and arabinonucleosides 
1.2. Synthesis of purine and pyrimidine nucleosides 
1.2.1. Chemical synthesis of purine and pyrimidine nucleosides 
Nucleosides have been synthesized by various chemical methods since the beginning of the last century, 
with a boost between the 1960s and 1990s.14 It soon turned out that the crucial issue of nucleoside 
synthesis is the formation and preservation of the C-N glycosydic bond. The glycosylation reaction is indeed 
still challenging. 
Among the current strategies, two main routes are of wide applicability: 
 the modification of preformed nucleoside substrates, in which the glycosydic bond is already a part 
of the structure; 
 glycosylation procedures, that are convergent approaches proceeding via the condensation of 
properly protected and/or activated heterocycles and sugar moieties, under conditions suitable to 
ensure regio- and stereoselectivity. 
Both methodologies may be useful for five- and six-membered sugars (e.g. ribose, arabinose, glucose, 
xylose…), as well as for purine and pyrimidine nucleobases. 
Concerning the first strategy, which can be defined as a functionalization approach, commercially available 
substrates are usually chosen as starting materials. Examples of this method are reported in literature with 
or without the proper protections on either the nucleobase or the sugar. Purine nucleosides are generally 
obtained by this strategy, whereas pyrimidine ones are frequently used as reagents. Yields are extremely 
variable depending on the specific reaction. 
A pivotal role is played by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICA-riboside, 
Acadesine), often converted into purine ribonucleosides and their analogues by ring annulations with 
reagents such as carboxylic esters15, dichlorocarbene (via a 5-dichloromethylamino intermediate)16 or 
sodium methylxanthate and phenylthioisocyanate17 (Scheme 1.1). 
 
Scheme 1.1. Examples of the synthesis of 2-substituted inosines and 2-thioinosine from AICA-riboside 
In order to obtain nucleosides with atypical structural features, such as 7-glycosylated purines, glycosylated 
imidazoles similar to AICA-riboside can be used. Purine bases tend indeed to react easily at N9 except for 
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theophylline. Imidazole elongation and diazine ring closing are performed with simple reagents such as 
orthoformates and amines (Scheme 1.2).18 
 
Scheme 1.2. Example of the synthesis of 7-glycosylated purines 
One of the most common functionalization methods to synthesize pyrimidine ribonucleosides exploits the 
already present C-N bond of fully protected N-substituted ribosylamines or ribosylureas. A significant 
feature of this strategy is the step-by-step construction of the whole heterocyclic ring, whose formation 
occurs only at the end of the sequence (Scheme 1.3). For instance, protected uridine and 2-thiothymidine 
can be constructed starting from 2,3,5-tri-O-benzyol-D-ribosylamine and β-ethoxy-N-
ethoxycarbonylacrylamide 19  or α-methyl-β-methoxyacryloyl isothiocyanate 20 , respectively. The latter 
product can be obtained by treating 2,3,5-tri-O-benzoyl-D-ribosylthiourea with ethyl α-formylpropionate.21 
 
Scheme 1.3. Examples of the synthesis of thymine nucleosides by ring closure of N-substutited 
ribosylamines and their thioureas 
A novel procedure for the functionalization of positions 2 and 6 of purine nucleosides was reported by G. 
Piccialli and co-workers in 2013 (Scheme 1.4).22 The protocol exploits the reactivity of the corresponding 
carbons in the N1-oxide of protected Nebularine (purine-9-riboside), which reacts with Grignard 
nucleophiles regioselectively on C6 and on C2 after aromatization. A ring opening to an oximealdimine and a 
second aromatization complete the sequence in 48-82% yield. This method is particularly useful for the 
introduction of functionalized 2-pyridyl moieties in position 6.23 
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Scheme 1.4. Synthesis of 2,6-alkyl(aryl)purine nucleosides from Nebularine N1-oxide 
Such a strategy can be used to synthesize a specific class of ring-expanded nucleosides (RENs, biologically 
relevant mimics of purine derivatives) containing 5:7-fused imidazo[4,5-d][1,2,6]oxadiazepine rings 
(Scheme 1.5). The reaction was speculated to proceed through an oxaziridine (formed by treatment of the 
oximealdimine intermediate with t-BuOOH in refluxed CCl4) which rearranges to a nitrone. Ring closure and 
dehydration afforded the 5,8-dialkyl(aryl)-REN.24 
 
Scheme 1.5. Synthesis of 5,8-dialkyl(aryl)-RENs (ring-expanded nucleosides) 
The alternative strategy to obtain either a purine or a pyrimidine nucleoside is to follow a convergent 
approach, in which a new C-N glycosydic bond is formed between the two structural components of the 
molecule (Scheme 1.6). Both nucleobase and sugar often need protections not only on acid/base-labile 
moieties but also on potential nucleophilic atoms (especially nitrogens), since all these methods consist of 
an SN1- or SN2-type reaction at low to high pH, catalyzed by Lewis acids, if necessary, or promoted under 
alkaline conditions. The attack of a heterocycle on the activated anomeric carbon in an electrophilic sugar 
(mostly ribose) gives better yields when the 2’-hydroxyl function is protected by an acyl group, selectively 
forming the β-nucleoside by virtue of neighbouring group participation. The use of chlorine and bromine is 
widespread to activate position 1’. 
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Scheme 1.6. General mechanism of glycosylations by the convergent approach 
The mechanism suggests that the stereoselective synthesis of 2’-deoxyribonucleosides directly from 1’-
chloro- or 1’-bromo-2’-deoxyribose is less efficient due to the absence of any assisting effect by adjacent 
positions. Experimental data confirm this behavior.25 
At least five different variations of such a direct strategy have been reported, depending on the reaction 
conditions: 
 uncatalyzed glycosylation of nucleobases or their metal salts; 
 acid-catalyzed fusion at high temperature; 
 classic Hilbert-Johnson reaction; 
 Vorbrüggen reaction (Hilbert-Johnson silyl variation); 
 Lewis acid-catalyzed chemical transglycosylation. 
The first method involves the combination of a nucleobase ring or its metal (Ag, Hg or Na) salt and a 
protected 1’-halosugar (Scheme 1.7).26 
 
Scheme 1.7. Examples of the uncatalyzed glycosylation of nucleobases and their metal salts 
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In the acid-catalyzed fusion, high temperatures (up to 150-170°C) allow the direct condensation of a free 
base with peracetylated ribose in a fuse state in the presence of a Lewis acid (Scheme 1.8).27 This simple 
procedure is incompatible with aliphatic halides and thermolabile moieties. Yields seldom exceed 70% and 
harsh conditions may also lead to inversion at C2’ in the formed nucleoside, as well as to complex mixtures. 
 
Scheme 1.8. Example of acid-catalyzed fusion 
The classic Hilbert-Johnson reaction has found a widespread use in the condensation of acylated furanoses 
and pyranoses under the influence of a Friedel-Crafts catalyst. For instance, 2,4-diprotected pyrimidines 
can react with activated 2’-deoxyribose to form a mixture of the α and β anomers, in which the first 
product predominates (Scheme 1.9).26d, 28 
 
Scheme 1.9. Example of the Hilbert-Johnson reaction 
Moreover, this protocol holds a number of drawbacks, first of all moderate yields because of extensive by-
products formation. They include undesired α anomers in high proportions with respect to the β ones, as 
well as O-glycosides and N-alkylated species. 
In order to overcome such shortcomings, in the 1970s Vorbrüggen and co-workers developed a “silyl 
version” of the Hilbert-Johnson glycosylation, so far one of the mildest general methods for nucleoside 
formation (Scheme 1.10).29 In this alternative, a Sn or Ti Lewis acid (such as SnCl4 or TiCl4) catalyzes the 
condensation of a sugar tetra-O-acetate and a silylated base, both more soluble than their parent 
compounds. Despite the evident improvements, regioselectivity is still often challenging since a nucleobase 
contains multiple basic sites and the reaction is seldom irreversible. 
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Scheme 1.10. Example of the Vorbrüggen glycosylation 
In 2007 the Vorbrüggen glycosylation was adapted by Bookser and Raffaele into a one-step 5’/130°C 
microwave assisted reaction (Scheme 1.11). After quenching by neutralization and direct MPLC (Medium 
Pressure Liquid Chromatography) purification, deprotection was performed with NH3/MeOH. This 
procedure was applied to the coupling of numerous bases with various sugars for the high-throughput 
preparation of nucleosides containing heterocyclic bases which would have required more effort according 
to previously published methods.30 
 
Scheme 1.11 Adapted Vorbrüggen glycosylation 
Finally, the idea to synthesize nucleosides by chemical transglycosylation came from the observation of the 
intramolecular migrations of glycosyl moieties from N1 or N3 to N9 in purines under acidic conditions 
(Scheme 1.12). In the presence of a suitable Lewis acid, this approach is unique and often useful, especially 
for the preparation of functionalized products unavailable through conventional methods.31 
 
Scheme 1.12. Example of chemical transglycosylation 
Nevertheless, all these convergent approaches are characterized by a number of drawbacks: 
 they all require multistep syntheses, frequently associated with protection/deprotection reactions 
and anomeric activation; 
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 synthetic schemes are complex and isolation of intermediates and products, as well as their 
purification, is tedious; 
 high/low temperatures are often necessary, as well as the use of organic solvents and metal 
catalysts, in syntheses frequently characterized by a high environmental impact and raising problems 
of waste disposal; 
 the formation of several undesired by-products from concurring side-reactions is often regular; 
 regio- and stereoselectivity in the C-N bond formation can be not satisfactory: 
 since heterocyclic bases are multidentate nucleophiles, glycosydic bond generation is inefficient 
on the desired nitrogen atom, leading to multiple products; 
 control of the anomeric configuration is low, especially for 2’-deoxyribonucleosides due to the 
lack of assistance by OH2’; 
For such reasons, the chemoenzymatic synthesis may be a complementary strategy. 
1.2.2. Chemoenzymatic synthesis of nucleosides 
Enzymatic syntheses based on glycosyl-transferring enzymes have been shown to be an advantageous 
alternative to chemical methods due to the high selectivity of biocatalysts, mild reaction conditions and 
the overall simplicity of the approach.32 Generally speaking, the use of one or more enzymatic steps in 
chemical synthetic routes has become very popular, showing that enzymes are considered powerful tools 
by chemists.33 
For synthetic purposes, enzymatic reactions can be performed using: 
1) whole cells34 or cell-free extracts; 
2) isolated and purified enzymes; 
3) immobilized enzymes. 
The use of whole cells or enzyme extracts requires the control of side-reactions which can result in the co-
occurrence of undesirable by-products, as well as possible contaminants in the final target, such as 
proteins or toxins from the organism that produces the catalyst. Moreover, intra- and extracellular 
diffusion problems have to be addressed. 
Isolated and purified enzymes considerably reduce some of the above mentioned drawbacks. However, 
the instability of the protein under non-physiological conditions (temperature, pH, ionic strength, co-
solvents, …), a difficult biocatalyst recovery from the reaction medium and high production costs may 
represent significant limitations. 
Enzymes immobilized on proper matrixes by either adsorption or covalent interactions are extremely 
attractive to overcome such problems, as well as their variants entrapped in soluble form inside devices 
(e.g. membranes and microcapsules). In the latter case, impermeability to the enzyme is necessary to 
ensure a continuous and efficient exchange of substrates and products.35 
A solid-supported enzyme can be separated from the reaction medium by filtration and is thus available for 
reuse. Depending on the immobilization technique, properties of the biocatalyst such as stability, selectivity 
and KM may be significantly affected.
33, 36 Indeed, the design of a tailor-made immobilization plays a pivotal 
role to take full advantage from this technology. In the view of preparative applications, it is mandatory to 
simplify the downstream process: the availability of an immobilized and stabilized enzyme meets this need 
both by virtue of its easy handling and operational stability for a repeated use. 
A range of drawbacks associated with soluble enzymes can be circumvented by switching from 
homogeneous to heterogeneous biocatalysis: 
 short and long term stability should be higher against a wide variety of conditions. In fact, harsh 
temperatures and pH are frequently essential to achieve the solubilization of substrates and products 
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at the high concentrations required by a preparative process, whereas native enzymes usually show 
narrow stability windows and shelf life; 
 denaturation is hardly an issue; 
 simple filtration can be relied on for enzyme removal from the reaction mixture; 
 recycle and reuse are highly feasible. 
Activity loss is one of the possible outcomes upon immobilization on solid supports, often due to 
conformational changes. However, it is frequently compensated by long-term stability. 
The idea to use enzymes as biocatalysts in the preparation of nucleosides was envisaged and carried out by 
Krenitsky and co-workers in the late 1960s, with the goal to overcome the typical drawbacks encountered 
in the chemical synthesis of these molecules.37 
To date, two main classes of enzymes have been employed in nucleoside synthesis: nucleoside 
phosphorylases (NPs, EC 2.4.2) and N-2’-deoxyribosyltransferases (DRTs, EC 2.4.2.6). Although by a 
different mechanism, they both catalyze the formation of the C-N glycosidic bond through the transfer of a 
carbohydrate residue to a nucleobase.32a 
1.3. Nucleoside phosphorylases (NPs, EC 2.4.2) 
1.3.1. Classifications 
Nucleoside phosphorylases (NPs, EC 2.4.2) are enzymes which catalyze the phosphorolysis of purine and 
pyrimidine ribo- and 2’-deoxyribonucleosides. This reversible cleavage of the C-N β-glycosydic bond occurs 
in the presence of an inorganic phosphate ion (Pi) as co-substrate to generate the corresponding α-D-
pentose-1-phosphate and the conjugated nucleobase (Scheme 1.13). 
 
Scheme 1.13. General reaction catalyzed by nucleoside phosphorylases (NPs) and common nucleobases 
As for thermodynamics, the reaction is shifted toward nucleoside synthesis, being the equilibrium constant 
for mammalian NPs about 50.38 However, in vivo phosphorolysis is often coupled with an enzymatic 
sequence based on oxidation and 5’-phosphoribosylation of the released nucleobase, favoring the 
glycosydic cleavage. The latter reactions are catalyzed by xanthine oxidase (XO) and hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT).12a 
NPs from various organisms are fundamental biocatalysts in the so-called “salvage pathway”, in which 
purine and pyrimidine nucleosides can be synthesized by recycling intermediates belonging to degradative 
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mechanisms of nucleic acids. The recycled materials can therefore be converted back into ribo- and 2’-
deoxyribonucleotides. The role of recycling alternatives is fundamental in most organisms, in that the de 
novo construction is not available for all tissues, especially because of its energy-costly nature.12a, 39 
Many attempts on different classifications of NPs have been tried over the last decades, yet none of them 
has resulted inclusive of all possible cases. Among the characteristics that can be assumed as classification 
elements, three are of particular importance: 
 nucleobase or nucleoside substrate specificity (purine or pyrimidine); 
 quaternary structure (dimeric, trimeric or hexameric); 
 molecular mass (low-MM or high-MM) only for PNPs. 
The first and simplest distinction between NPs depends on their substrate specificity and divides them into 
purine nucleoside phosphorylases (PNPs, EC 2.4.2.1) and pyrimidine nucleoside phosphorylases (PyNPs, EC 
2.4.2.2), the first ones specific for purine nucleosides (e.g. inosine, guanosine, adenosine, …) and the latter 
for pyrimidine derivatives (e.g. uridine, thymidine, …) (Scheme 1.14). 
 
Scheme 1.14. General phosphorolysis catalyzed by PNPs and PyNPs 
Another possible classification of NPs introduced by Pugmire and Ealick started from the analysis of the 
protein structure along with their ability to process specific substrates.13a The first class, nucleoside 
phosphorylases-I (NPs-I), includes enzymes with a common single-domain subunit and an either trimeric or 
hexameric quaternary structure, able to recognize a broad variety of purine nucleosides (PNPs) and uridine 
analogues (UPs) as substrates. Examples are human (Hs), Escherichia coli (Ec) and Bacillus subtilis (Bs) PNPs, 
as well uridine phosphorylase from E. coli (EcUP). Enzymes belonging to the second family, nucleoside 
phosphorylases-II (NPs-II), show a dimeric quaternary structure, contain a two-domain recurring in their 
subunit fold and accept only pyrimidine substrates (PyNPs). Thymidine and uridine nucleosides are 
recognized by these enzymes in lower organisms, while in higher ones only thymidine substrates are. 
Among them uridine and thymidine phosphorylases (for instance, TPs from E. coli and Lactobacillus casei) 
are worth mentioning. 
In 2000, Shugar and co-workers reported a tentative classification of PNPs based on their molecular mass 
(MM), ranging from  ̴ 80 and   ̴180 kDa.12a PNPs were divided into low- and high-MM enzymes. Interestingly, 
members belonging to the same group shared not only equal quaternary structure but also subunit 
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composition and definite activity toward specific substrates. A third class was composed of PNPs from 
bacteria, parasites and mammals which were not ascribed to either groups. 
The first two classes (Table 1.1) were defined as follows: 
 low-MM homotrimers (  ̴ 80-100 kDa), specific for 6-oxopurines and their related nucleosides, often 
referred to as “Ino-Guo phosphorylases”; 
 high-MM homohexamers (  ̴ 110-160 kDa) with a broader substrate specificity extended to both 6-
oxo- and 6-aminonucleosides, being adenosine a much better substrate than inosine and guanosine 
(e.g. in B. subtilis). 
 PNP class 
Low-MM High-MM Others 
  
Molecular mass ̴ 800-100 kDa ̴ 110-160 kDa ̴ 60-180 kDa 
 
Quaternary structure 
 
homotrimers 
 
homohexamers 
homodimers, -trimers, -tetramers, 
-pentamers and -hexamers 
 
 
 
 
Specificity 
 
6-oxopurines, their 
nucleosides and some 
analogues 
very broad (6-oxo and 6-
aminopurines, their 
nucleosides and many 
analogues) 
• 1ST group: specificity as for low-
MM PNPs, but not homotrimers 
• 2ND group: specificity as high-MM 
PNPs, but not homohexamers 
Natural substrates Ino, Guo Ino, Guo, Ado various 
 
 
 
 
Sources 
mainly mammals (human, 
calf) and some bacteria 
(B. subtilis PNPI, 
Cellulomonas) 
mainly bacteria (E. coli, S. 
typhi, S. sulfataricum) and 
Mycoplasma (M. 
pneumoniae) 
some bacteria (P. vulgaria), 
mammals (bovine liver 
mitochondria) and parasites (P. 
falciparum) 
  
 
Table 1.1. Classification of PNPs by Shugar and co-workers 
Typical models of trimeric PNPs are the ones from Homo sapiens and Mycobacterium tuberculosis40, while 
hexameric structures can be represented by PNPs from E. coli (EcPNP), Salmonella typhimurium (StPNP), 
Plasmodium falciparum (PfPNP), B. subtilis (BsPNP) and Proteus vulgaris (PvPNP)12a. Hs and EcPNP are 
depicted in Figure 1.3a and 1.3b, respectively. 
    
Figure 1.3. Structures of: a) HsPNP (Reprinted with permission from J. Struct. Biol. 2010, 169, 379-388)41; b) 
EcPNP42. 
a) b) 
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1.3.2. Active sites 
As for all PNPs, each active site can be divided into three parts: 
 phosphate ion binding site; 
 sugar binding site; 
 purine binding site. 
The active site of the HsPNP complex with Immucillin-H (a transition state analogue inhibitor, see 1.3.4) and 
a phosphate ion is represented in Figure 1.4.12a, 43 
 
Figure 1.4. Active site of the HsPNP complex with Immucillin-H and a phosphate ion (Adapted from 
Biochemistry 2010, 49, 2058-2067. Copyright 2013 American Chemical Society)44 
Each subunit of this trimeric PNP is constituted by a distorted β-barrel made of a five- and an eight-
stranded mixed β-sheet and flanked by seven α-helices. The active site is located near the boundaries 
between subunits and protected by Phe159 acting as a lid from the nearest neighboring portion. 
The least profound part of the site is localized near to a Gly-rich loop and hosts the co-substrate phosphate 
in a largely hydrophilic environment with Ser33, Arg84, His86 and Ser220. 
The sugar moiety binds to HsPNP in a rather hydrophobic pocket that allows an optimal alignment of the 
anomeric centre with the phosphate ion. Tyr88, the backbone amide nitrogen of Met219 and His86 are 
notable exceptions, interacting by hydrogen bonds with the polar part of the pentose ring (OH3’ specifically 
points toward Tyr88). Several aromatic residues, such as Phe159 (from the adjacent subunit), Phe200, His86 and 
Tyr88, are placed very close to the rear part of ribose or 2’-deoxyribose and assist the ones interfaced with 
the other sugar portion. 
The purine binding site is buried deeply inside the core of the active one and its distinguishing residues are 
partly polar and partly hydrophobic. The first group allows the strong selectivity of HsPNP for 6-
oxonucleosides and bases, driven by a compact series of hydrogen bonds of Glu201, Lys244, Thr242 and Asn243 
with N1H, N2H2, O
6 and N7. The ability of Asn243 to block the CO group in position 6 is assured by a 
polarization in the γ-amide through another similar interaction with OH of Thr242. As for apolar residues, the 
core of the purine ring is involved in a series of hydrophobic touches with Ala116, Phe200, Val217, Met219, 
Gly218 and Thr242. 
The hexameric PNP from E. coli was studied by XRD at a 2.0 Å resolution by Mao et al. in 1997.45 Although 
its crystal structure showed an overall similarity with the human PNP in terms of subunit and active site 
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geometry (especially the secondary structure around substrates), it also contained a series of residues 
remarkably dissimilar from the ones in trimeric enzymes. EcPNP is a disc-shaped hexamer that may be 
viewed as a trimer of dimers, each containing two active sites. 
The active site of the EcPNP complex with Formycin B (a weak inhibitor of PNPs) and a phosphate ion is 
depicted in Figure 1.5. Its higher openness may account for the wider substrate acceptance of hexameric 
PNPs, if compared with trimers. 
 
Figure 1.5. Active site of the EcPNP complex with Formycin B and a phosphate ion (Adapted from Croat. 
Chem. Acta 2013, 86, 117-127)46 
The polar interactions with the inorganic ion involving Arg84, His86 and Ser220 in the human enzyme are 
reproduced by Arg24, Arg87 and Arg43 in the bacterial one. A few additional hydrogen bonds are generated 
with both the backbone amide and side chain of Gly20 and Ser90. 
Van der Waals contacts are generated by Val178, Glu179 and Met180 and exploited by EcPNP to anchor the 
ribose moiety and align its anomeric carbon against the phosphate ion oxygens. These hydrophobic bonds 
are assisted by a supplementary electron-rich interaction involving Phe159 and the pentose apolar side 
containing O4’. The role of this residue is both as a lid-like fragment and a hydrophobic contributor. Upon 
substrate binding, a large loop is subjected to movements shifting His4 and His47 near to the ribose moiety 
allowing them to interact with OH3’ and OH4’, respectively. 
As in the HsPNP, the purine binding pocket is neither entirely hydrophobic nor hydrophilic. Phe167 and Ile206 
are added to Val178, Met180 and Phe159, the latter from a second subunit, strengthening the apolar 
interactions. As for polar residues, once again Glu201 and Lys244 cooperate in binding to N
1H, N2H2 and the 6-
carbonyl group. However, the hydrogen bonding pattern between Glu201, Asn243 and the base, typical of 
mammalian PNPs, is not retained since the latter residue is shifted with Asp204. This catalytically relevant 
residue lies very close to N7. 
1.3.3. Catalytic mechanism 
Despite the presence of different PNP classes with specific activities toward nucleosides, the catalytic 
mechanism of these enzymes has been generalized since the late 1990s. All literature sources agree with 
the formation of a transition state (TS) characterized by a strong oxacarbenium ion character. The ribosyl 
electrophile then migrates from the nucleobase, which acts as a leaving group, to the deprotonated 
phosphate nucleophile through either a concerted or a stepwise mechanism. 
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More in details, two similar models have been proposed by Canduri et al.47, Bennett et al.48 and Koellner et 
al.
49 for Hs and EcPNP, respectively, to explain the catalytic mechanism of both enzyme classes (I and II) 
(Figure 1.6). Crystallographic information and functional analysis were carried out to support them. 
 
Figure 1.6. Proposed TSs and catalytic mechanisms for class I and II PNPs (e.g. Hs and EcPNP, respectively) 
The analysis of several PNP-substrate complexes suggests that the binding pose of the β-D-nucleoside 
presents a high-energy anticlinal torsion angle of the C-N bond and the ribose group in an uncommon C4 
endo sugar pucker. Such an unstable conformation should induce a weakening of the glycosydic bond. 
Cleavage at position 1’ is also promoted by an electronic flow from the endocyclic oxygen, triggered by the 
deprotonation of the phosphate co-substrate. As a result, the lone pair on O4’ is forced closer enough to the 
glycosydic bond to disrupt its stability. An oxocarbenium ion stabilized by the phosphate ion is formed as a 
transient intermediate and is captured by one of the nucleophile oxygens in a SN1-type attack. The 
nucleobase is released after protonation.50 
As for class I enzymes (low-MM, trimeric or tetrameric), a carbonyl or thiocarbonyl moiety in position 6 is 
necessary to form a key hydrogen bond with an Asn residue (Asn243 in HsPNP) and to stabilize the partial 
negative charge delocalized on the purine ring. The wider substrate specificity shown by class II PNPs (high-
MM, hexameric), on the contrary, is caused by a relocation of the stabilizing hydrogen bond on N7. In this 
case, an Asp residue (Asp204 in EcPNP) is likely to protonate the leaving purine base. This suggests why PNP 
class II can recognize adenosines and 6-substituted congeners too. Another interesting difference with 
respect to the first class is a second interaction between N1H and a Glu residue (Glu201 in HsPNP) which 
alters the keto-enol tautomeric equilibrium, preventing the reconstitution of the carbonyl form. 
        
Figure 1.7. Schematic and molecular representations of the electron transition nO4’ → σ*C1’-N9 (Adapted from 
J. Phys. Chem. B, 2013, 117, 6019-6026. Copyright 2013 American Chemical Society)51 
According to dynamic simulations reported in 2013 by Barnett and Naidoo, the trimeric bovine PNP (Bos 
taurus PNP, structurally similar to the human one) forces the substrate in an unnatural flattened endo 
conformation anchored by hydrogen bonds between the phosphate dianion and OH2’-OH3’. The additional 
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interactions of N1H with Glu201 and of the aromatic bicycle with Phe200 further increase the restriction of the 
base movements and therefore the alteration of the sugar pucker preferred conformation. As a result, an 
elongation of the glycosydic bond is generated by a massive electron migration from the nonbonding 
orbital of the endocyclic oxygen (nO4’) to the antibonding one associated to the C
1’-N9 bond (σ*C1’-N9). The 
consequent transition (nO4’ → σ*C1’-N9) causes a weakening of the glycosydic bond and a reduction of the 
activation barrier for the nucleophilic attack by the phosphate ion on C1’ (Figure 1.7).51 
However, a real understanding of the molecular mechanism of hexameric PNPs is still ahead, with some 
recent results opening new questions whose complexity is higher than expected.46 
1.3.4. Transition state 
In 2015 Evans, Schramm and Tyler published a review on Immucillins, useful mimics of the transition state 
of PNPs which can act as strong inhibitors to be used as antibiotics or with other potential clinical 
applications, such as toward leukemia, gout, autoimmune disorders, solid tumors.52 Human and bovine 
PNPs were studied by the kinetic isotopic effect (KIE) measured in arsenolysis of inosine and compared in 
terms of their transition state structures (Figure 1.8). 
 
Figure 1.8. Transition states of arsenolysis catalyzed by bovine and human PNP (Adapted from Curr. Med. 
Chem. 2015, 22, 3897-3909)52 
Experimental data obtained with the bovine PNP allowed to identify an early dissociative TS bearing a 
significant ribocation character and still a partial bond order associated to the glycosydic bond, elongated 
to 1.77 Å. The arsenate dianion, however, lies still separated from the sugar unit at a 3.00 Å distance in the 
active site. This TS was noted to surprisingly differ from the one of the human enzyme, despite the very 
high sequence alignment match (87% in total and 100% regarding the active site residues which bind to the 
substrate).53 
HsPNP is indeed characterized by a transition state involving an already departed nucleobase and a 
nucleophile still not attacking the anomeric carbon. In this SN1-type configuration, a fully developed 
ribocation is located at about the same 3.00 Å distance from both hypoxanthine and arsenate.54 
The features of the two TSs are reproduced by Immucillin-H (Forodesine) and DADMe-Immucillin-H 
(Urodesine), respectively, because of their striking structural similarities to the C1’-N9 distance in both of 
them. Furthermore, they can be employed as models for PNPs belonging to different classes. For example, 
PfPNP is a hexameric structure whose phosphorolysis mechanism proceeds through a very similar TS to 
HsPNP (highly dissociative) in spite of different catalytic residues.55 
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1.3.5. Chemoenzymatic synthesis of nucleosides by transglycosylation catalyzed by NPs 
Since the phosphorolysis reaction catalyzed by NPs is reversible, if a second base is added into the reaction 
medium, a transglycosylation process may occur, namely the transfer of the ribose or 2’-deoxyribose 
moiety from the nucleoside to the additional base, leading to the formation of a new β-nucleoside (Scheme 
1.15). 
 
Scheme 1.15. General transglycosylation catalyzed by NPs 
The final yield strongly depends on the extent of the phosphorolysis equilibrium. Concerning 
stereochemistry, the pentose donor substrate undergoes a nucleophilic attack by phosphate on the bottom 
face to form the corresponding α-D-sugar-1-phosphate intermediate, which is then subjected to the same 
type of reaction by the acceptor base. Since each step occurs with inversion of configuration, the final 
effect is an overall retention. 
The most common strategy, the so-called “one-pot, two-enzyme” approach, requires two different NPs in 
the same vessel (e.g. a PyNP to release the α-D-pentose-1-phosphate and a PNP to couple the glycosyl 
intermediate to the desired base). Following this approach, in 1981 Krenitsky and co-workers reported the 
synthesis of a group of purine nucleosides in excellent yields from thymidine and uridine promoted by UP 
or TP and EcPNP (Scheme 1.16).56 
 
Scheme 1.16. “One-pot, two-enzyme” transglycosylations 
On the contrary, the use of the same NP as biocatalyst for both steps allows a “one-pot, one-enzyme” 
strategy, in which a pentose donor, an acceptor heterocyclic nucleobase, a phosphate source and only one 
catalyst are mixed together. The use of one enzyme able to perform more than one reaction in the same 
time is rather convenient in terms of procedure simplification and cost decrease. 
An important limitation of using NPs is represented by the need to shift the equilibrium toward product 
formation. An interesting way of overcoming such a problem was proposed by Hennen and Wong in 1989 
by using 7-methylinosine or 7-methylguanosine as sugar donors in a PNP-catalyzed transglycosylation 
(Scheme 1.17).57 
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Scheme 1.17. “One-pot, one-enzyme” transglycosylation 
Since the reverse transglycosylation is totally interdicted, in that the 7-methylpurine base is not a substrate 
of PNP, 7-methylated purine nucleosides may be chosen as a convenient pool of sugar donors. 
Very recent examples of NP-catalyzed transglycosylations have revealed the great potential of enzymatic 
methods for the production of nucleoside analogues, such as Vidarabine (arabinosyladenine), a second-line 
antiherpes drug10c, 58 , Clofarabine (2-chloro-2’-fluoroarabinosyladenine), a second-generation purine 
nucleoside analogue used for the treatment of pediatric acute leukemia59, and some 2,6-dihalogenated 
purine nucleosides as precursors for the synthesis of many anti-leukaemia drugs (e.g. Cladribine, 
Clofarabine and Fludarabine)60. 
Since a pentose-1-phosphate is the key intermediate, its chemical synthesis followed by an enzymatic 
glycosylation may be preferred. In 2011, Mikhailopulo and co-workers reported the monoenzymatic 
synthesis of Fludarabine and Vidarabine catalyzed by EcPNP (Scheme 1.18).61 1,2,3,5-tetra-O-acetyl-D-
arabinofuranose, methyl-2,3,5-tri-O-benzoyl-α-D-arabinofuranoside and 1-O-acetyl-2,3,5-tri-O-benzoyl-α-D-
arabinofuranose were chemically phosphorolyzed with H3PO4 to a mixture of the furanose and pyranose 
forms of α-D-arabinose-1-phosphate, the first of which was processed by the enzyme as glycosylation 
reagent, yielding Nelarabine and Fludarabine in 40 and 77% yield, respectively. The first reaction was 
demonstrated to reach the equilibrium at almost 1:1 base/Nelarabine ratio, whereas the second one was 
shifted toward Fludarabine formation. In addition, the presence of the pyranose-1-phosphate did not 
interfere with the glycosylation reaction. 
 
Scheme 1.18. Synthesis of Nelarabine and Fludarabine by the EcPNP-catalyzed glycosylation of an α-D-
arabinofuranose/pyranose-1-phosphate mixture 
1.3.6. PNP from Aeromonas hydrophila (AhPNP, EC 2.4.2.1) 
In 2005 Trelles et al. performed an extensive screening of various microorganisms in order to synthesize 6-
substituted ribo- and 2’-deoxyribonucleosides by a biocatalyzed transglycosylation. A pyrimidine nucleoside 
(uridine or thymidine) was exploited as β-D-ribose donor and 6-substituted purines as acceptors. Among all 
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the tested microorganisms, the broad substrate specificity of Aeromonas hydrophila (Ah) resulted quite 
attractive from a synthetic viewpoint (Table 1.2).62 
 
Nucleoside Product formation (%)a) Time (h) 
   
Adenosine 33 4 
2’-Deoxyadenosine 89 4 
6-Chloroinosine 10 1 
6-Methoxyinosine 41 1 
6-Thioinosine - - 
6-Iodoinosine - - 
   
 
a) HPLC conversions 
Table 1.2. Synthesis of 6-substituted purine ribonucleosides by transglycosylation catalyzed by A. hydrophila 
cells 
In the recent past, from the strain of A. hydrophila reported by Trelles et al., the purine nucleoside 
phosphorylase encoded by the deoD gene was cloned, over-expressed in E. coli and purified by Ubiali, 
Speranza and co-workers. From its high MM (155 kDa) and substrate specificity directed to inosine, 
guanosine and adenosine, AhPNP was assumed to be a PNPII belonging to NP-I family (see 1.3.1)13a, thus 
having a hexameric quaternary structure. Purity, assessed by SDS-PAGE (Sodium Dodecyl Sulphate - 
PolyAcrylamide Gel Electrophoresis), was more than 90% and protein concentration 4.0-6.0 mg·mL-1.63 
1.3.7. UP from Clostridium perfringens (CpUP, EC 2.4.2.3) 
The uridine phosphorylase from Clostridium perfringens (CpUP) belongs to a family of enzymes crucial for 
the metabolism of pyrimidine nucleosides and nucleotides. They are selective for uridine and 2’-
deoxyuridine, spanning from prokariotes to yeasts and higher organisms, and together with thymidine 
phosphorylases (TPs), they constitute the two major classes of PyNPs.13a 
To date, neither any structure has been proposed for CpUP nor any sequence alignments have been 
performed to investigate the arrangement of aminoacidic residues in the catalytic site. The quaternary 
structures of other UPs have been elucidated both in bacteria and in humans. 
Given the high structural conservation of UPs, literature information allows to predict the main features of 
CpUP monomers. Most subunits in known bacterial UPs are arranged in a toroid configuration composed of 
three dimers with a three-layered α/β/α sandwich. Concerning the active site, uridine interacts on its 
hydroxyl and carbonyl groups with polar residues such as Glu and Arg, which are also catalytically active. 
Hydrophobic side chains generate an arrangement of apolar contacts with the sugar and the inner 
nucleobase. The phosphate ion is anchored by hydrogen bonds in a binding site considerably similar to the 
one in NPs.64 
The SN1-type catalytic mechanism shared by most UPs is similar to that of PNPs (Figure 1.9). In essence, the 
usual oxonium ion is formed and the conjugate nucleobase is released upon weakening of the glycosydic 
  
bond. Two hydrogen bonds between 
charge as a hydroxyl group from Ser prevents tautomerization
α-D-ribose-1-phosphate.13a 
Figure 
1.4. Purine nucleoside phosphorylase from 
1.4.1. Tuberculosis (TB) 
Tuberculosis (TB), caused by Mycobacterium
causes in emerging parts of the world as well as a resurgent disease in 
by the World Health Organization (WHO), which has been publishing an
1997, in 2015 there were 10.4 million new TB cases (11.5% of which involved co
in HIV-positive people) and 1.4 million TB deaths to be added to 0.4 million supplementary deceases among 
HIV-positive patients (Figure 1.10).65
Figure 1.10. TB incidence rate and case fatality ratio for HIV
Since efficient vaccines and fast-acting drugs are still 
against human health. Drugs such as 
remission in 95% cases, but at the same tim
consequences of intermittent dosing, patient non
co-infection by HIV.66 
In the last years several multi- and extensively drug resistant (
tuberculosis have been developing, 
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1.9. General catalytic mechanism of UPs 
Mycobacterium tuberculosis
 tuberculosis (Mt), still represents one of the top ten death 
developing countries
nual reports on this subject since 
-infection with the HIV virus 
 
    
-positive and negative people (2015)
being sought, TB is regarded as a global emergency 
Rifampicin, Isoniazid, pyrazinamide and Ethambutol ge
e TB relapse and drug resistance can likely occur as 
-compliance, advanced disease, immunosuppression and 
MDR and XDR, respectively
making medical treatments often unsuccessful (Figure 
ǀ INTRODUCTION 
 (MtPNP) 
. As pointed out 
 
65 
nerally lead to 
) strains of M. 
1.11).67 
  
Figure 1.11. MDR-TB incidence and number of patients with laboratory
Programs centered on TB medical treatment are being defied by the ongoing emergence of MDR, XDR and 
even totally drug-resistant (TRD) M. tubercul
viruses. Unfortunately, although new drugs are now essential, only a few candidate leads are now being 
tested in clinical trials against them (
In essence, one of the most relevant goals of WHO is the worldwide eradication of TB by 2050, hence the 
need for the discovery of new antituberular 
interest registered in the last 20 years, 
needed. 
1.4.2. PNP from Mycobacterium tuberculosis
Due to their vast presence in organisms, enzymes often represent ideal targets for the action of new 
chemical entities (NCEs), many of them through selective inhibition.
Briefly, an ideal pharmacological target for TB treatment should 
 growth and persistence of M. tuberculosis
 selectivity must be assured, by either 
preservation of its host counterpart;
 bacterial barriers must not hamper 
Since 2011, enzymes of the purine salvage pathway in 
targets for the development of new antitubercular agents.
microorganism sways from the de novo
is preferred under stressful conditions (
M. tuberculosis (MtPNP) might be a potential 
inhibit Mtb replication and survival,
TB strains. Promising results have already been obtained with such an approach targeting the PNP from 
falciparum, responsible for malaria.
1.4.3. Similarities and differences between 
In the classification on PNPs proposed by 
and the one from M. tuberculosis belong to the class of low
the superior limit of 100 kDa. 
Information gathered in the last decades 
and transition state73 of MtPNP with respect to
The two enzymes have only 40% aminoacidic sequence identity even though their structur
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-confirmed XDR
osis strains, which have evolved into 
e.g. diarylquinolines).68 
agents has become a global priority. 
novel and improved strategies to control this 
 (MtPNP) as a potential drug target
 
answer at least three 
 must be strictly dependent on it; 
the exclusive presence of the target in the pathogen or 
 
the physical access of the drug.69 
M. tuberculosis have been suggested as 
70 Although it has not been yet clarified when the 
 to the salvage nucleic acid pathway, it is clear
i.e. cell replication and lack of energy). In this frame, the 
target for the rational design of analog
 thus answering the urgent need of new agents against MDR
71 
HsPNP and MtPNP 
Shugar and co-workers (see 1.3.1)12a, both the human enzyme 
-MM homotrimers with a weight 
has demonstrated that the differences in structural 
 the human homologue are modest but
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-TB (2015)65 
completely irresponsive 
In spite of the renewed 
infection are urgently 
 
requisites: 
the 
potential 
 that the latter route 
PNP from 
ues that can selectively 
-XDR-TDR 
P. 
approaching 
features41, 72 
 potentially useful. 
es and catalytic 
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mechanisms are similar, as verified by the Basic Local Alignment Search Tool (BLAST) based on the Kegg 
database. 
The active site structure of MtPNP and the main interactions between its residues and inosine are reported 
in Figure 1.12a and 1.12b, respectively.72b, 73, 74 
       
Figure 1.12. MtPNP-Immucillin-H complex: a) active site (Phe153 from an adjacent subunit is highlighted in 
violet) (Reprinted from Biochemistry 2001, 40, 8204-8215. Copyright 2001 American Chemical Society)74a; b) 
interactions of inosine with the active site residues of MtPNP in the TS. 
Phe200 in HsPNP is replaced by a Tyr188 residue, whose phenolic ring, perpendicular to the nucleobase plane, 
forms a 2.8 Å hydrogen bond with OH5’ in nucleoside substrates and other equivalent moieties of analogues 
(iminoribitol, 2’-deoxyguanosine and inhibitors such as Immucillin-H and DADMe-Immucillin-H (see 1.4.4)54, 
76, 77). As the single binding element not retained in MtPNP, Tyr188 may play the role of a discriminating 
anchor for modified ligands, potentially triggering stronger contacts with the bacterial target. Such a 
hydrogen bond is clearly prevented in mammalian PNPs by the presence of hydrophobic Phe200.
13a 
Another interesting alteration defined by molecular dynamics (MD) is the role of Phe159, which operates as 
a lid in HsPNP, whereas in MtPNP does not form any π-π contact with the purine ring. This residue appears 
to intervene in sugar binding instead, lying close to C3’ and C5’. Taking into account the diffuse nature of a 
hydrophobic interaction, this variation is likely less reliable for further inhibitors.40 
The dissimilar role of some amino acids in PNPs with comparable structures and sequences allows 
structure-based drug design strategies, as confirmed by the case of the human and bovine PNPs. Although 
their sequences are 87% superimposable, including all catalytic residues, various inhibitors exhibit different 
specificity toward them.75 
1.4.4. Analogues of ground and transition states as inhibitors of PNPs 
Inhibitors of trimeric PNPs, with Ki ranging from mM to pM, have been studied and synthesized in the last 
decades and may be divided into two major categories: 
 analogues of the ground state; 
 analogues of the transition state, divided into four generations (the first mimicking an early TS and 
the remaining three a late one, see 1.3.4). 
b) a) 
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Nucleosides mimicking the features of the ground state in PNP substrates (Figure 1.12) are usually either 
moderately weak or good inhibitors (IC50 in the mM-nM range) and display modifications on the 
nucleobase, by large 9-deazotation and substitution on C8 with a limited range of simple groups, as well as 
on the ribose moiety.76 To improve their potency by additional interactions with the polar residues located 
in the orthophosphate sub-pocket, the β-sugar group can be linked to a phosphate/phosphonate group 
triggering a double competition against both co-substrates. This choice can be made also in acyclic 
derivatives. 
 
Figure 1.12. Examples of ground state analogues of trimeric PNPs 
As outlined above, the three main groups of ground state analogs are 9-deaza-, 8-substituted- and 
acyclonucleoside analogs. The first class shows a C1’-C9 bond resistant to phosphorolysis and includes true 
inhibitors, contrary to molecules as 8-amino and 8-hydroxy derivatives. The latter could be rather defined 
as slow-reacting substrates. Concerning open-structures, the Acyclovir series plays a major role. 
A pivotal innovation in the context of PNP-selective inhibitors has been introduced since the middle 
2000s.77 Potent inhibitors (Ki in the pM range) mimicking the TS have been proposed, all fulfilling the 
following requirements: 
 a ribocation mimic in an appropriate geometry to allow the formation of an ion pair with the 
phosphate ion; 
 a 6-oxo-9-deazapurine base with elevated pKa, able to interact with the residues that stabilize the 
leaving group; 
 two or three hydroxyl moieties to reproduce the network of hydrogen bonds with either ribose or 2’-
deoxyribose. 
Owing to the scarce difference between ground and transition state in terms of the phosphate ion, its 
mimics are generally not studied. The described strategy has led to potent analogs classified in four 
generations, the first similar to an early TS and the remaining ones to a late one (Figure 1.13). Bovine, 
malarial, human and tubercular PNPs are successfully affected by them.54, 75a 
 
Figure 1.13. Examples of transition state analogues of trimeric PNPs 
Immucillin-H (Ki = 58 pM) is the lead of the first generation family, containing an iminoribitol portion 
protonated in the active site to reproduce the oxocarbenium ion. The second generation of TS mimics is 
associated with DADMe-Immucillin-H (Ki = 9 pM), which contains a methylene spacer unifying 9-
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deazahypoxanthine and a chiral dihydroxypyrrolidine. By virtue of the CH2 bridge, the distance between the 
two portions is similar to that of the leaving nucleobase in a late TS (3.0 Å). The oxonium ion can be 
replicated once again by protonation of the tertiary nitrogen atom. The two remaining series contain open-
chain aminoalcohols and may be rationalized as acyclic Immucillin-H-like compounds, whose simplified 
structures have been developed in order to reduce the complexity and length of synthetic preparation, as 
well as to enhance their flexibility. Both DATMe-Immucillin-H (Ki = 9 pM) and SerMe-Immucillin-H (Ki = 5 
pM) are among the strongest inhibitors known for PNPs. The main difference between them is the higher 
stereochemical simplification of the fourth generation, caused by an achiral serinol moiety. 
Noticeably, a number of second generation TS mimics have shown activity against not only the human 
enzyme, but also other ones, such as MtPNP.73 
1.4.5. Conformation of 8-substituted purine ribonucleosides 
The glycosydic bond in nucleosides is a free rotor which can allow the molecule to adopt different 
conformations in solution. The torsion angle χ has been chosen as the variable to describe the relative 
position of the nucleobase with respect to the sugar ring, and in purine nucleosides is defined as the 
dihedral angle associated to the O4’-C1’-N9-C4 segment, while it is measured around O4’-C1’-N1-C2 in 
pyrimidine species (Figure 1.14).78 
      
      
Figure 1.14. Conformations accessible to purine and pyrimidine ribonucleosides by rotation around the 
glycosydic bond (Adapted from Nucleic acids in chemistry and biology, Oxford University Press 1996)78 
The extreme syn (60 to 80°) and anti (-110 to -180°) conformations are available for all purine nucleosides 
in dynamic equilibria, with an additional high anti area (-60 to -110°) for molecules with serious steric 
impediments. Apart from specific cases, pyrimidine nucleosides can exist only as anti conformers (-115 to    
-180°). 
However, not all χ values are accessible to every nucleoside, strongly depending on either the sugar or 
nucleobase substitution. Concerning natural purine nucleosides, most of them notoriously prefer the anti 
conformation both in solution and in crystals. On the other hand, a number of properly functionalized ones 
are known to exist either as syn conformers or as a syn-anti equilibrium mixture, whose composition is 
determined by the nature of substituents.79 
Substitution at position 8 is a key requirement to obtain the syn conformation, and by far the most 
effective factor eclipsing the base over the sugar ring is the necessity to keep the 8-moiety as far as possible 
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from steric hindrance and electronic repulsions. As proof of its relevance in terms of biologically active 
analogues (e.g. nucleotides and oligonucleotides, both cyclic and linear80), this phenomenon has been 
extensively studied over the last decades.81 Some authors have also suggested a possible hydrogen bond 
between N3 and OH5’, capable of modifying the electronic properties of the aromatic nitrogens. Therefore, 
the syn conformation energy can be lowered, making it accessible even at room temperature. On the other 
hand, the increase in size of the 8-substituent leads to an enhancement of steric hindrance and, 
consequently, to a reduction in stability of the anti conformer.82 
Specific elements in 1H and 13C NMR have been studied to assess the conformation of 8-substituted 
nucleosides around the glycosydic bond. 
In proton spectra, H2’ undergoes a distinctive downfield shift up to 0.5 ppm. The corresponding 
unsubstituted nucleoside must always be taken into account as reference. A possible explanation 
speculates the existence of a current deshielding effect generated on position 2’ by N3, whose lone pair is 
located closer to the sugar pucker in the syn conformation.83 
Besides, the use of 13C-NMR appears to be more reliable, since carbon shifts span across a larger range and 
Δδ is easily measurable. Reporting several δ values of 8-substitued adenosines, guanosines and inosines, 
Uesugi noticed that the effect of the syn conformation on 13C signals is opposite with respect to 1H, leading 
to an upfield shift (1-4 ppm) and, therefore, a shorter distance between C2’ and C3’. This phenomenon 
seems dependent only on the conformational anti-syn shift, regardless of the 8-substituent.84 
In 1987, on the basis of Δδ trends and high-field 13C-NMR data, Nair and Young proposed a practical 
method to argue the conformation of 8-substituted purine ribonucleosides with no need for reference 
compounds. For candidates with free hydroxyls, the syn conformation shows ΔδC
2’
-C
3’ < 0.5 ppm, whilst in 
the opposite case of the anti structure ΔδC
2’
-C
3’ > 2.8 ppm (absolute values must be considered). A Δδ 
ranging in between indicates a dynamic syn-anti equilibrium shifted toward either left or right according to 
the distance from the two extremes.85 
By using this rule, 8-bromo-, 8-methoxy- and 8-p-chlorophenylthioadenosine, 8-bromoguanosine and 8-
bromo- and 8-dimethylaminoguanosine have been confirmed as predominant syn conformers. 8-Amino 
and 8-methylaminoguanosine exist in a flexible syn-anti mixture. Spectra were recorded in D2O and DMSO-
d6.
85, 86 
1.5. Immobilized Enzyme Reactors (IMERs) 
1.5.1. Immobilized Enzyme Reactors (IMERs) 
The very first step in developing a biocatalytic process is to investigate the substrate specificity of any 
involved enzyme. For instance, in the case of NPs such an evaluation is typically carried out by submitting 
nucleoside libraries to phosphorolysis and measuring conversion, which can be indicative of the enzymatic 
ability to catalyze the reverse reaction. 
In order to speed up the enzymatic screening of libraries, miniaturized analytical tools are at the center of 
research interest. In the last decades, the higher availability of bioactive supports obtained by enzyme 
immobilization has sustained a great expansion in the bioanalysis field.87 
Enzymes can be immobilized on a suitable chromatographic support to form Immobilized Enzyme Reactors 
(IMERs), in which the biocatalyzed reaction occurs upon substrates injection during their elution (Figure 
1.16).88 
  
Figure 1.16. Example of the preparation and use of an
nucleosides 
Various benefits can be granted by these devices:
 immobilized enzymes are more stable than their soluble counterparts;
 enzymatic structure and activity are generally conserved, if the binding chemistry and physico
chemical properties of the stationary phase are neutral 
 reusability is assured, allowing simple elution and easy recovery of the enzyme;
 experimental data are more reproducible;
 analysis time and costs can be greatly reduced due to automatization, allowing the sequential 
screening of extended libraries in 
 miniaturization into columns and capillaries requires very low sample amount in ana
(often only a few μL). 
The insertion of such tools into systems with 
reaction monitoring and purification may result in the set
and synthesis (Figure 1.17). 
Figure 1.17. Schematic representation of an IMER
From the preparative viewpoint, an ideal arrangement for IMERs is their incorporation in tools for 
continuous flow synthesis as an alternative to batch rea
by a pump with solvents tanks to generate the flow and transfer reagents from their reservoir to a proper 
mixing system, the reactor (also broadened to coils, chips and vessels if necessary), a monitoring
unit and a vessel to collect products. An upgraded equipped system also presents multiple reactors, 
recycling coils, supported scavengers to eliminate waste and quench promoters, as well as initiators and a 
back-pressure regulator to avoid over
Flow equipments like the one reported 
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 IMER for the chemoenzymatic synthesis of modified 
 
 
toward them; 
 
a short time; 
an autosampler and an on-line integrated apparatus for 
-up of bioreactors capable of carry out screening 
 
-based apparatus for screening
ctions. The overall equipment is typically composed 
heating and irregular flows. 
in Figure 1.17 allow the following key advantages:
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 automation simplifies the precise control of reaction parameters, such as flow rate of reagents and 
hence their relative ratio, mixing and reaction rate; 
 reproducibility, safety and reaction time can be optimized; 
 operations concerning sample handling and purification are greatly reduced; 
 the minimal scale leads to an improved heat-mass transfer; 
 balance issues can be secured due to the regular amount of reagents flowing in the system in each 
time unit, even at high scale; 
 it becomes much simpler to scale up a reaction from mg to g scale with no need to repeat the 
operation on the whole equipment, since the reaction flow through the IMER is constant and the 
same effect can result from increased processing times (and therefore volumes). 
While flow methods have been developed to aid in synthetic and medicinal chemistry as an alternative to 
batch processing, on the contrary the use of flow bioprocesses is still in its infancy.89 Anyway, the coupling 
of benefits from biocatalysis and continuous flow synthesis is likely to allow this new technology to grow 
rapidly, as demonstrated by novel IMER-based applications.90 
An early significant example of IMERs, reported in 1999 by Sotolongo et al., was based on a horse liver 
alcohol dehydrogenase (HLADH) non-covalently bonded to an immobilized artificial membrane (IAM)-based 
HPLC support.91 In 2012, de Moraes et al. described the testing of potential HsPNP ligands through a 
HsPNP-based IMER obtained by immobilizing the enzyme in a fused silica Open Tubular Capillary (OTC) and 
using DI4G, a fourth generation Immucillin-like derivative, as reference compound.87e 
1.5.2. Enzyme immobilization 
Since the second half of the 20TH century, countless efforts have been oriented at developing strategies for 
enzyme immobilization, which can be carried out either by linking them to solid supports (or carriers) or by 
entrapping them in a proper matrix. Less explored strategies involve the support-free cross-linking of two 
or more catalysts with each other.92 As of the first category, covalent or noncovalent bonds may be 
selected, depending on protein, reaction conditions or specific necessities. 
The choice of a suitable carrier is pivotal since it impacts on the microenvironment conditions for the 
desired transformation. Dimension of particles, pores and channels, hydro- or lipophilicity, mechanical and 
physical resistance against stresses, surface-to-volume ratio, lack of reactivity as substrate of the enzyme, 
accessibility, inertness toward microbic attack and ease of derivatization are relevant factors. An ideal 
carrier should obviously display all these properties in the best combination at a reasonable cost.93 
Covalent immobilization is the paramount choice in the case of pharmaceutical and food industry 
applications, as it minimizes product contamination by enzyme leaching. 
Depending on the properties of the carrier and of the protein, immobilization can be performed either 
directly or upon functionalization of the matrix with an activating agent (Figure 1.18a). The latter can be a 
bi-functional reagent such as a dialdehyde (e.g. glutaraldehyde), which also acts as spacer to keep the 
enzyme far from the carrier surface. Such a strategy reduces steric hindrance effects around the enzyme, 
thereby favouring the catalysis.94  
Lysines are the most generally useful residues for covalent immobilization of enzymes. In this case the pH 
of the reacting solution must be controlled, as imines/iminium ions are key intermediates in the binding 
process. Furthermore, the nucleophilicity of NH2 groups on the protein changes according to their different 
pKa (approximately 9 and 10.5 for the α and γ positions, respectively). This indirect selection can result in 
the generation of either one covalent bond or a multipoint attachment on the support, increasing the 
catalyst stability in the latter case.95 
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Figure 1.18. Examples of enzyme immobilization: a) covalent immobilization; b) adsorption by ionic 
interactions; c) entrapment and cross-linking. 
Many other carriers functionalized with a variety of electrophiles (e.g. epoxides) are currently accessible at 
reasonable costs. The best combination of enzyme, support and possible linker(s) has to be determined in a 
“tailor-made” fashion for each protein. 
Milder adsorption techniques may also be used, relying on nonspecific interactions based on physical or 
ionic binding. The first case includes hydrogen bonds (e.g. with cellulose), Van der Waals contacts or 
hydrophobic ones (i.e. on acrylamide or carbon surfaces), whereas the other set includes ion pairs (e.g. in 
ion exchange resins) (Figure 1.18b).96 
The need for stronger non-covalent interactions has led to the design of entrapments, in which the catalyst 
is incorporated in a polymeric network directly produced in the enzyme solution (Figure 1.18c). Neither 
organic polymers (gelatin, alginate, polyacrylamide, …) nor silica sol-gels, hollow fibers and microcapsules 
can avoid catalyst detachment, making it necessary to proceed with additional cross-linking using 
multifunctional assistants (dextran sulfate, polyethylamine, …).97 
To date, only a few examples of NPs immobilization on solid supports have been reported for analytical and 
synthetic purposes. For instance, IMERs containing the PNP from Schistosoma mansoni98 and the human 
one87e were exploited for inhibitors screening. 
Concerning nucleoside synthesis, some NPs have been immobilized on Sepabeads® coated with 
polyethylenediamine/imine or on aldehyde-activated agarose (e.g. glyoxylagarose). Cross-linking with 
aldehyde dextran was required in the first case to strengthen the non-covalent interactions between the 
enzyme and the cationic support. The high activity and stability of the immobilized biocatalysts allowed to 
synthesize 2’-deoxyguanosine in 92% yield (with a UP and a PNP from B. subtilis under strong temperature 
and pH conditions)99, Floxuridine in 62% and 74-76% conversion (with a TP from E. coli and a PyNP from B. 
subtilis, respectively)95b, 100, Vidarabine and Didanosine in 74 and 44% conversion respectively (with a UP 
from either C. perfringens or Streptococcus pyogenes coupled with a PNP from either A. hydrophila or 
Citrobacter koseri)101 and Vidarabine in 53% yield and high purity (98.7%) (with a UP from C. perfringens 
and a PNP from A. hydrophila)10c. 
A PyNP from Thermus thermophilus and a PNP from Geobacillus thermoglucosidasius were recently 
immobilized on epoxide beads to catalyze the bienzymatic trasglycosylation of 2’-substituted ribo- and 
arabino-like uracils with 2,6-disubstituted purines to the corresponding nucleosides, which are important 
intermediates in the synthesis of biologically active products. By virtue of the thermostability of both 
enzymes, the preparation of 6-chloro-2-fluoropurine-9-riboside was run under high substrate 
concentrations at 60°C and successfully scaled up to multimilligram scale (60% yield).60 
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1.6. Background studies on the purine nucleoside phosphorylase from Aeromonas 
hydrophila (AhPNP) 
1.6.1. Characterization and synthetic applications of AhPNP 
As already explained, in 2012 a purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNP) was 
over-expressed in E. coli and purified by Ubiali, Speranza and co-workers (see 1.3.6).63b 
The enzyme was characterized by studying the phosphorolysis of the six natural purine ribo- and 2’-
deoxyribonucleosides, which were easily processed with a strong preference for 2’-deoxyinosine (Table 
1.3). 
Substrate Specific activity (IU·mg-1)a) 
  
Inosine 75 
2’-Deoxyinosine 137 
Guanosineb) 26 
2’-Deoxyguanosineb) 28 
Adenosine 35 
2’-Deoxyadenosine 28 
  
 
a) IU = μmol·min-1 
b) [substrate] = 1 mM 
Experimental conditions: 50 mM K2HPO4 buffer (pH 7.5), RT, volume = 10 mL, [substrate] = 5 mM 
Table 1.3. Activity of AhPNP toward six natural purine ribonucleosides 
AhPNP was found to be quite stable, retaining 100% initial activity after a 24 h incubation in 50 mM K2HPO4 
buffer containing 20% glycerol (v/v) at pH 7.5. 
The substrate specificity of AhPNP was further investigated by submitting a series of 1-, 2-, 6-, 7- and 8-
substituted purine ribonucleosides to the phosphorolysis reaction (Figure 1.19). 
From the inspection of experimental data, some consideration on the substrate specificity of AhPNP can be 
drawn: 
 all 1-, 2-, 6- and 7-substituted nucleosides were recognized by the enzyme. Of course, the 
phosphorolysis extent depended on the position and nature of the substitution, with the best results 
for N1-methylinosine, N2-methylguanosine, 6-chloroinosine, 6-methoxyinosine and 6-
methylthioinosine (30-50% unreacted nucleoside); 
 7-methylguanosine iodide was the only analogue showing a complete phosphorolysis to 7-
methylguanine and α-D-ribose-1-phosphate; 
 concerning 6-substituted analogues, conversions were in the range 23-59%, pointing out the broad 
substrate specificity of AhPNP; 
 by contrast, 8-substituted ribonucleosides were not tolerated by AhPNP. This lack of recognition may 
be related to their preferred syn conformation in aqueous solution, which should be adopted if the 8-
group is bulky enough to generate steric constraints (see 1.4.5).81,82 The forced conformational 
change from anti to syn may generate a structure incompatible with the active site of AhPNP. 
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a) Estimated by HPLC 
Experimental conditions: 50 mM K2HPO4 buffer (pH 7.5) with 20% (v/v) glycerol, RT, volume = 20 mL, 
[substrate] = 5 mM (Ino = inosine, Guo = guanosine, Ado = adenosine) 
Figure 1.19. Unreacted nucleoside at 6 h in the AhPNP-catalyzed phosphorolysis of 1-, 2-, 6-, 7- and 8-
substituted purine ribonucleosides 
In order to explore the synthetic potential of AhPNP, a few “one-pot, one-enzyme” transglycosylations 
were carried out. Four 6-substituted purines were used as sugar acceptors, whereas 7-methylguanosine 
iodide was chosen as D-ribose donor for several reasons (Table 1.4). First of all, its phosphorolysis catalyzed 
by AhPNP is rapid, complete and irreversible under the selected conditions. Secondly, its conjugated 
nucleobase is scarcely soluble in aqueous solvents, so it can precipitate thus shifting the equilibrium to 
product formation. In addition, it is neither a substrate nor an inhibitor of AhPNP. 7-methylguanosine 
iodide can be synthesized very easily by direct methylation of guanosine in high yield and purity. 
On semi-preparative scale, three 6-substituted purine ribonucleosides were prepared and isolated in very 
high yield (71-93%) and purity. 
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Table 1.4. Synthesis of 6-substituted ribonucleosides 
1.6.2. AhPNP as an on-line Immobilized Enzyme Reactor (
The broad substrate specificity shown by 
forward the development an Immobilized Enzyme Reactor (IMER) 
robust screening of modified nucleosides, thus exploring its use in the synthesis of nucleoside analo
transglycosylation. The resulting Ah
determined with the soluble enzyme, thus validating the biochromatografic system for a routin
reported by Speranza, Ubiali and co
Specifically, AhPNP was covalently immobilized on the inner
(OTC) by following a previously reported protocol 
against HsPNP87e and the one from Schistosoma mansoni
The AhPNP-IMER was introduced into a 
analytical HPLC system by a six-port switching valve (
Figure 1.20. Sketch of the AhPNP-
Chromatogr. B 2014, 968, 79-86
The sample was loaded with the valve in position A, directly connected with pump 1 
the IMER capillary, where the reaction 
analytes (products and unreacted reagents) were loaded dir
analytical HPLC column for subsequent separation, identification and quantification as the original position 
A was selected again. An example of the resulting chromatogram is presented in 
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AhPNP
Pi
R
Donor/acceptor ratio Isolated yield (%)
  
3:1 93 
3 4:1 71 
3 4:1 93 
 4:1 not isolateda) 
  
 
a) Synthesized on analytical scale 
: 50 mM K2HPO4 buffer (pH 7.5), RT, volume = 20 mL
via AhPNP-catalyzed transglycosylation
AhPNP-IMER) 
AhPNP toward purine- and sugar-modified nucleosides 
based on this enzyme 
PNP-IMER was able to assess the same activity ranking order as 
-workers in 2013.102 
 surface of a fused silica Open Tubular Capillary 
used to assay the inhibitory activity of new compounds 
 (SmPNP).98 
bi-dimensional column-switching apparatus and connected to an 
Figure 1.20). 
IMER connected to the analytical HPLC (Reprinted with permission from
)102 
occurred. The valve was then switched to position B and
ectly in a 20 μL loop on the head of the 
Figure 
ǀ INTRODUCTION 
H
NH2
+ HI
 
 
 
 
pushed 
for a rapid and 
gues by 
ary use as 
  
 J. 
to deliver the eluent in 
, as a result, 
1.21. 
  
 
Figure 1.21. Chromatogram obtained 
Chromatogr. B 2014, 968, 79-86
The immobilization process was reproducible, as 
by using    ̴200-300 μg of protein that afforded a yield of 7
respectively. Kinetic parameters (KM
by using inosine as substrate of the phosphorolysis reaction.
 
 
KM (μM)
a) 
Vmax (μmol·min
-1) 4.0 x 10
Enzyme (mg) 
Immobilization yield (%) 
 
Table 1.5. Immobilization yields and kinetic parameters of soluble 
The IMER catalyzed 60 reactions/capillary with no activity loss, 
screening of nucleoside analogues. Long
month. 
A number of natural and modified nucleosides were assayed in phosphorolysis catalyzed by 
(Figure 1.22), exploiting the apparatus depicted in 
showed the same activity ranking order as determined with the soluble enzyme
the catalytic activity in solution. 
N
6-substituted adenosines (31-36) were 
validation, but also in order to explore the possibility to prepare them by transglycosylation 
the substrate specificity of AhPNP). 
substituted purine ribonucleosides (
neither by the native enzyme, nor by the IMER
7-Methylguanosine iodide (65) deserve
between the evaluation with the free and the immob
phosphorolysis was complete when the reaction 
occur through the IMER. It was hypothesized that 
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from the AhPNP-IMER apparatus (Reprinted with permission from
)102 
resulted from the comparison of two bioreactors prepared 
% and 10% for AhPNP-IMER 
 and Vmax) were also determined (Table 1.5). KM
 
Soluble AhPNP AhPNP-IMER I 
  
1.8 ± 0.5   10.2 ± 1.4 
2 ± 2.0 x 102 9.3 x 10-4 ± 4.0 x 10-5 1.5 x 10
0.001 0.030 
- 10 
  
 
a) The reaction was stopped after 1’ 
AhPNP and Ah
thus resulting a reliable tool for repeated 
-term storage was remarkable, with 100% residual activity after 1 
Figure 1.20. It is worth noting that the 
, being 
submitted to phosphorolysis not only to support the IMER 
Experimental data showed that the IMER was active toward
31, 33 and 34), with the only exception of 36, which was not processed 
. 
d a specific comment because of the strikingly different values 
ilized enzyme. As mentioned before, 
was catalyzed by the native catalyst, whereas
the permanent charge of the analyte might
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 J. 
I and AhPNP-IMER II, 
 values were measured 
AhPNP-IMER II 
 
6.0 ± 2.2 
-4 ± 1.2 x 10-5 
0.021 
7 
 
PNP-IMERs 
AhPNP-IMER 
AhPNP-IMER 
indeed predictive of 
(according to 
 different 6-
the 
 it did not 
 generate 
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repulsive interactions with the positively charged surface of the immobilized PNP, preventing the 
phosphorolysis from occurring. 
 
 
Figure 1.22. Comparison between the activity ranking order of soluble AhPNP and AhPNP-IMER 
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2 ǀ AIMS 
The research work described in this PhD Thesis was developed along three parallel but intertwining lines: 
 the exploitation of the purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNP) and 
the uridine phosphorylase from Clostridium perfringens (CpUP) as biocatalysts in the 
chemoenzymatic “one-pot, one-enzyme” or “one-pot, two-enzyme” synthesis of 2- and 6- 
substituted purine ribo-, 2’-deoxyribo- and arabinonucleosides by “in batch” and “in flow” 
transglycosylations, starting from a wide array of sugar donors and purine acceptors, mostly 
synthesized on purpose; 
 the synthesis and screening of the inhibitory activity of some 8-substituted purine ribonucleosides 
toward the purine nucleoside phosphorylase from Mycobacterium tuberculosis (MtPNP) by a 
medium-throughput LC-ESI-MS/MS assay, also assessing the selectivity of the prepared compounds 
against the bacterial enzyme with respect to the human one (HsPNP); 
 the synthesis of a small library of 8- and N2-substituted derivatives of inosinic and guanylic acids on 
the basis of in silico molecular modeling studies and in view of their use as potential ligands of the 
human GPR17 receptor. 
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3 ǀ PURINE NUCLEOSIDE PHOSPHORYLASES AS 
BIOCATALYSTS AND PHARMACOLOGICAL 
TARGETS 
3.1. Chemical synthesis of structurally modified purine nucleobases and nucleosides 
3.1.1. Synthesis of 6-substituted purines (2-10, 12-24) 
A series of twenty-four 6-substituted purine nucleobases (1-22) were used as sugar acceptors in 
transglycosylations catalyzed by the PNP from Aeromonas hydrophila (Figure 3.1). 
 
Figure 3.1. 6-Substituted purines (1-22) 
Among them, adenine (1), hypoxanthine (11) and 6-methylpurine (24) were purchased from commercial 
sources. All other substrates were prepared by synthetic procedures either already known in literature or 
originally developed in the Laboratory of Organic Chemistry (Prof. Giovanna Speranza) at the Department 
of Chemistry of the University of Milan. 
The retrosynthetic strategy is shown in Scheme 3.1. 6-Chloro- (23) and 6-thiopurine (17) were identified as 
precursors for N6-monosubstituted and N6,N6-disubstituted adenines, 6-alkoxypurines and 6-thiopurines. 
Both intermediates can be obtained from hypoxanthine (11). Alkylamino, alkoxy and alkylthio derivatives 
were prepared by halogen displacement, while an S-alkylation strategy was devised for the remaining 
substituents. 
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Scheme 3.1. Retrosynthetic analysis of 6-substituted purines 
The main issue of such functionalizations is that the 6-carbonyl group of hypoxanthine (11), belonging to an 
amido moiety, is quite unreactive toward primary or secondary amines, alkoxydes, alkanethiolates and alkyl 
halides. Therefore, the basic strategy was to convert it into either an effective leaving group or a suitable 
nucleophile. According to this approach, 6-chloro- (23) and 6-thiopurine (17) were considered the best 
choices as intermediates. 
A chlorine atom was directly installed on C6 of hypoxanthine (11) by treatment with POCl3 in refluxed N,N-
DMA. Dry reagents and solvents were essential to avoid side reactions and to obtain a clear product. P2S5 in 
refluxed pyridine was exploited to convert the carbonyl group into a thiocarbonyl moiety. Purification of 
the resulting products proceeded by crystallization from H2O and EtOH, respectively (Scheme 3.2). 
 
Reagents and conditions (yield): a) POCl3, N,N-DMA, reflux (89%); b) P2S5, Py, reflux (80%). 
Scheme 3.2. Synthesis of 6-chloro- (23) and 6-thiopurine (17) 
N
6-Substituted (2-8) and N6,N6-disubstituted (9 and 10) adenines were prepared by treatment of 23 with 
the proper primary or secondary amine or amine solution, choosing an alcohol (EtOH or n-BuOH) as solvent 
under reflux and adding TEA as base, if necessary (Scheme 3.3). All products were purified by precipitation, 
flash column chromatography or semi-preparative HPLC. 
The synthesis of aryl ethers by aromatic nucleophilic substitution was performed under reflux to synthesize 
6-alkoxypurines 12-16 (Scheme 3.4). The necessary sodium alkoxydes were obtained in situ by dissolving 
metallic Na in the corresponding dry alcohols, with dry THF as solvent in the case of 16, and semi-
preparative HPLC was exploited to purify all products in good to high yield, with the only exception of 14. 
The lower yield of the latter compound can probably be ascribed to the slow dissolution of Na in the 
secondary alcohol and to the steric hindrance of the corresponding alkoxyde. Treatment of i-PrOH with 
NaH was therefore selected as an alternative for a faster and more efficient deprotonation, yielding the 
desired purine in almost quantitative yield. 
6-Alkylthiopurines (18-22) were prepared either by halogen substitution on 6-chloropurine (23) with the 
proper thiol, deprotonated in situ by 1 M NaOH as solvent, or by S-alkylation of 6-thiopurine (17) in the 
presence of a base (Scheme 3.5). In the first case, temperature was always kept 10°C below the boiling 
point of the thiol in order to prevent its volatilization. In the latter approach, alkyl bromides or iodides were 
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used. The synthesis of 22 required the use of DMF in place of an aqueous solvent and the substitution of 
NaOH with K2CO3 to achieve better results. Neutralization and precipitation afforded the target products. 
 
Reagents and conditions (yield): a) 40% aq. CH3NH2, TEA, n-BuOH, reflux (64%); b) 70% aq. CH3CH2NH2, 
EtOH, reflux (78%); c) R1R2NH, TEA (for 4 and 10), EtOH, reflux (62-86%); d) RNH2, EtOH, reflux (80-88%); 
e) 2.0 M (CH3)2NH in THF, EtOH, reflux (40%). 
Scheme 3.3. Synthesis of N6-substituted and N6,N6-disubstituted adenines (2-10) 
 
Reagents and conditions (yield): a) Na, ROH, THF (for 16), reflux (50-84%); b) Na, i-PrOH, reflux (16%) or 
NaH, i-PrOH, reflux (97%). 
Scheme 3.4. Synthesis of 6-alkoxypurines (12-16) 
 
Reagents and conditions (yield): a) RX, 1 M NaOH (59%-73%); b) PhCH2CH2Br, 1 M NaOH (12%) or 
PhCH2CH2I, K2CO3, DMF (66%); c) RSH, 1 M NaOH, 10°C below RSH b.p. (50-85%). 
Scheme 3.5. Synthesis of 6-alkylthiopurines (18-22) 
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3.1.2. Synthesis of 2-amino-6-methoxypurine (26) 
The same protocol used for most 6-alkoxypurines was repeated to convert commercial 2-amino-6-
chloropurine (25) into 2-amino-6-methoxypurine (26) in NaOMe/MeOH under reflux (Scheme 3.6). 
 
Reagents and conditions (yield): a) Na, MeOH, reflux (70-94%). 
Scheme 3.6. Synthesis of 2-amino-6-methoxyguanine (26) 
3.1.3. Synthesis of 6-substituted inosines (28-36, 38-48) 
In order to proceed with the HPLC analysis of transglycosylation mixtures, the ribonucleoside counterparts 
of 6-substituted purine acceptors (27-50) were required as reference compounds (Figure 3.2). 
 
Figure 3.2. 6-substituted inosines (27-50) 
Only adenosine (27), inosine (37) and 6-methylthioinosine (44) were purchased from commercial sources.  
The synthesis of the remaining nucleosides was carried out by following a strategy similar to that adopted 
with the nucleobases (Scheme 3.7), starting from the activation of position 6 by either halogenation or 
thienation. Owing to the very low nucleophilicity of the amino group in adenosine, N6-substituted and 
N
6,N6-disubstituted derivatives had to be synthesized starting from 6-chloropurine riboside (49) by 
substitution with the suitable primary or secondary amine. The same strategy was followed to obtain 6-
alkoxyinosines and three 6-alkylthio derivatives (45-47), whereas S-alkylation was repeated for the 
remaining thionucleosides. 
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Scheme 3.7. Retrosynthetic analysis of 6-substituted purine ribonucleosides 
Inosine (37) was chosen as starting material in all cases (Scheme 3.8). Since both chlorination and 
introduction of a thiocarbonyl group at position 6 may lead to unwanted side reactions of the hydroxyl 
moieties, the sugar portion was protected by acetylation with Ac2O, TEA and a catalytic amount of DMAP (7 
mol %) in CH3CN at room temperature. Chlorination of 51 was performed with SOCl2 in a refluxed 
CH2Cl2/DMF mixture, whereas thienation was carried out with Lawesson’s reagent (2,4-bis-(4-
methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) in refluxed pyridine (see 6.1.1).152 Attempts 
with POCl3 in the presence of TEA and N,N-DMA or PPh3/CCl4 (Appel’s protocol)
103 and with P2S5 gave worse 
results, because of overphosphorylated by-products formation and poor substrate conversion, respectively. 
Either aminolysis with NH4OH or alcoholysis with NaOMe on intermediates 52 and 53 allowed the removal 
of the protecting acetyl moieties, the latter treatment in poorer yield and purity. 49 and 43 were purified 
by flash column chromatography and recrystallization, respectively. 
 
Reagents and conditions (yield): a) Ac2O, TEA, 7 mol % DMAP, CH3CN (95%); b) SOCl2, CH2Cl2/DMF, reflux 
(98%); c) 33% aq. NH4OH, MeOH (69%); d) Lawesson’s reagent, Py, reflux (77%); e) NaOMe, MeOH (58%) or 
28% aq. NH4OH, MeOH (74%). 
Scheme 3.8. Synthesis of 6-chloro- (49) and 6-thioinosine (43) 
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Primary or secondary amines and TEA in refluxed EtOH were used to obtain all N6-substituted and N6,N6-
disubstituted adenosines (28-36) in very good yields (Scheme 3.9). Purification was carried out either by 
flash column chromatography or by precipitation. 
 
Reagents and conditions (yield): a) R1R2NH, TEA, EtOH, reflux (65-94%). 
Scheme 3.9. Synthesis of N6-substituted and N6,N6-disubstituted adenosines (28-36) 
Since acetyl protecting groups are cleaved by simple alcoholysis to volatile acetate esters, deprotection of 
the ribose moiety was not necessary in the course of the synthesis of most O6-alkyl derivatives of inosine 
(38, 39, 41 and 42) (Scheme 3.10). An excess of Na in the suitable refluxed alcohol was used as reagent (for 
38, 39 and 41) and THF was chosen as solvent in the case of the 2-phenylethoxy group (42). Neutralization 
with NH4Cl and either flash column chromatography or precipitation afforded the products. The alternative 
synthesis of 41 with n-BuONa, prepared in situ from Na in a n-BuOH/DMSO mixture, gave poorer results in 
terms of yield (from 86 to 59%) and was plagued by significant drawbacks, such as the residual presence of 
DMSO after flash column chromatography, which made freeze-drying necessary to purify the product. Once 
again, i-PrOH was deprotonated to the corresponding alkoxyde by NaH and reacted with the deprotected 6-
chloro precursor 49 to form product 40. 
 
Reagents and conditions (yield): a) Na, ROH, THF (for 42), reflux (29%-quantitative); b) NaH, i-PrOH, reflux 
(for 40, 32%) or Na, n-BuOH/DMSO, reflux (for 41, 59%). 
Scheme 3.10. Synthesis of 6-alkoxyinosines (38-42) 
Unlike purines (see 3.1.1), the chlorine displacement strategy was selected for most S-alkyl derivatives of 6-
thioinosine (45-47), while only 48 was synthesized by the S-alkylation approach (Scheme 3.11). The low 
yield of the latter method with respect to the first one may be ascribed to the extremely high reactivity of 
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free hydroxyl groups in aqueous NaOH and the subsequent formation of overalkylated by-products. The 
proper thiol was deprotonated in situ by Na2CO3 in EtOH. The mixture was always refluxed with the only 
exception of the one containing CH3CH2SH, for which the temperature was kept at 30°C due to its volatility. 
Once again, purification was obtained by flash column chromatography. 48 was prepared according to a 
similar procedure to the synthesis of 22. PhCH2CH2Br was added directly to a suspension of 43 and Na2CO3 
in DMF, premixed in order to allow the quantitative formation of the thiolate anion. 
 
Reagents and conditions (yield): a) RSH, Na2CO3, EtOH, 30°C (for 45) or reflux (for 46 and 47) (59-88%);      
b) PhCH2CH2Br, K2CO3, DMF (47%). 
Scheme 3.11. Synthesis of 6-alkylthioinosines (45-48) 
The introduction of a methyl group in position 6 of the purine ring was performed by a Pd-mediated Negishi 
cross-coupling on 52 (see 6.1.3)155, followed by acetate removal with NH4OH in MeOH (Scheme 3.12). A 2.0 
M solution of (CH3)2Zn in toluene, Pd(PPh3)4 (15 mol %) and dry THF were chosen as methylating agent, 
catalyst and solvent for the first reaction, respectively. 
 
Reagents and conditions (yield): a) 2.0 M (CH3)2Zn in toluene, 15 mol % Pd(PPh3)4, THF, 55°C → RT (81%);  
c) 33% aq. NH4OH, MeOH (66%). 
Scheme 3.12. Synthesis of 6-methylinosine (50) 
3.1.4. Synthesis of 6-O-methylguanosine (58) 
To obtain 6-O-methylguanosine (58), the 6-carbonyl group of guanosine (55) was chlorinated by treatment 
with POCl3, N,N-DMA and Et4NCl in refluxed CH3CN, in analogy with 6-chloropurine (23), and subsequent 
reaction of 56 with NaOMe in dry MeOH at RT (Scheme 3.13). As usual, no further hydroxyl 
transesterification was needed after flash column chromatography. 
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Reagents and conditions (yield): a) Ac2O, TEA, 7 mol % DMAP, CH3CN (94%); b) POCl3, N,N-DMA, Et4NCl, 
CH3CN, reflux (76%); c) Na, MeOH (57%). 
Scheme 3.13. Synthesis of 6-O-methylguanosine (58) 
3.1.5. Synthesis of arabinosylguanine (59) 
In order to synthesize purine arabinosyl derivatives by a “one-pot, one-enzyme” transglycosylation 
catalyzed by AhPNP, 7-methylarabinosylguanine iodide may be used as a convenient sugar donor, following 
the synthetic scheme developed for the enzymatic synthesis of 6-substituted purine ribonucleosides where 
7-methylguanosine iodide was chosen as D-ribose source (see 3.2.1).57, 63, 104 The advantage of this approach 
relies on the formation of 7-methylguanine as by-product that is neither a substrate nor an inhibitor of the 
enzyme. As a result, the equilibrium-controlled transglycosylation can be completely shifted toward 
product formation (see 1.6.1).57, 63b 
The synthesis of 7-methylarabinosylguanine (67) was undertaken starting from arabinosylguanine (59) 
(Figure 3.3). 
 
Figure 3.3. Arabinosylguanine (59) 
Almost all reported strategies to prepare arabinosylguanine start from guanosine (55). Since the two 
molecules are epimers, differing only in the opposite configuration of C2’, all procedures involve its 
stereochemical inversion. One of the first protocols described in literature was reported by Hansske et al.. 
According to it, the reaction requires a Moffatt oxidation with DMSO/Ac2O followed by reduction with 
NaBH4. The formal hydride attack occurs specifically on the α side of the sugar largely due to the steric 
hindrance around the guanine base.105 In a more recent variant developed by Mehta et al. in 2014, the 
Swern-like reagent couple was substituted by Dess-Martin periodinane.106 Gruen et al. managed to achieve 
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the same result by an SN2 strategy (Scheme 3.14), according to which OH
2’ was converted into a stable 
leaving group by triflation, followed by displacement with NaOAc and deacetylation. The other two 
hydroxyl groups needed a non-orthogonal protection to prevent inversion at C3’ and side reactions at the 
5’-position.107 
 
Scheme 3.14. Retrosynthetic analysis of arabinosylguanine 
The first step of the sequence was the preliminary double protection of ribose in 55 by the use of the well-
known Markiewicz reagent (1,3-dichloro-1,1,3,3-tetra-i-propyldisiolxane, TIPDSCl2) on OH
3’ and OH5’ 
(Scheme 3.15). An excess of imidazole in dry DMF was necessary to promote the displacement of the two 
chlorine atoms on the reagent first by OH5’ and then by OH3’, with a consequential eight-membered ring 
closure. Water addition provided 60 by precipitation in almost quantitative yield. 
 
Reagents and conditions (yield): a) TIPDSCl2, imidazole, DMF (98%). 
Scheme 3.15. Protection of OH3’ and OH5’ of 55 
The triflation of 60 was carried out by treatment with TfCl in dry CH2Cl2, DMAP as a catalyst and TEA to 
neutralize HCl. Control of the reaction temperature was crucial during the addition of the chloride at 0°C, 
while the reaction was allowed to proceed at RT until completion. The relatively limited reactivity of C2’ 
toward nucleophiles, likely caused by the detrimental presence of a sterically hindered nucleobase, made it 
possible to purify 61 by flash column chromatography without decomposition. Nevertheless, the product 
was reacted as soon as possible with an acetate salt in DMF. Cs+ was chosen as alkaline ion to maximize the 
nucleophilicity of the counter anion, which was introduced in position 2’ by an SN2 mechanism with 
concurrent inversion of configuration (Scheme 3.16). It was not surprising that this reaction took 24 h, 
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given that the heterocyclic portion shields the reacting carbon. Ester 62 was purified by flash column 
chromatography. 
 
Reagents and conditions (yield): a) TfCl, TEA, DMAP, CH2Cl2 (69%); b) CsOAc, DMF (55%). 
Scheme 3.16. Triflation of 60 and SN2 displacement at C
2’ of 61 
The remaining acetyl group of 62 was removed by aminolysis with NH4OH in MeOH/1,4-dioxane. Reaction 
time was prolonged to 24 h in order to circumvent any detrimental effect of the combined steric 
hindrances of the nucleobase and the disyloxane. Finally, double desilylation of 63 with TBAF·3H2O in THF 
was performed to cleave the protections on the two ribose hydroxyl groups (Scheme 3.17). Semi-
preparative HPLC afforded arabinosylguanine (59) in good yield. 
 
Reagents and conditions (yield): a) 33% aq. NH4OH, MeOH/1,4-dioxane (80%); b) TBAF·3H2O, THF (67%). 
Scheme 3.17. Aminolysis of 62 and desilylation of OH2’ and OH5’ of 63 
3.1.6. Synthesis of 7-methylpurine and 7-methylguanine nucleoside iodides (64-67) 
7-Methylpurine riboside iodide (64) and 7-methylguanine ribo-, 2’-deoxyribo- and arabinonucleoside 
iodides (65-67) were prepared to be used as sugar donors in transglycosylation reactions catalyzed by 
AhPNP, although only 65 and 66 were used (Figure 3.4). 
 
Figure 3.4. 7-Methylpurine and 7-methylguanine nucleoside iodides (64-67) 
As of 64 and 65, the choice of MeI as methylating agent and of the proper solvent for SN2 reactions (DMSO 
or a DMF/DMSO mixture) led to the regioselective formation of the iodide salts at N7 (Scheme 3.18). Since 
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they are too polar to be detected by TLC, the disappearance of the reagent was monitored instead, to 
assess when the reaction was complete. In addition, light exposure during the reaction at RT was avoided 
to prevent decomposition of reagents and final products, which had to be stored at -20°C until use. No 
synthesis of 7-methylarabinosylguanine iodide (67) has been reported in literature to date, thus a similar 
strategy was successfully applied to the methylation of arabinosylguanine (59) with MeI in a DMSO/DMF 
mixture, obtaining a similar yield (83%). After freeze-drying to remove the high-boiling solvent, isolation 
and purification were carried out in all cases by either precipitation in dry acetone or CHCl3, if necessary 
followed by grinding of the resulting syrup in dry acetone. 
 
Reagents and conditions (yield): a) CH3I, DMSO (for 64, 67%) or CH3I, DMF/DMSO, 30°C (for 65) or RT (for 
67) (87-89%). 
Scheme 3.18. Synthesis of 7-methylinosine, -guanosine and -arabinosylguanine iodides (64, 65 and 67) 
The stability of 7-methylated nucleosides in DMSO or DMSO/DMF mixtures varies largely, depending on the 
nature of the sugar moiety, and was a serious issue in the synthesis of 7-methyl-2’-deoxyguanosine iodide 
(66) (Scheme 3.19). The reaction was performed by modifying a previous protocol reported by Voegel et 
al., under controlled temperature (20°C), short reaction time and excess methyl iodide in order to avoid any 
decomposition of 66 in DMSO.108 Attempts under both higher temperatures (25-30°C) and longer reaction 
times did not afford any product, probably because of its low stability in such conditions. The synthesis was 
therefore controlled by TLC to stop it by adding cold CHCl3 as soon as reagent consumption was complete 
and collecting the obtained solid by filtration before other by-products could be formed. The resulting yield 
was comparable to the one reported in literature (80% vs. 77%). 
 
Reagents and conditions (yield): a) CH3I, DMSO, 20°C (80%). 
Scheme 3.19. Synthesis of 7-methyl-2’-deoxyguanosine iodide (66) 
3.1.7. Synthesis of 8-substituted inosines, guanosines and adenosines (69-80) 
With the aim to develop selective inhibitors of the purine nucleoside phosphorylase from Mycobacterium 
tuberculosis (MtPNP), a small library of 8-substituted purine ribonucleosides (69-80) was synthesized and 
assayed, owing to the evidence that some similar analogues had been reported to inhibit PNPs, such as the 
human enzyme (e.g. 8-aminoguanosine, Ki = 17 μM) and that from Plasmodium falciparum (e.g. 8-aryl 
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substituted inosines, Ki in the μM range). To date, no 8-oxy or 8-thio substituted nucleosides have been 
proposed as inhibitors of either human or microbial PNPs. 
Seven of the obtained molecules (70, 71, 74, 76, 77, 79 and 80) were screened by a newly developed LC-
ESI-MS/MS assay (Figure 3.5). 
 
Figure 3.5. 8-Substituted inosines, guanosines and adenosines (69-80) 
Following an approach similar to that adopted for the functionalization of position 6 of the purine ring, the 
synthetic strategy consisted of the substitution of H8 with a proper halide. Bromination either on the free 
nucleosides or on the protected ones was followed by treatment with the appropriate nucleophile and 
successive manipulations, when necessary (Scheme 3.20). 
 
Scheme 3.20. Retrosynthetic analysis of 8-substituted inosines, guanosines and adenosines 
To obtain 8-substituted inosines, the triacetylated nucleoside 51 was directly brominated by reaction with 
Br2 in a 10% aqueous Na2HPO4/1,4-dioxane mixture at moderately basic pH (Scheme 3.21). Since this 
electrophilic aromatic displacement was found to be exceptionally slow, numerous bromine additions were 
needed at fixed times and the reaction was stopped after 8 days at more than 90% conversion (roughly 
evaluated by TLC). Intermediate 81 was obtained after flash column chromatography in 83% yield. 
 
Reagents and conditions (yield): a) Br2, 10% aq. Na2HPO4, 1,4-dioxane (83%). 
Scheme 3.21. Synthesis of 8-bromo-2’,3’5’-tri-O-acetylinosine (81) 
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Most of the following reactions were performed according to similar procedures previously used for other 
functionalizations. 
Primary or secondary amines were used on 81 to synthesize 8-alkylamino- and 8-N,N-dialkylaminoinosines 
(70-74), respectively, in 1,4-dioxane at 80°C (Scheme 3.22). In contrast to previous similar reactions, time 
had to be extended (between 1 and 3 days) because of the slow reactivity of position 8 in purines, which is 
generally less prone to nucleophilic attacks than C2 and C6 and makes it necessary to select longer times, as 
well as higher reagent concentrations and temperatures. The very low yield of 72 can be attributed to the 
steric hindrance of i-PrNH2, in sharp contrast even to disubstituted (CH3)2NH2. Because of their low Rf in TLC 
on silica, all products were purified by reverse phase semi-preparative HPLC. 
 
Reagents and conditions (yield): a) R1R2NH, 1,4-dioxane, 80°C (18-87%). 
Scheme 3.22. Synthesis of 8-alkylamino- and 8-N,N-dialkylaminoinosines (70-74) 
Since the direct reaction of 81 with NH4OH gave no significant results, 8-aminoinosine (69) was obtained by 
prolonged hydrogenolysis of benzyl derivative 73 with HCOONH4 in MeOH (Scheme 3.23). Pd-C (10 mol %) 
was chosen as heterogeneous catalyst. Reflux was needed to speed up the reaction, which is slower for 
benzylamines than for the corresponding ethers. 
 
Reagents and conditions (yield): a) HCOONH4, 10 mol % Pd-C, MeOH, reflux (96%). 
Scheme 3.23. Synthesis of 8-aminoinosine (69) 
As for 8-alkoxyinosines, sodium alkoxydes in the corresponding refluxed alcohols were selected to both 
displace bromine and the three hydroxyl acetates of 81 (Scheme 3.24). Shorter reaction times were 
allowed by their higher nucleophilic strength. 76 and 77 were both purified by semi-preparative HPLC. 
 
Reagents and conditions (yield): a) Na, ROH, reflux (74-87%). 
Scheme 3.24. Synthesis of 8-alkoxyinoinosines (76 and 77) 
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As with 69 regarding NH4OH, direct hydroxylation of 81 with NaOH and other similar reagents proved to be 
unsuccessful. The introduction of an 8-oxo moiety was performed by treating 81 with NaOAc in glacial 
AcOH at 110-115°C (Scheme 3.25). The reaction proceeded through nucleophilic displacement of bromine 
by the acetate ion followed by hydrolysis of the resulting 2-imidazolyl-like acetate (see 6.1.2).154 Usual 
deprotection of 82 with either NaOMe in dry MeOH or 1.8 M NaOH afforded product 74 after 
neutralization and precipitation. 
 
Reagents and conditions (yield): a) NaOAc, AcOH, 110-125°C (93%); b) NaOMe, MeOH (50%) or 1.8 M 
NaOH (65%). 
Scheme 3.25. Synthesis of 8-oxoinosine (75) 
8-Bromoinosine (78) was prepared by deprotection of 81 with either NaOMe in MeOH or 1.0 M NaOH and 
subsequent precipitation by neutralization (Scheme 3.26). 
 
Reagents and conditions (yield): a) 1.0 M NaOH (64%) or NaOMe, MeOH (90%). 
Scheme 3.26. Synthesis of 8-bromoinosine (78) 
Unlike inosine, the two 8-bromo derivatives of guanosine and adenosine (79 and 80, respectively) could be 
obtained by direct halogenation with less strong reagents, owing to the greater electronic density 
delocalized on C8, which resulted in increased nucleophilicity and reactivity toward electrophiles (Scheme 
3.27). The presence of a free amino group at position 2 of guanosine further increases this behavior, 
allowing the use of NBS in H2O for the synthesis of 79 in 5 h at RT. A similar strategy was devised for 
adenosine, despite a lower yield and longer reaction times (4 days). This result led to the choice of bromine 
water to get 80 much more efficiently in terms of yield (83 vs. 58%) and time (2 days). In order to avoid any 
oxidation of the sugar moiety, pH of the reaction mixture had to be kept at 4.0 by using 0.5 M aqueous 
NaOAc as solvent. Either precipitation or recrystallization yielded the desired compound. 
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Reagents and conditions (yield): a) NBS, H2O (89%); b) NBS, H2O (58%) or bromine water, 0.5 M NaOAc,   
pH 4.0 (83%). 
Scheme 3.27. Synthesis of 8-bromoguanosine (79) and 8-bromoadenosine (80) 
3.2. Chemoenzymatic synthesis of nucleosides catalyzed by the PNP from Aeromonas 
hydrophila (AhPNP) 
3.2.1. Chemoenzymatic synthesis of 6-substituted purine ribonucleosides catalyzed by AhPNP (“in 
batch” reaction)109 
“One-pot, one-enzyme” transglycosylations were performed according to the following conditions (Scheme 
3.28): 50 mM aqueous K2HPO4 buffer containing 20% (v/v) glycerol, room temperature and pH 7.5. 1.15 IU 
of free AhPNP were added to catalyze both reactions and HI was neutralized by the buffer. Concentrations 
were 1 mM for both donor and acceptor (1:1 ratio). In agreement with the previous studies on AhPNP (see 
1.6.1)57, 63b, 7-methylguanosine iodide (65) was chosen as a convenient ribose source and the series of 
synthesized 6-substituted purines (1-24) as ribose acceptors. 
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Scheme 3.28. “One-pot, one-enzyme” transglycosylations catalyzed by AhPNP 
The use of glycerol was addressed by the need to preserve enzyme activity and to increase substrate 
solubility. In fact, this co-solvent is routinely used up to 60% for enzyme storage. It was also reported that 
glycerol can enhance the solubility of nucleoside analogues and nucleobases, which are scarcely soluble in 
polar solvents such as H2O.
104  
65 was selected because its phosphorolysis catalyzed by AhPNP is rapid, complete and irreversible, leading 
to 100% conversion to the α-D-ribose-1-phosphate intermediate under optimized conditions. In fact, the 
generated nucleobase, 7-methylguanine (83), is neither a substrate nor an inhibitor due to the presence of 
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the methyl group which prevents proton extraction from N7 and therefore the reverse reaction to the 
nucleoside iodide. In addition, the nucleobase is poorly soluble in aqueous media and its consequent 
precipitation shifts the phosphorolysis equilibrium to product formation. In this study, however, the goal 
was not to maximize the transglycosylation conversion in the view of a preparative synthesis but, under the 
same “standard” conditions, to assay the substrate specificity of AhPNP toward a collection of substituted 
purines. 
In this frame, aliquots (200 μL) of transglycosylation mixtures were withdrawn at fixed times (0’, 10’, 30’, 1 
h, 3 h, 6 h and 24 h), centrifuged and subsequently analyzed by HPLC. All peaks identities were assigned by 
comparison of their tR with those of pure references, either commercially available or synthesized as 
previously described (see 3.1.3). Analyses were carried out in duplicate. 
Base conversion was calculated according to the following equation: 
Conversion % = 
nucleoside area
nucleoside area + base area 
 · 100 
Conversions at 6 h were chosen as reference values to determine the reaction progress (Table 3.1). 
From the collected experimental data, it clearly appears that transglycosylation equilibria are shifted to 
either the base or the corresponding nucleoside to a different extent, depending on the nature of the 6-
substituent. Five observations can be drawn: 
 twenty-three out of twenty-four 6-monosubstituted purine nucleobases are recognized as substrates 
by the enzyme; 
 within the whole series, the only exception is N6,N6-bis-hydroxyethyladenine (10) (0% conversion, 
even when the reaction was carried out for a prolonged time up to 24 h), probably because the bulky 
and very polar side chains of this compound might be not compatible with the recognition pattern of 
the enzyme; 
 in the adenine series, disubstitution on N6 results detrimental for the recognition by AhPNP, based on 
the decrease in conversion between 2 and 9 (46 vs. 29%) and 8 and 10 (47 vs. 0%); 
 if the base is monosubstituted, bulky and polar groups appear, however, quite well tolerated (4-8, 
14-16 and 21 span from 38 to 65% conversion); 
 the comparison between 23 and 24 (20 and 18% conversion) suggests a very poor influence of the 
electronic properties associated to the 6-substituent on the transglycosylation extent. 
Generally, these results confirm the broad substrate specificity of AhPNP (see 1.6.1)63b, which can thus be 
exploited for preparative applications. 
Structural and kinetic analyses, which are out of the scope of this Thesis, would be needed for a deeper and 
more rigorous insight into structural requirements imposed on substrates by the active site of the enzyme, 
specifically concerning the 6-substitution pattern. These studies will need the available structure of the 
enzyme or, alternatively, to build up an homology model based on an enzyme of the same class (high-MM 
PNPs). Indeed, many studies have been and are still being carried out on the PNP from Escherichia coli 
(EcPNP), which represents the model enzyme for that group and shows a high identity degree at 
aminoacidic level (> 80%) with AhPNP (Figure 3.6). 
In particular, AhPNP conserves the same four residues involved in the catalytic mechanism of E. coli (His4, 
Asp204, Arg43 and Arg217).
12a 
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Base 
(acceptor) 
Nucleoside 
(product) 
 
X 
   
1 27 NH2
2 28 NHCH3
3 29 NHCH2CH3
4 30 NHCH(CH3)2
5 31 NHCH2CH2CH2CH3
6 32 NHcyclohexyl 
7 33 NHCH2CH2Ph
8 34 NHCH2CH2OH 
9 35 N(CH3)2
10 36 N(CH2CH2OH)2
  
11 37 OH 
12 38 OCH3
13 39 OCH2CH3
14 40 OCH(CH3)2
15 41 OCH2CH2CH2CH3
16 42 OCH2CH2Ph
  
17 43 SH 
18 44 SCH3
19 45 SCH2CH3
20 46 SCH(CH3)2
21 47 SCH2CH2CH2CH3
22 48 SCH2CH2Ph
  
23 49 Cl 
  
24 50 CH3
   
AAAAAAAAAAAA  
Table 3.1. Synthesis of 6-substituted ribonucleosides catalyzed by AhPNP and base conversion at 6 h (%) 
 
Figure 3.6. Sequence alignment of AhPNP and EcPNP 
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3.2.2. Chemoenzymatic synthesis of 6-substituted purine ribonucleosides catalyzed by AhPNP-IMER 
(“in flow” reaction)110 
3.2.2.1. Covalent immobilization of AhPNP and IMER preparation 
To develop an “in continuum” transglycosylation process which might combine biotransformation, reaction 
monitoring and product isolation, a few reactions described above (see 3.2.1)109 were transferred from 
batch into a flow system. To this aim, the enzyme was immobilized in a pre-packed stainless steel column 
(50 mm x 4.6 mm) to give an Immobilized Enzyme Reactor (IMER) that was connected to an HPLC apparatus 
for on-line monitoring and purification of the reaction. 
Covalent immobilization was carried out in a column containing aminopropylsilica particles (5 μm, 100 Å) by 
following the protocol previously used to bind the same enzyme on the inner surface of a fused silica Open 
Tubular Capillary (OTC) (Scheme 3.29, see 1.6.2).102 
 
Scheme 3.29. Covalent immobilization of AhPNP on aminopropylsilica particles 
First, the aminopropylsilica stationary phase was introduced into a HPLC system and flushed with a 10% 
(v/v) glutaraldehyde solution in 50 mM K2HPO4 (pH 7.5), forming the first transient imine bond. A 2 mg·mL
-1 
AhPNP solution was then recirculated through the whole system overnight at 20°C, in order to allow the 
superficial amino groups on the enzyme to react with the aldehyde. Lys residues were mostly involved in 
this interaction with the aldehyde groups provided by the linker. Since imines are prone to hydrolysis, they 
were reduced in the final step with a 0.1 M NaBH3CN solution to form stable covalent amine bonds, able to 
resist hydrolysis.111 
The amount of immobilized catalyst was calculated by the Bradford assay, that is by measuring the 
difference in UV absorbance of the enzyme solution between the beginning and the end of the 
immobilization process.112 Roughly, 25 mg of AhPNP were successfully immobilized, corresponding to 53% 
yield. It is important to point out that this satisfactory result was likely due to the higher active surface area 
of the packed silica bed with respect to the inner surface of the OT capillary used before, which had 
allowed the immobilization of 30 μg (10% yield). 
The AhPNP-IMER is represented in Figure 3.7. 
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Figure 3.
3.2.2.2. Activity and stability of AhPNP
The standard activity assay relies on 
hypoxanthine (11). This test was carried out periodically on the 
bioreactor over time. Activity and stability, the latter calculated as residual activity with respect to the 
initial one, were assessed from the following equation:
Conversion 
Stability was measured weekly, demonstrating that the IMER retained its initial activity 
reactions in 10 months. Whenever not in use, 
7.5) at 4°C. 
3.2.2.3. Analytical apparatus and optimization of 
From a general viewpoint, the analytical apparatus containing the 
previously reported one (see 1.6.2
contained the IMER and the second one an analytical HPLC column for
were interfaced by a six-port switching valve
from the bioreactor to the HPLC column.
            
               
Figure 3.8. IMER-based system (analytical apparatus)
2015, 357, 2520-2528)110 
The system can adopt two different configuration
switching valve (V). As V is in position
reaction 
mixture
AhPNPpump 1
Position b 
Position a
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7. AhPNP-IMER (5 μm, 100 Å, 50 mm x 4 mm) 
-IMER 
the measurement of the phosphorolysis of inosine 
AhPNP-IMER to evaluate the 
 
% = 
product area
product area + substrate area
 · 100 
the AhPNP-IMER was stored in 100 mM K
the reaction conditions 
AhPNP-IMER was set up 
)102, composed of two coupled systems (Figure 
 reaction monitoring
 (V) containing a 5 μL loop in order to transfer 
 
 (Adapted with permission from 
s depending on the position (
 a, the reaction mixture is recirculated continuously through the IMER 
analytical 
column UV 
detector
5 µL
-IMER
pump 2
mobile 
phase
System 1  
V
 
(37) to 
stability of the 
for more than 50 
2HPO4 buffer (pH 
by modifying the 
3.8). The first one 
. The systems 
analytes directly 
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a or b) of the six-port 
waste
System 2  
Chapter 3 ǀ PNPs AS BIOCATALYSTS AND PHARMACOLOGICAL TARGETS 
 
 
54 
to allow the reaction to progress. At fixed times, the valve is automatically switched to position b and an 
aliquot of the mixture is diverted to the analytical apparatus for on-line monitoring, allowing an assessment 
of the time necessary to reach the equilibrium. This value is crucial for preparative purposes, as purification 
is performed once the highest conversion has been achieved. The 5 μL aliquot is loaded in the loop and 
then onto the head of the analytical HPLC column, where substrates (nucleoside donor and purine 
acceptor) and products (donor conjugated nucleobase and final ribonucleoside) can be separated and 
identified at 260 nm. 
To optimize the reaction conditions, a “two-level, five-factor” fractional factorial design was performed by 
using the synthesis of adenosine (27) as model reaction (Scheme 3.30). Conversion was 78%. 
 
Scheme 3.30. Synthesis of adenosine (27) by AhPNP-catalyzed transglycosylation  
Five factors, whose values were selected on the basis of theoretical considerations and/or preliminary 
experiments, were taken into consideration: 
 inosine (37)/adenine (1) ratio (x1); 
 K2HPO4 buffer concentration (x2); 
 temperature (x3); 
 flow rate (x4); 
 pH (x5). 
Three parameters were chosen as responses: 
 phosphorolysis % (y1); 
 transglycosylation % (y2); 
 reaction time (y3). 
The following linear equation was elaborated to fit the mathematical model: 
y1/2/3 = b0 + b1x1 + b2x2 + b3x3 + b4x4 + b5x5 
All regression coefficients were calculated using Matlab® 5.2 (The Math Works Inc., Natrick Ma, US). 
Concerning the three responses (Figure 3.9): 
 the highest phosphorolysis percentage (y1) was obtained with the lowest donor/base ratio tested 
(1:1.5 mM) and the highest co-substrate concentration (100 mM K2HPO4 buffer). This behavior is 
justified by the fact that a high phosphate concentration shifts the phosphorolysis equilibrium to the 
formation of α-D-ribose-1-phosphate; 
 on the other hand, opposite conditions (donor/base ratio 2:1 and 10 mM K2HPO4 buffer) produced 
the highest transglycosylation percentage (y2). Since the phosphate ion is a co-substrate in the 
phosphorolysis reaction and a co-product in the transglycosylation step, a lower buffer concentration 
and a higher donor/base ratio synergistically enhance the equilibrium toward product formation; 
 in each reaction set, the equilibrium was reached as soon as the entire volume of the reaction 
mixture was pumped through the IMER. Any further investigation of the reaction time (y3) was 
therefore dropped. 
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 positive effect      negative effect 
Figure 3.9. Fractional factorial design for the AhPNP-IMER 
As a result, the flow synthesis of 6-substituted ribonucleosides was performed with a 2:1 donor/acceptor 
ratio (10:5 mM) and in 10 mM K2HPO4 buffer as solvent. Other less significant factors were set to enhance 
substrates solubility (37°C), reduce reaction time (0.5 mL·min-1) and preserve long term IMER stability (pH 
7.5). Nevertheless, H2O was found to hardly solubilize purines, which often require the use of co-solvents. 
As reported, DMSO and glycerol are compatible with AhPNP, at least at low concentrations, typically below 
10 or 20% (v/v), respectively.102 DMSO was preferred due to its higher dissolving capacities and added in 
variable percentages depending on the nature of the nucleobase. 
3.2.2.4. Enzymatic synthesis, on-line monitoring and purification of 6-substituted purine ribonucleosides 
First of all, a series of five 6-substituted purine ribonucleosides (31, 32, 34, 49 and 58) were synthesized on 
analytical scale in the conditions described below (Table 3.2). Each reaction mixture loaded in the IMER 
system contained inosine (37) as ribose donor and the appropriate nucleobase (5, 6, 8, 23 or 26) in K2HPO4 
buffer (pH 7.5) with a variable amount of DMSO (0-7.5% (v/v)). 
 
X 
X 
X 
Y 
Nucleobase 
(mM) 
 
Nucleoside 
Volume 
(mL) 
DMSO 
(%) 
Conversion 
(%) 
Time 
(min)a) 
Yield 
(mg)b) 
         
NHCH2CH2CH2CH3 H 2.5 (5) 31 10 7.5 77 20 5.9 
NHCyclohexyl H 2.5 (6) 32 10 0 87 20 7.5 
NHCH2CH2OH H 5.0 (8) 34 5 5.0 81 10 6.1 
Cl H 5.0 (23) 49 5 5.0 52 30 3.8 
OCH3 NH2 5.0 (26) 58 5 0 89 10 6.6 
         
 
a) Time required to reach the equilibrium 
b) Data referred to the semi-preparative synthesis 
Table 3.2. Synthesis of 6-substituted purine ribonucleosides catalyzed by the AhPNP-IMER 
0 1 2 3 4 5 6 7 8 9 10
Molar ratio donor/base
Phosphate (mM)
Temperarure (°C)
Flow rate (mL·min-1)
pH
0 1 2 3 4 5 6 7 8 9 10
PHOSPHOROLYSIS GLYCOSYLATION 
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The choice of 37 as D-ribose donor
substrate of AhPNP, but also by its relatively good solubility in aqueous media. Furthermore, in contrast 
with 7-methylguanine (83) generated by 7
37 is more soluble in H2O. Substrate/product precipitation 
flow process. 
Each reaction mixture was pumped 
depending on the nature of the nucleobase substituents and ranging from 10 to 30’.
chromatograms related to the synthesis of 
arrows indicate the start of each run acquired after switching the 6
the peak area of 49 can be observed, with the highest conversion reached after only 30’.
  
Figure 3.10. Synthesis of 49 by transglycosylation of 
permission from Adv. Synth. Catal.
Conversions were calculated from the depletion of the purine base and the formation of the nucleoside 
according to the equation previously reported for batch reactions (see 
flow approach in terms of yield, reaction time, purif
batch synthesis can be drawn from the experimental data presented in 
for all nucleobases (77-89% with the only exception of 52% for 
Starting from the conditions optimized on analytical scale, the synthesis of ribonucleosides 
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 was addressed not only by the fact that it is an inexpensive natural 
-methylguanosine iodide (65), hypoxanthine
would be of course highly detrimental 
through the IMER until the equilibrium was reached, in a time 
49 at 10’, 30’, 60’ and 90’ is reported in 
-way valve. The progressive increase of 
 
23 and 37 catalyzed by AhPNP
 2015, 357, 2520-2528)110 
3.2.1).109 The
ication and, generally speaking, 
Table 3.2. T
23) was achieved after only 30’
-preparative scale (Figure 3.11). The on-line monitoring 
atus very similar to the one already employed, with two exceptions: 
-preparative HPLC column in System 2. 
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Reaction time (min)
49
23
 
 (11) released from 
for the 
 The sequence of four 
Figure 3.10, where 
 
 
-IMER (Adapted with 
 advantage of such a 
simplification over the 
he highest conversion 
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31, 32, 34, 49 
and purification 
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Figure 3.11. IMER-based system (semi
Catal. 2015, 357, 2520-2528)110 
As V and Y are in position a and c
recirculated through the IMER; meanwhile, the column is
can be loaded into the loop (1.4 mL) 
completely automated procedure was repeated 
line sample transfer, to purify the desired product. All 
preparative HPLC column. The aliquot corresponding to the product 
and characterized by 1H-NMR, 
chromatograms, 1H-NMR, 13C-NMR and Uv
the 1H-NMR spectrum of 32 are reported, as examples, in 
The five products were obtained in high purity and yields, corresponding to their analytical conversio
ranging between 52 and 89% (3.8-7.5 mg)
Among the assayed purines, 26 represents an interesting
(Nelarabine) is an anticancer drug currently used in therapy.
Figure 3.12a. Semi-preparative c
2015, 357, 2520-2528)110 
reaction 
mixture
AhPNP-pump 1
Position b 
Position a
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-preparative apparatus) (Adapted with permission from 
, respectively, the two systems are disconnected and the reaction is 
 conditioning. Once again, portions of the mixture 
and transferred to the column as V switches to 
until the whole mixture was consumed
reaction mixtures were eluted through the semi
nucleoside was 
13C-NMR, MS and UV-Vis spectroscopy 
-Vis spectra, see 6.3). The semi-preparative chromatogram and 
Figures 3.12a and 3.12b. 
, as reported in Table 3.2. 
 substrate because its arabinosyl derivative 
113 
hromatogram of 32 (Adapted with permission from 
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Figure 3.12b. 1H-NMR spectrum of 32 (CD3OD) (Adapted with permission from Adv. Synth. Catal. 2015, 357, 
2520-2528)110 
It must be pointed out that this work was stimulated by the previous phosphorolysis studies that suggested 
the possibility of synthesizing 6-substituted purine ribonucleosides by a AhPNP-catalyzed 
transglycosylation. Indeed, rather than being aimed at developing a preparative process to obtain the 
corresponding nucleosides, their goal had been the preliminary definition of substrate specificity for a 
scaled up process based on that information. In addition, although a direct comparison between a batch 
and a flow system is not correct because of the different experimental conditions (enzyme amount, ribose 
donor, …), the advantages of the AhPNP-IMER in terms of catalyst reuse, stability, reduced times and 
circumvention of downstream processing are undeniable. 
3.2.3. Chemoenzymatic synthesis of 6-substituted purine 2’-deoxyribo- and arabinonucleosides 
catalyzed by AhPNP 
Starting from the encouraging results obtained in the chemoenzymatic synthesis of ribonucleosides by a 
“one pot, one enzyme” approach, both under batch and flow conditions (see 3.2.1109 and 3.2.2110), the 
synthesis of other analogues via the same strategy was explored. In this case, however, the focus was 
shifted from base-modified ribonucleosides to sugar-modified purine nucleosides. Indeed, the high 
promiscuity of AhPNP had emerged also toward 2’-deoxyribose and, to a lesser extent, arabinose.10c 
2’-Deoxyribo- and arabinonucleosides can be found among relevant molecules endowed with a wide array 
of pharmacological activities (Figure 3.13). In this respect, the chance to access these molecules through 
innovative and straightforward synthetic routes makes the chemoenzymatic procedures here developed of 
a wide applicative interest. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
ppm
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Figure 3.13. Examples of pharmacologically active 2’-deoxyribo- and arabinonucleoside analogues 
To obtain a simple and straightforward “one-enzyme” process, 7-methyl-2’-deoxyguanosine and 7-
methylarabinosylguanine iodides (66 and 67, respectively) were envisaged, and thus prepared and used, as 
convenient sugar donors, according to the previously described strategy. 
Before running the enzymatic transglycosylations with 66 and 67, their stability was assessed (Figures 3.14a 
and 3.14b). 
 
 
Figure 3.14. Comparison of 13C-NMR spectra of 66 in DMSO-d6 (0.05 M): a) after 2 h; b) after 4 h. 
After 48 h, no decomposition/hydrolysis products were detected in batch. However, NMR analysis clearly 
highlighted the instability of salt 66 in DMSO solution (0.05 M in DMSO-d6) at 25°C. In contrast to 67, 66 
0102030405060708090100110120130140150160170
ppm
a) 
b) 
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apparently undergoes a rapid partial decomposition generating new carbon signals after only 4 h (Figure 
3.14b) and confirming the validity of the precautions taken during its synthesis. The 13C-NMR spectrum of 
66 was therefore registered within 2 h at 25°C, showing no sign of decomposition (Figure 3.14a). 
Transglycosylation reactions were carried out in agreement with the standard protocol (Table 3.3), at 25°C 
in 50 mM K2HPO4 buffer (pH 7.5) containing 20% (v/v) glycerol at 1 mM concentration. The nucleoside 
donor and the nucleobase acceptor were used in 1:1 molar ratio. Being accepted by AhPNP, adenine (1) 
was selected as acceptor to assess the feasibility of the approach. 
 
XX Nucleoside Donor conversion (%)a) Nucleoside formation (%)a) 
    
H 84 > 99 66 
OH 85 0 0 
    
 
a) Determined at 6 h 
Table 3.3. Synthesis of 84 and 85 by “one-pot, one-enzyme” transglycosylation catalyzed by AhPNP 
Reaction progress was monitored by HPLC and conversions were calculated from the sugar donor 
consumption and product formation according to the following equations: 
Phosphorolysis % = 
sugar donor area
iniaal sugar donor area + base area 
 · f ·100      f = 
IS area
iniaal IS area
 · 100 
Transglycosylaaon % = 
product area
product area + base area
 · 100 
A conversion factor f was calculated to assess the percentage of phosphorolysis, as the area of 7-
methylguanine could not be considered reliable due to its poor water solubility. Uracil (87) was added to 
the reaction mixture as internal standard for this purpose. 
Upon the total conversion of 66, the formation of 84 reached 66% at equilibrium. On the other hand, 
neither the phosphorolysis of 67 or the formation of 85 were detected (Figure 3.15). 
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Figure 3.15. Phosphorolysis of 66 and formation of 84 catalyzed by AhPNP 
Such preliminary results proved the feasibility of this method for the synthesis of 2’-deoxyadenosine (84), 
but opened the issue of the “lack of fit” between 7-methylarabinosylguanine iodide (67) and AhPNP. On 
one hand, this result appeared consistent with the moderate preference of the enzyme toward arabinosyl 
derivatives with respect to natural nucleosides.101 On the other hand, however, AhPNP was previously 
demonstrated to accept α-D-arabinose-1-phosphate as substrate in the synthesis of arabinosyladenine (85, 
Vidarabine), a known antiviral drug.10c In the latter case, the sugar phosphate was produced through the 
phosphorolysis of arabinosyluracil catalyzed by a uridine phosphorylase from Clostridium perfringens 
(CpUP) in a “two-enzyme, one-pot” reaction. This evidence suggests that, whereas α-D-arabinose-1-
phosphate is accepted as substrate, 7-methylarabinosylguanine is not phosphorolyzed by AhPNP. Further 
experiments are in progress. 
3.2.4. Chemoenzymatic synthesis of adenosine, 2’-deoxyadenosine and arabinosyladenine catalyzed 
by a CpUP-IMER coupled with a AhPNP-IMER (“in flow” reaction) 
3.2.4.1. Development, activity and stability of CpUP/AhPNP-IMER and CpUP-IMER 
Starting from the flow-based approach for the synthesis and the on-line purification of 6-substituted purine 
ribonucleosides by transglycosylations catalyzed by the AhPNP-IMER (see 3.2.2)110, the following step was 
to explore the development of a similar system to perform a bi-enzymatic reaction. This approach, which 
relies on the coupling of a pyrimidine nucleoside phosphorylase (PyNP) with a purine nucleoside 
phosphorylase (PNP), is the most frequently exploited scheme, where the pyrimidine nucleoside acts as the 
donor of α-D-pentofuranose-1-phosphate and the purine base as the acceptor.32e In this case, the focus was 
shifted toward the “one-pot, two-enzyme” synthesis of sugar-modified adenine nucleosides, including 
arabinosyladenine (Vidarabine, 85), an antiviral drug previously synthesized by the same couple of enzymes 
but in batch conditions.10c 
Since the co-immobilization of both enzymes on the same particle-based support resulted in excessive 
back-pressures (data not shown), it was decided to explore the use of independent stationary phases for 
each catalyst to be connected in series. An advantage of this set-up would be the availability of single 
bioreactors that could be used independently, either for a “one-enzyme” synthesis or in a different 
sequence. However, the use of two particle bioreactors in series can be critical due to the overall back-
pressure of the system. Therefore, an aminopropylsilica monolithic support was selected for CpUP to 
maintain the same immobilization chemistry used for AhPNP (see 3.2.2.1).114 CpUP (20 mg) was submitted 
to the immobilization reaction affording a good yield (13 mg, 66%). 
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24
C
o
n
ve
rs
io
n
 (
%
)
Reaction time (h)
66
84
Chapter 3 ǀ PNPs AS BIOCATALYSTS AND PHARMACOLOGICAL TARGETS 
 
 
62 
When not in use, the CpUP-IMER was stored at 4 °C in 100 mM K2HPO4 buffer (pH 7.5). It was also 
completely stable upon 25 reactions in one month. 
3.2.4.2. CpUP-IMER/AhPNP-IMER apparatus and optimization of the reaction conditions 
The two IMERs containing CpUP and AhPNP were connected in series in the usual bidimensional 
chromatographic apparatus (Figure 3.16). 
      
                   
Figure 3.16. Bi-enzymatic IMER-based system (analytical apparatus) 
As usual, the biotransformation occurs when the reagents are continuously recirculated through the 
bioreactors. Conversion is monitored on-line by automatically sampling, at fixed times, the reaction mixture 
that is analyzed by HPLC. 
The system was characterized by using the synthesis of 2’-deoxyadenosine (84) as the model 
transglycosylation reaction (Scheme 3.31). 
 
Scheme 3.31. Synthesis of 2’-deoxyadenosine (84) by transglycosylation catalyzed by the CpUP-
IMER/AhPNP-IMER system 
A fractional factorial experimental design was performed to optimize the experimental conditions and the 
same five factors focused upon for the system containing the AhPNP-IMER (see 3.2.2.3)110 were included 
again: 
 2’-deoxyuridine (86)/adenine(1) ratio (x1); 
 K2HPO4 buffer concentration (x2); 
 temperature (x3); 
 flow rate (x4); 
 pH (x5)). 
As before, responses were: 
 phosphorolysis % (y1); 
 transglycosylation % (y2); 
 reaction time (y3). 
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Following the same linear regression model previously assumed to represent the system, all responses 
were elaborated, clearly showing similar requirements (Figure 3.17): 
 values associated with both phosphorolysis (y1) and transglycosylation (y2) were essentially in 
agreement with the results for the AhPNP-IMER. The two key factors were indeed donor/base ratio 
and K2HPO4 buffer concentration; 
 a major deviation from the previous model was the role of flow rate, which resulted beneficial for 
the first time in terms of transglycosylation percentage (y2) and able to significantly reduce 
equilibrium time (y3). 
As with the mono-enzymatic apparatus, temperature and pH were set at values compatible with the 
activity and stability of AhPNP and CpUP. 
 
                  
Figure 3.17. Fractional factorial design for the CpUP-IMER/AhPNP-IMER system 
3.2.4.3. Synthesis of 2’-deoxyadenosine, adenosine and arabinosyladenine 
The optimized conditions (5 mM 1, 2:1 donor/acceptor ratio, 10 mM (for 86 and 88) or 2 mM (for 89) 
K2HPO4 buffer (pH 7.25), 37°C, flow rate 0.5 mL·min
-1) were applied to the synthesis of 2’-deoxyadenosine 
(84), adenosine (27) and arabinosyladenine (85) (Figure 3.18). Therefore, 2’-deoxyuridine (86), uridine (88) 
and arabinosyluracil (89), respectively, were chosen as sugar donors for the formation of the corresponding 
α-D-pentofuranose-1-phosphate by the CpUP-IMER-catalyzed phosphorylation, whereas adenine (1) was 
selected as the purine acceptor for the glycosylation catalyzed by the AhPNP-IMER. The lower 
concentration used for 89 was addressed by the poor solubility of the corresponding product 85 (   ̴2 mM) 
under experimental conditions. 
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Figure 3.18. Synthesis of 84, 27 and 85 catalyzed by the CpUP-IMER/AhPNP-IMER system 
As an example, the sequential chromatogram for the synthesis of 84 is reported in Figure 3.19. By 
comparing the reaction profile after 30’ and 90’, it is possible to notice the progressive formation of the 
target nucleoside 84 and of 87, as well as the decrease of 86 and 1. 
 
Figure 3.19. Sequential chromatogram for the synthesis of 84 
Moreover, an additional peak between 87 and 89 with a constant area over time was detected. Considering 
its retention time, it was roughly attributed to hypoxanthine (11). In fact, this nucleobase might be a 
contaminant deriving from the phosphorolysis of inosine (37), periodically carried out to test the activity 
and stability of the AhPNP-IMER. 
Transglycosylation percentages were calculated as with the AhPNP-IMER system. While the synthesis of 84 
and 27 reached a plateau corresponding to 95 and 90% conversion (55 and 50% phosphorolysis), 
respectively, such a trend did not occur in the case of 85. In fact, after 5 h, the highest obtained conversion 
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was approximately 20%. These transglycosylation results reflect the substrate specificity of 
(68 IU·mg-1), 88 (60 IU·mg-1) and 89 
deoxyribose-1-phosphate with respect to their arabinose counterpart for the subsequent 
transglycosylation.10c For this reason, the synthesis of 
chromatographic profile was not as expected (
  
Figure 3.20. Chromatograms for the synthesis of 
85: arabinosyladenine, 87: uracyl, 
unknown peak)) 
In fact, two additional peaks with variable area over time (
expected ones. As the area of A decreased while the one of 
method was transferred to an LC
hypoxanthine (11), whereas B to arabinosylhypoxanthine (
might occur involving 11 as a competitive 
same reaction in batch by using soluble 
agreement with this hypothesis, since both the formation of 
It was speculated that 11 might exclusively derive from the standard activity assay based on the 
phosphorolysis of inosine (27), which was carried out at a very high substrate concentration. Therefore, a 
contamination of the bioreactor could not be ruled out. It could no
reaction would happen also in the case of
conversion in less than 2 h and were stopped immediately after.
This study has paved the way to the transition from an 
meso-scale platform for the preparative synthesis of nucleosides, as well as to the further implementation 
of such a system with more bioreactors to perform multi
3.3. Evaluation of the inhibitory activity of 8
the PNP from Mycobacterium tuberculosis
3.3.1. LC-ESI-MS/MS enzymatic assay
One of the goals of the research reported in 
inhibitors of the purine nucleoside phosphorylase from 
new medium/high throughput LC-
number of 8-substituted purine ribonucleos
87 
89 
1
A 
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(3 IU·mg-1), which reveals the higher availability of 
85 was run overnight (24 h). 
Figure 3.20). 
   
85 at 60’, 180’ and 300’ (89: arabinosyluracyl, 
A: hypoxanthine (1ST unknown peak), B: arabinosylhypoxanthine (2
A and B) were revealed besides the four 
B increased proportionally, the analytical 
-UV-ESI-MS/MS apparatus and A was unequivocally attributed to 
90), suggesting that a parallel transglycosylation 
acceptor. On this ground, the results obtained by running the 
CpUP and AhPNP under the same experimental conditions were in 
85 and 90 were observed.
t be excluded that the same competitive 
 27 and 84, although both reactions reached the highest 
 
analytical scale device to the development of a 
-enzymatic reactions. 
-substituted purine ribonucleosides against 
 (MtPNP)115 
 
this Thesis was to prepare modified nucleosides as
Mycobacterium tuberculosis
ESI-MS/MS method was set up to assess the inhibition activity of 
ides (70, 71, 74, 76, 77, 79 and 80, see 
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A 
 
CpUP toward 86 
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Surprisingly, the 
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bacterial PNPs (AhPNP and MtPNP) as well as the human one (
model enzyme, whereas assays with 
compounds might show different selectivities in the
role of PNPs in the in vivo synthesis of nucleosides
target to control certain bacterial or parasitic 
inhibitors of PNPs, i.e. Acyclovir (91
first one being able to inhibit both Hs
The inhibitory activity was assessed
routinely used to test the activity of PNPs, as previously discussed (
37
N
N
O
N
O
HO OH
HO
Scheme 
The inhibition assay was performed in a 96
an overall time of about 15 min·plate
Figure 3.21. Schetch of the LC-ESI
Acta 2016, 943, 89-97)115 
A mixture of 37, K2HPO4 buffer and 
solutions in the 96-well plate, and after the addition of the enzyme (
was heated at 37°C in a water-shaking bath for the required time.
of CH3CN (1:20) to inactivate the enzyme
solution was diluted again for LC separation and ESI
3.3.2. Kinetic parameters of Ah, Hs
The Michaelis-Menten curve describes the velocity
product produced per minute, also
substrate ([S]) in a range between 0.1
ǀ PNPs AS BIOCATALYSTS AND PHARMACOLOGICAL TARGETS
66 
HsPNP). Specifically, 
HsPNP and MtPNP were carried out to determine if
 inhibition of these enzymes. Indeed, based on the key 
, they have been identified as a potential
infections.70, 98, 116 In the validation of the method, two known 
) and Formycin A (92), were chosen as reference compounds
PNP and MtPNP). 
 through the phosphorolysis assay of inosine (37
Scheme 3.32, see 
MtPNP
P i N
N
O
N
H
11
+
NH
O
HO OH
HO
OPO3
2-
3.32. Phosphorolysis of 37 catalyzed by MtPNP 
-well plate (volume = 0.5 mL, enzyme < 0.2 
-1 for sample processing and 2 min·sample-1 for analysis 
-MS/MS analytical apparatus (Adapted with permission from 
the selected analyte was prepared by pipetting the corresponding 
AhPNP, HsPNP 
 Each mixture was quenched 
. Internal standards (ISs) were added as well, then the obtained 
-MS/MS quantification. 
 and MtPNP 
 of an enzymatic reaction (v, µmol
 called IU = international unit) under increasing
 and 10 times the expected KM value (0.1KM < K
 
AhPNP was used as the 
 the selected 
 therapeutic 
 (only the 
) to hypoxanthine (11), 
3.2.2.2). 
NH
 
µg·well-1, 37°C) with 
(Figure 3.21). 
 
Anal. Chim. 
or MtPNP), the reaction 
by addition 
·min-1 = µmoles of 
 concentrations of 
M < 10KM). 
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The following equation describes the classic Michaelis-Menten model: 
v = 
Vmax S
KM + S
      Vmax = kcat E0 
KM is the substrate concentration at which the reaction rate is ½ Vmax (maximum reaction rate), while kcat is 
defined as the maximum number of substrate molecules that an enzyme can convert to product per 
catalytic site in the unit of time and can be calculated as kcat = Vmax·[E]0
-1 ([E]0 = enzyme concentration). 
As already mentioned, the phosphorolysis reaction requires inorganic phosphate (Pi) and inosine (37). The 
source of Pi is the assay buffer (NH4H2PO4, pH 7.5). The kinetic constants (KM, Vmax and kcat) were 
determined using increasing concentrations of 37 (0.01-20 mM) under a saturating concentration of Pi and 
vice versa (1 µM-20 mM Pi). The resulting kinetic constants are reported in Table 3.4. The kinetic profile of 
AhPNP is depicted in Figure 3.22. 
 
a) Values reported in literature 
 Table 3.4. Kinetic parameters (KM, Vmax and kcat) of 37 and Pi for AhPNP, HsPNP and MtPNP 
 
 Figure 3.22. Kinetic profile of AhPNP with respect to 37 and Pi  
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Constant 
Substrate 
 Inosine (37)  Pi 
value standard error value standard error 
      
 
 
AhPNP 
KM (mM) 1.30 [1.8]
a) 7·10-2 0.19 2·10-2 
Vmax (μmol·min
-1) 42 1 49.3 0.9 
Kcat (s
-1) 3.73·105 9·103 4.43·105 8·103 
Kcat/KM (s
-1·M-1) 288 9 2289 8 
 
 
HsPNP 
KM (mM) 0.15 [0.133]a) 2·10-2 0.66 5·10-2 
Vmax (μmol·min
-1) 0.0022 3·10-4 0.0123 3·10-4 
Kcat (s
-1) 14 2 76 2 
Kcat/KM (s
-1·M-1) 0.09 2·10-3 0.11 2·10-3 
 
 
MtPNP 
KM (mM) 0.06 [0.04]a) 9·10-3 0.15 [0.583]a) 2·10-2 
Vmax (μmol·min
-1) 0.00908 9·10-5 0.0026 1·10-4 
Kcat (s
-1) 15.7 [5.4]a) 0.2 4.5 [6.9]a) 0.2 
Kcat/KM (s
-1·M-1) 0.24 2·10-4 0.03 2·10-4 
      
kjhh  
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The obtained KM for AhPNP with respect to 37 is in agreement with literature.
102 Indeed, the reported KM 
value is 1.8 ± 0.5 mM at 25 °C, therefore a slight difference in the KM at 37 °C can be expected. The same 
consideration could be done with HsPNP for which the KM value measured by de Moraes et al. (0.133 ± 0.15 
mM) was considered as a comparison, since it was assessed by using the same enzymatic preparation.87e 
Slight differences of MtPNP kinetic values reported in literature with respect to the obtained data might be 
ascribed to the different experimental conditions (temperature and buffer).75b 
3.3.3. Inhibition screening assays 
A set of nucleoside-based structures (70, 71, 74, 76, 77, 79, 80, 91 and 92) were assayed as potential 
inhibitors of MtPNP (Figure 3.23). Only seven out of the overall pool of the synthesized 8-substituted 
inosines, guanosines and adenosines (see 3.1.7) were selected for this purpose. Acyclovir (91) and Formycin 
A (92) were used as negative and positive controls, being known inhibitors of trimeric PNPs (such as HsPNP 
and MtPNP) and hexameric ones, respectively. 
 
Figure 3.23. Structures of compounds tested as inhibitors (70-80, 91 and 92) 
The phosphorolysis reaction was performed by using a concentration of 37 close to the KM value of the 
specific enzyme under a saturating concentration of Pi, in the presence of a defined amount of inhibitor (1-
0.5 mM). 
From the inspection of Figure 3.24 (data about AhPNP are not reported), it can be noted that only a few 
compounds showed an activity toward HsPNP and MtPNP, namely 70 and 79, besides the expected 
inhibition exerted by 91. 
 
Figure 3.24. Screening of potential inhibitors of HsPNP and MtPNP 
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These compounds (91, 70 and 79), which mildly inhibited the target enzymes, were selected for the 
assessment of their Ki values. The assay was performed at a fixed substrate concentration close to the KM 
value for each enzyme, and by increasing the concentration of the inhibitor. All other conditions were the 
same as in the enzymatic assay. The results, reported in Table 3.5, were compared with the activity in 
absence of inhibitor (100% activity). 
 
Compound 
HsPNP MtPNP 
-Log(Ki) SD -Log(Ki) SD 
     
91 3.186 0.666 4.511 0.210 
70 2.932 1.172 < 3a) - 
79 < 3a) - < 3a) - 
     
 
a) Not calculated in the selected concentration range (0.1-1 mM) 
Table 3.5. Ki values of 91, 70 and 79 for HsPNP and MtPNP 
From these experimental data, the following observations can be drawn: 
 the Ki value of 91 for HsPNP, evaluated by Tuttle and Krenitsky et al. through a spectrophotometric 
assay, was found to be 100 µM117, while the determined one was   ̴ 600. 
 a generally low potency in the studied concentration range was assessed not only for 70 (Ki = 1.1 mM 
for HsPNP) but also for 79, whose Ki was not even computable for both enzymes, as for 70 with 
respect to MtPNP. 
Such preliminary results might be correlated with the same structural impediments which do not allow 
AhPNP to phosphorolyze 8-substituted ribonucleosides (see 1.4.581,82 and 1.6.163b), since these molecules 
are likely to adopt a syn conformation due to steric constraints at C8. As already reported, this probably 
leads to a lack of recognition by the enzyme. 
In order to verify this hypothesis, the empirical method reported by Nair and Young (see 1.4.5)85, which 
correlates the conformational preference of purine nucleosides to the extent of the 13C NMR chemical shift 
difference between C2’ and C3’, was applied to the tested 8-substituted purine nucleosides (Table 3.6). 
Compound δC2’ δC3’ ΔδC
2’
-C
3’ a) 
    
70 71.3 71.7 0.4 
71 71.0 71.2 0.2 
74 71.4 71.1 0.3 
76 71.8 71.4 0.4 
77 71.7 71.2 0.5 
79 70.8 71.0 0.2 
80 71.6 71.3 0.3 
    
 
a) Reported as absolute values 
Table 3.6. Calculated ΔδC
2’
-C
3’ values for the tested 8-substituted ribonucleosides 
The 13C-NMR ΔδC
2’
-C
3’ values were found to be < 0.5 in all tested compounds, thus hinting a predominant syn 
conformation. These results suggest a relevant role of conformation in all the tested potential inhibitors, 
which may justify a lack of recognition by not only AhPNP (data not reported) but also at the one from M. 
tuberculosis. 
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Moreover, although the assayed compounds did not show a relevant inhibitory activity, it is worth pointing 
out that the developed method is reliable and depends upon on a straightforward and very rapid sample 
processing and analysis. 
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4 ǀ SYNTHESIS OF POTENTIAL LIGANDS OF THE 
HUMAN GPR17 RECEPTOR 
4.1. Role of GPR17 in neurodegenerative disorders 
4.1.1. Neurodegenerative disorders 
Many neurodegenerative disorders are closely linked to metabolic dysregulations of the central nervous 
system (CNS) caused by the deterioration and malfunction of myelinating cells.118 The myelin sheath is a 
thin fat layer concentrically convoluted around neuronal axons, whose function is to insulate them to 
ensure an effective signal transmission in a cell network by protecting its integrity.118, 119 Extracellular ATP 
and uracil nucleosides have been identified as signaling agents. G Protein-Coupled Receptors (GPCRs) play a 
relevant role in many stages of glial cells development.120 
Therefore, the demyelination of axons results in exposure toward permanent degeneration, as well as to a 
number of neurological diseases (multiple sclerosis, ischemia, amyotrophic lateral sclerosis (ALS), 
Alzheimer’s disease and miscellaneous psychiatric disorders such as schizophrenia, depression, autism, 
dyslexia and dipolar disorder). 
For all the reasons described above, remyelination processes may embody an original way to treat 
disorders of the CNS. Pharmacological treatments can be expected to restore the minimal conditions for 
myeline production by selectively targeting purinergic receptors (e.g. specific GPCRs).  
4.1.2. G Protein-Coupled Receptors (GPCRs) 
Being the leading group of transmembranal proteins encoded in the human genome, GPCRs represent 
important drug targets in medicinal chemistry. 
As of 2011, six receptors with medium to high resolution crystal structures have been studied with multiple 
small ligands (rhodopsin, β1 and β2 adrenergic receptors, adenosine A2A receptor, chemokine CXCR4 
receptor and dopamine D3 receptor). The first four GPCRs have been isolated in complex with both agonists 
and antagonists. This protein class is currently vital in drug discovery, as more than 70 new drugs affecting 
the metabolism of GPCRs have been commercialized in the last fifteen years, representing roughly 24% of 
all drugs reaching the market during this period.121 
Several common elements can be identified in the structures of GPCRs belonging to various organisms 
(Figure 4.1a). The core of each receptor is an almost perpendicular transmembrane domain (TMD) 
consisting of seven R-helices (TMs) arranged in a cylindrical fashion and tilted out of plane. Their outer 
surfaces are largely hydrophobic, confining all binding interactions to the side chains or the intra- and 
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extracellular domains. The C-terminal region usually resides in the cytosol, while the remaining amino end 
protrudes from the cellular surface. Ligands can bind by hydrogen bonds to either a deeply hydrophobic 
cavity or a specific domain, depending on structural features. G Protein likely interacts with extended 
intracellular loops 2 and 3 (ICL2 and ICL3) connecting TM3-TM4 and TM5-TM6, respectively, thus triggering 
signal transduction. 
       
Figure 4.1. GPCR receptors: a) general structure (residues interacting with the ligand, in this case 
norepinephrine, are highlighted) (Adapted with permission from Biochim. Biophys. Acta 2007, 1768, 794-
807)122; b) three major families (A, B and C) (Reprinted from J. Med. Chem. 2011, 54, 4283-4311)121 
The 390 known GPCRs in human organisms can be classified into three major families123 (Figure 4.1b): 
 family A (rhodopsin family or class I): the most populated and assorted group, especially concerning 
ligand typologies. Ligands are allocated in the top of the TMD bundle; 
 family B (secretin and adhesion families or class II): specific for peptide-based hormones (secretin 
subfamily) or mostly orphan receptors (adhesion subfamily). Ligand anchoring relies on the 
cooperation between the TMB pocket and a glycosylated N-terminal region;  
 family C (glutamate family or class III): specific for Glu and γ-aminobutyric acid (GABA). The binding 
site is located out of the TMD in a “Venus fly trap” N-terminal domain. They are sensitive to Ca2+ ions 
as well as to taste-active molecules. 
4.1.3. GPR17 as a potential target against neurodegeneration 
Among the GPCR receptors involved in myelin production, GPR17 holds a special position of interest in the 
eyes of medicinal chemists. Being considered orphan for many years, it has been recently matter of a 
deeper investigation.124 
The structure of the human GPR17 maintains all the common features of GPCRs, namely the seven 
transmembrane R-helices in the main domain, but its 3D structure has not been resolved in details yet, 
since its isolation has always eluded any effort. The spatial arrangement of GPR17 still remains largely 
unknown, therefore an aminoacidic sequence comparison with similar receptors is necessary to clarify it. In 
particular, human P2Y receptors (belonging to family A) show almost 48% sequence identity, especially with 
conserved motifs essential for ligand recognition and binding such as His-X-X-Arg/Lys in TM6 and Lys-Glu-X-
X-Leu in TM7.125 
The identification of both endogenous and novel synthetic ligands has proceeded through in silico analyses 
based on homology models.126 Experimental data generally suggest that GPR17 can interact with a variety 
of agonist and antagonist agents (Figure 4.2). 
a) 
b) 
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Figure 4.2. Examples of GPR17 agonists and antagonists 
GPR17 has been found to be responsive to agonists such as not only nucleotides and their adducts (UDP, 
UDP-glucose, UDP-galactose), but also radically different messengers, for example cysteinyl leukotrienes 
(LTE4, LTD4 and LTC4), oxysterols and a wide variety of molecules having quite diverse structures.127 This 
promiscuity largely depends on specific pathologies and physical conditions, as well as emergency 
situations and association with P2Y receptors.128 The extensive diversity in the structures of agonists and 
antagonists may also be justified by such a potential heterodimerization to adapt and enlarge the substrate 
pool. Among the antagonists, the antiplatelet drug Cangrelor (Kengreal® or Kengrexal®) and the 
antiasthmatic Montelukast (Singulair®) are worth mentioning. 
Since the late 2000s, research efforts have been focused on studying the involvement of GPR17 in neuronal 
myelination.119e, 129 It appears that the receptor exerts opposed functions depending on the specific stage, 
enhancing the process in the early steps and exerting a negative control in the following ones, up to total 
receptor silencing in the final maturation phase. 
Since nucleosides and leukotrienes are produced in massive concentrations during brain trauma, GPR17 
expression is highly probable. In such occasions, several receptor units are recruited in regions surrounding 
the damaged area.125b, 127b, 129a, 130  Medical observations confirm that myelin disturbance is indeed 
characterized by an abnormal activity of GPR17, generating a physiological block against cells which 
prevents the maturation toward tissue regeneration. Therefore, medical treatment with antagonists may 
reduce the extent of neurodegeneration. 
4.2. In silico screening and synthesis of potential GPR17 ligands 
4.2.1. In silico screening of potential GPR17 ligands 
As a first approach, a virtual screening was carried out through molecular docking to identify new ligands 
for GPR17 and to estimate their binding free energy. 
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This work was performed within 
Giovanna Speranza) and the Laboratory 
(Dr. Stefania Ceruti and Dr. Chiara Parravicini
Pharmacological and Biomolecular Sciences
Laboratory of Pharmaceutical Biocatalysis (Dr. Daniela Ubiali) and the Lab
Analysis (Prof. Enrica Calleri) at the Department of Drug Sciences of the University of Pavia
Two main constraints had to be faced:
 the absence of any structural information about the receptor
 the selection of the pool of candid
to serve as potential leads. 
The first issue was addressed by choosing a homology 
receptor is known to be phylogenetically related to GPR17 and, among the available GPCR structures, it 
shares the highest sequence identity 
its known structure in the Protein Data
complex of P2Y1 and its antagonist MRS2500 (
homology modelling procedures, t
homology model to simulate its general position in the binding pocket of GPR17 (
Figure 4.3. Homology model of the GPR17
The binding site of GPR17 was identified by an automatic tool and
by the reference ligand 93, resulted to be quite enlarged, spanning across both extracel
transmembrane domains. In terms of the most significant binding residues, the two phosphate groups were 
found to form electrostatic interactions with the protonated guanidine side chains of Arg
while additional hydrogen bonds were dete
the purine. Other contacts involved apolar residues and the rest of the heterobicycle, as well as hydrophilic 
side chains and specific polar anchors on the ligand (Glu and N
(Figure 4.3b). 
The successful validation of the homology model 
Given the reported affinity of the receptor for nucleosides and nucleotides, not to mention the striking 
structure similarity of 93 with such
following candidates: 
a) 
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a collaboration among the Laboratory of Organic Chemistry (Prof. 
of Molecular and Cellular Pharmacology of Purinergic Transmission
) at the Department of Chemistry and Department of 
, respectively, of the University of Milan, as well as 
oratory o
 
; 
ates from literature and/or from proprietary molecule collections 
modeling strategy. Since the human 
with it125a,b, a homology model was built up as template 
 Bank (PDB). Indeed, in 2015 Zhang et al.
93, Table 4.1), resolved by XRD (2.7 Å).
he ligand coordinates were transferred from the template to the 
Figure 4.
      
-93 complex: a) overall structure; b) details 
, when compared to the pocket occupied 
cted between the remaining Arg186 and the N
1H, Tyr and the secondar
justified the use of GPR17-93. 
 compounds, three distinct databases were generated including the 
b) 
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f Pharmaceutical 
. 
membrane P2Y1 
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 isolated and purified a 
131 During the 
3a). 
 
of the binding site. 
lular regions and 
255 and Arg280, 
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 entries 1-49: 6-, 7- and 8-substutited ribo
reported in this PhD Thesis (see
 entries 50-130: 2-, 6-, 7- and 8
nucleotides, either reported
Giovanna Speranza) at the Department of Chemistry of the University of Milan 
Pharmaceutical Biocatalysis (Dr. Daniela Ubiali) at the 
of Pavia since the late 2000s, 
 entry 131: 93 (MRS2500, reference antagonist).
All 131 compounds were submitted
model (Figure 4.4). 
Figure 
Three observations can be drawn from the coarse analysis of energies:
 MRS2500 (93) is one of the best ligand
to one literature molecule (95
 concerning molecules 1-49, neither 
significant among them (ΔE   ̴ 
 a 5’-phosphate group is present in most candidates with favorable docking energy, remarking the 
role of Arg255 and Arg280 in the binding network. Such 
responsibility in the wide ΔE value (5 kcal·mol
library). 
More in details about entries 1-49, four out of the five possible substitution generated results in the 
interval between -7.5815 and -6.4027. 
iodide salts of inosine, guanosine and their 2’
with the receptor binding site containing an array of positive charg
quite massive (+13, derived from 17 Arg, 8 Lys, 7 Glu and 5 Asp, with 13 additional His which may be 
protonated depending on pH and chemical enviro
substrates. 
Other than 93, the top scoring candidates were 8
isopropilydeneguanylic acid (95, entry 113) (
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Code 
  
 
 
113 
 
 
95 
 
 
131 
 
 
93 
 
 
33 
 
 
70 
  
Table 
A noteworthy element was the extreme dissimilarity between the poses of 
octyl chain of the latter ligand indeed points 
with hydrophobic residues able to host alkyl moieties by Van der Waals contacts. This tunnel
allows the 5’-phosphate group to overlap with that of 
direction. To rationalize such a sudden shift, all 17 top scoring entries from the second collection were 
superimposed (Figure 4.5b). 
Figure 4.5. Superimposition of ligand poses 
50-130 (superimposed phosphate groups are circled in red).
As poses were rather dispersed in the binding pocket of GPR17, a rational structure
could not be defined. The mentioned site is 
a) 
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Structure 
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-7.5815
  
 
4.1. Best scoring compounds for each library 
93 and 
toward the inner core of the GPR17 model, which is covered 
93 albeit forcing the purine ring in the opp
     
in GPR17: a) 93 and 95; b) 17 top scoring entries in the range 
 
indeed wide and extends also over extracellular loops. Another 
b) 
 
-1) 
 
 
 
95 (Figure 4.5a). The n-
-like anchor 
osite 
 
-activity relationship 
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evidence is that small ligands tend to occupy the deeper portion of the binding pocket. Anyway, all poses 
maintain the essential hydrogen bonds with Arg255 and Arg280. 
Despite irregularities, the similarity between a 2’,3’-O-isopropylidene group and a cyclopropyl ring may 
justify the small energy difference between 93 and 95. Furthermore, the addition of long-chain groups 
especially on N2 seems to increase the affinity toward the receptor. 
To obtain more accurate data, the docking protocol was modified. New ligands, bearing substituents with 
different steric hindrance and/or a diverse number of phosphate groups, were included in the dataset, 
poses sampling was increased and candidates were relocated to a deeper position with respect to the 
binding region of 93. Plural binding sites were indirectly confirmed, but no further in silico studies have 
been carried out to date. 
Since a long apolar chain in position 2 seems to be essential for stronger energy ties (see Table 4.1), the 
functionalization of N2 was explored. Accordingly, N2-acyl groups with increasing chain length were tested, 
leaving the structure of 95 intact in all other respects. The new molecular modeling computation gave 
promising results (Figure 4.6). 
                                                              
Figure 4.6. Binding free energy of N2-acylpurine 5’-ribonucleotides 
Although the even/odd classification does not determine any regular trend, longer chains are definitely 
preferred by the receptor pocket (cf. n = 3, 4 and 9). N2-n-undecanoyl-2’,3’-O-isopropilydeneguanylic acid 
(97, n = 9) exhibits the topmost affinity. 
4.2.2. N2-Alkylation, N2-acylation and 2-halogenation of guanosine 
The functionalization of adenine, hypoxanthine and guanine ribonucleosides has been a topic of great 
interest in the Laboratory of Organic Chemistry (Prof. Giovanna Speranza) at the Department of Chemistry 
of the University of Milan and therefore has been studied extensively since the first 2000s. This work has 
been performed as a part of the study on the so-called umami taste, specifically to investigate the capacity 
of 5’-ribonucleotides to enhance the taste intensity of monosodium glutamate (MSG), thus acting as flavor 
enhancers.6, 133 
A number of N2-alkyl and N2-acyl derivatives of guanosine 5′-phosphate (GMP) were prepared by 
functionalization of the exocyclic 2-amino group of guanosine.134 Since the tautomeric keto form of the 
nucleobase is preferred, the carbonyl oxygen in position 6 withdraws electron density from N2, making it 
considerably less nucleophilic than other amino groups in simple aromatic rings (Scheme 4.1). 
-9.50
-9.61
-9.60 -9.56
-10.69
-10.50
-10.37
-10.61
-10.49
-11.57
-11.12
-12,00
-11,50
-11,00
-10,50
-10,00
-9,50
-9,00
0 1 2 3 4 5 6 7 8 9 10
B
in
d
in
g 
en
er
gy
 (
kc
al
·m
o
l-1
)
n
NH
N
N
O
N N
H
O
CH3
nO
O O
O
P
O
HO
HO
Chapter 4 ǀ SYNTHESIS OF POTENTIAL LIGANDS OF THE HUMAN GPR17 RECEPTOR 
 
 
78 
 
Scheme 4.1. Tautomeric structures of guanine N9-derivatives 
The prevailing 2-amino-6-keto tautomer provides the exocyclic C-N bond with an additional partial doublet, 
making it much shorter (1.336 Å) than a typical single one in aromatic rings (1.426 Å) and more similar to an 
imino one (1.322 Å), as demonstrated by structural measurements (Table 4.2). 
  
Bond type 
Observed bond 
lenght (Å) 
Calculated bond 
lenght (Å) 
 
Reference 
     
  1.336 1.377 135 
Guanine C2-NH2 1.341  136 
  1.330  137 
 
PhNH2 C
Ar-NH2 1.426   
 
138 
AllylNH2 C
sp2-NH2 1.340  
AlkylNH2 C
sp3-NH2 1.472  
(CH3)2C=NH C
sp2-NH2 1.322  
     
 
Table 4.2. Measurement and calculations on different C-N bonds lengths 
Therefore, the reactivity of N2H2 in guanosine as a nucleophile is scarce and no conventional functionalizing 
methods (e.g. alkylation, reductive amination, azide reduction, …) can be selected. A number of N2-alkyl- 
and N2-acylguanylic acids were prepared by alkylation and acylation (Scheme 4.2).6a 
 
Reagents and conditions (yield): a) 2,2-DMP, p-TsOH·H2O, acetone; b) i) RCHO, p-thiocresol, EtOH, AcOH, 
reflux, ii) NaBH4, EtOH, reflux (43-61%); c) i) TMSCl, Py, CH2Cl2, ii) RCOCl, iii) HCl, THF (52-78%); d) POCl3, 
H2O, TEP, 0°C (67-81%). 
Scheme 4.2. Synthesis of N2-alkyl and N2-acylguanylic acids as potential umami active compounds 
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The first strategy was followed according to the procedure reported by Kemal and Reese in 1980, properly 
modified with the use of 2’,3’-O-isopropilydeneguanosine (Scheme 4.3).139 The N2 exocyclic group was 
indirectly alkylated in a two-step protocol, first forming a thioaminal with excess RCHO and p-thiocresol, 
whose roles were to form a transient iminium ion and trap it by nucleophilic sulfur attack, respectively. 
Next, NaBH4 was added to perform a reductive decomposition of the intermediate. Due to the formation of 
several by-products in the last step, it was sometimes necessary to operate on a temporarily 5’-protected 
nucleoside. 
 
Scheme 4.3. N2-Alkylation of 2’,3’-O-isopropilydene-5’-O-R-guanosines 
Similarly, the exocyclic N2-acylation proceeded through a non-isolated intermediate temporarily protected 
with silyl groups. Following the concept of transient protection exploited by Fan et al., excess TMSCl in a 
CH2Cl2/pyridine mixture was selected as protecting mixture, followed by the addition of an acyl chloride 
under mild conditions to get the desired N2-acyl derivative (Scheme 4.4). The mechanism of this procedure 
is characterized by a trisilylated intermediate, protected not only at the 5’-hydroxyl group but also at O6 
and N2H2 to prevent the formation of dark impurities and accelerate nitrogen functionalization. A final 
hydrolysis step could be performed by acidic treatment.140 
 
Scheme 4.4. N2-Acylation of 2’,3’-O-isopropilydeneguanosine 
All products were subjected to a final phosphorylation reaction with POCl3 and H2O in TEP at 0°C. A few 
sulfoxide moieties in the alkyl or acyl side chain (CH2CH2SOCH3 and CH2CH2CH2SOCH3) were also introduced 
by controlled oxidation of the corresponding S-containing analogues.6b 
Due to unsatisfactory results in terms of isolation and yields, the preparation of N2-alkylguanosine 
derivatives required a different strategy. Instead of strengthening the nucleophilicity of the exocyclic amine 
at position C2, it was decided to convert it into a proper leaving group, specifically a halogen. In the course 
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of a research aimed at the synthesis of guanosine 5’-monophosphate (GMP)-MSG conjugates with the two 
“umami” units linked by a diamine spacer141, numerous variations of the Sandmeyer reaction were 
investigated. 
The first attempts were carried out to introduce an iodine atom (Scheme 4.5). 
 
Reagents and conditions (yield): a) POCl3, Et4NCl, N,N-DMA, CH3CN, reflux (40%); b) t-BuONO, CH2I2, CH3CN, 
reflux (75%); c) i-amyl nitrite, CH3I, CH3CN, 0-90°C (traces, not isolated); d) i-amyl nitrite, CH3I, ClCH2CH2Cl, 
65°C (< 30%); e) i-amyl nitrite, CH3I, ClCH2CH2Cl, 65°C (not isolated). 
Scheme 4.5. Studies on iodination of N2H2 in protected guanosines 
First of all, the procedure reported by Ohno et al. with t-BuONO and CH2I2 in refluxed CH3CN was repeated 
on triacetylated 6-chloroguanosine with good results. 142  In order to leave the 6-carbonyl moiety 
unprotected and simplify the synthetic route, the protocol was modified according to Nair et al. by 
replacing t-BuONO with i-amylnitrite and excess CHI3, and varying the temperature between 0 and 90°C.
143 
Severe drawbacks were encountered in purifying the 2-iodo analogue. In addition, the main product was a 
triacetylated N2-acetylguanosine arising from the radical presumably formed by CH3CN which had entered 
the propagation cycle. To avoid solvent reaction, the latter was varied along with the temperature until the 
desired product was obtained with ClCH2CH2Cl at 65°C, in less than 30% yield. The introduction of a 2’,3’-O-
isopropylidene and a 5’-O-TBDMS group on ribose did not give the desired outcome. 
However, since the stability of 2-iodoguanosines was hampered by spontaneous decomposition, the 
halogen had to be replaced with chlorine. The only successful attempt was made by slightly modifying a 
procedure reported by Qian and Glaser with SbCl3 and t-BuONO in CH2Cl2 at -10°C, which led to the 2-
chloro derivative in low yield (Scheme 4.6).144 
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Reagents and conditions (yield): a) SbCl3, t-BuONO, CH2I2, -10°C (31%). 
Scheme 4.6. Chlorination of N2H2 in protected guanosine 
Finally bromine was introduced on C2 in the presence of SbBr3 and CH2Br2, keeping all other conditions 
unvaried. With the aim of further increasing the yield and avoiding toxic reagents such as SbX3 (X = F, Cl, Br, 
I), a procedure was developed based on the use at -10°C of t-BuONO to promote the formation of the 
necessary diazonium salt and with TMSBr/CH2Br2 as a halogen source and catalytic system (Scheme 4.7) 
(see 6.1.4).145 
 
Reagents and conditions (yield): a) SbBr3, t-BuONO, CH2Br2, -10°C (60%) or TMSBr, t-BuONO, CH2Br2, -10°C 
(70%). 
Scheme 4.7. Studies on bromination of N2H2 in protected guanosine 
This approach is totally unprecedented with respect to known procedures, which always require the 
modification of O6 in the purine ring as either chlorine or alkoxyde as a temporary protection (M. Rabuffetti 
et al., unpublished results). 
4.2.3. Synthesis of potential GPR17 ligands 
4.2.3.1. 8-Alkylamino-, N2-alkyl- and N2-acylpurine 5’-ribonucleotides (94-97) 
The energy values calculated in docking studies (see 4.2.1) were exploited to assist the chemical synthesis 
of potential GPR17 ligands. Four 8-alkylamino-, N2-alkyl- and N2-acylpurine 5’-ribonucleotides were selected 
(Figure 4.8). 
 
Figure 4.8. Potential ligands of GPR17 (94-97) 
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97 was selected as the best pose in terms of docking score. Unlike 95 and 96, 94 was not present in the 
original pool but was added to the list by phosphorylation of 70, owing to an assumed beneficial effect of a 
5’-phosphate on binding energy. The rationale for the synthesis of 96 was to provide a candidate with 
worse theoretical affinity, useful as negative control. 
4.2.3.2. Synthesis of 8-methylaminoinosinic acid (94) 
The synthesis of 8-methylaminoinosinic acid (94) is quite simple, consisting of the direct phosphorylation of 
8-methylaminoinosine (70) on its primary OH group (Scheme 4.8). 
 
Scheme 4.8. Retrosynthetic analysis of 8-methylaminoinosinic acid 
Phosphorylation was carried out following the procedure already experimented by Ikemoto et al. (see 
6.1.5) (Scheme 4.9).146 Under inert atmosphere, the activated 70-TEP complex was allowed to form at 50-
60°C, then excess POCl3 (6:1) and stoichiometric H2O were carefully added dropwise at 0°C and the solution 
was stirred at the same temperature for 6 h, monitoring the disappearance of 70 by TLC until almost 
quantitative conversion was achieved. Dilution with H2O, basification to pH 2 and heating at 70°C for 1 h 30’ 
led to the hydrolysis of the intermediate dichlorophosphate, followed by semi-preparative HPCL. 
 
Reagents and conditions (yield): a) i) TEP, 50-60°C; ii) POCl3, H2O, 0°C; iii) H2O, 6 M NaOH (to pH 2); iv) 70°C 
(75%). 
Scheme 4.9. Phosphorylation of 70 
4.2.3.3. Synthesis of N2-n-octyl-2’,3’-O-isopropylideneguanylic acid (95) 
The retrosynthetic strategy for N2-n-octyl-2’,3’-O-isopropylideneguanylic acid (95) required the 
disconnection of the C-N exocyclic bond. Position 2 of guanosine could be activated by introducing a 
bromine leaving group (see 4.2.2) to be displaced by an amine. In order to simplify purifications and 
preserve the three hydroxyl groups against brominating agents, the ribose moiety had to be protected 
(Scheme 4.10). 
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Scheme 4.10. Retrosynthetic analysis of N2-n-octyl-2’,3’-O-isopropylideneguanylic acid 
Accordingly, the first synthetic step was the conversion of OH2’ and OH3’ of guanosine (55) to a 2’,3’-O-
isopropylidene with 2,2-dimethoxypropane (2,2-DMP) and a stoichiometric amount of p-TsOH·H2O in 
acetone. The isolation of 98 proceeded by precipitation and filtration in almost quantitative yield. OH5’ was 
subsequently masked with an orthogonal protection. TBDMSCl was chosen as silylating agent with excess 
imidazole in dry DMF to give 99, purified by flash column chromatography (Scheme 4.11). 
 
Reagents and conditions (yield): a) 2,2-DMP, p-TsOH·H2O, acetone (96%); b) TBDMSCl, imidazole, DMF 
(95%). 
Scheme 4.11. Protection of OH2’, OH3’ and OH5’ of 55 
The bromination step was attempted directly on intermediate 98 to simplify the sequence. According to 
the previously optimized procedure, 98 was reacted with t-BuONO and TMSBr in CH2Br2 at -10°C. Reagents 
were carefully added dropwise under inert atmosphere and the mixture was allowed to warm to 5-10°C for 
7 h, avoiding any exposure to light sources to prevent the decomposition of both intermediates, as well as 
of the newly formed C-Br bond. The progress of the reaction, likely to proceed via a radical Sandmeyer-type 
mechanism (see 6.1.4)158, was monitored by TLC in order to stop it prior to product decomposition. The 
subsequent work-up had to be performed quickly by solubilization of the crude in AcOEt and neutralization 
of HBr with a saturated aqueous NaHCO3 solution. The crude product was quite unstable and had to be 
purified by double flash column chromatography as soon as possible, since TLC analysis showed the 
formation of a few by-products which could not be easily separated from the brominated derivative. It was 
not surprinsing that the yield was not very high. The same protocol was therefore applied to 99, which was 
supposed to benefit from the TBDMS protection to reduce side reactions. This procedure resulted in a 
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higher number of unexpected TLC spots, although only one flash column chromatography was necessary 
and the final yield was notably higher (70 vs. 21%) (Scheme 4.12). 
 
Reagents and conditions (yield): a) TMSBr, t-BuONO, CH2Br2, -10°C → 5-10°C (21% for 100 and 70% for 
101). 
Scheme 4.12. Bromination of 98 and 99 
Both 100 and 101 were subjected to amination by bromide displacement with n-OctNH2 in 2-
methoxyethanol at 80°C, under previously optimized conditions (Scheme 4.13). As already noticed with 
similar products, the reaction required a long time to be completed (3 and 8 days to form 103 and 102, 
respectively) and had to be protected from light exposure. After a mildly acidic work-up with 1 M HCl, flash 
column chromatography afforded 102 and 103, the former in lower yield (39 vs. 69% yield). 
 
Reagents and conditions (yield): a) n-OctNH2, 2-methoxyethanol, 85°C (39% for 102 and 69% for 103). 
Scheme 4.13. Amination of 100 and 101 
103 was then treated with TBAF·3H2O in THF at RT to remove the 5’-O-silyl ether and obtain 102 after flash 
column chromatography, with free OH5’ ready for phosphorylation (Scheme 4.14). 
 
Reagents and conditions (yield): a) TBAF·3H2O, THF (60%). 
Scheme 4.14. Desilylation of 103 
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In addition, since a partial removal of the TBDMS group occurred in the course of the work-up of the 
amination reaction, the latter procedure was modified by filtering the crude product on a short silica pad 
and by increasing HCl concentration from 1 to 2 M (Scheme 4.15). Such modifications provided 102 in place 
of 103, in overall higher yield with respect to the two sequential steps (55 vs.41%). 
 
Reagents and conditions (yield): a) i) n-OctNH2, 2-methoxyethanol, 85°C; ii) 2 M HCl (work-up) (55%). 
Scheme 4.15. Sequential amination-desilylation of 102 
Based on the obtained results, the strategy of bromination and amination on the 5’-O-protected nucleoside 
appears to be more convenient. 
The same procedure carried out for the previous phosphorylation was applied to 102 with very few 
modifications (Scheme 4.16). The concomitant removal of the 2’,3’-O-isopropilydene group could not be 
avoided, although undesired. Freeze-drying and purification by semi-preparative HPLC afforded 104. 
 
Reagents and conditions (yield): a) i) TEP, 50°C; ii) POCl3, H2O, 0°C; iii) 6 M NaOH (to pH 2); iv) 70°C (73%). 
Scheme 416. Phosphorylation of 102 
The 2’,3’-O-isopropilydene moiety was finally reintroduced with 2,2-dimethoxypropane (2,2-DMP) and 
stoichiometric p-TsOH·H2O. This time, a dry 8:1 acetone-DMF mixture was necessary to overcome the 
scarce solubility of the phosphate ester and the reaction temperature was raised to reflux (Scheme 4.17). 
The final product 95 was isolated once again by semi-preparative HPLC. 
 
Reagents and conditions (yield): a) 2,2-DMP, p-TsOH·H2O, acetone/DMF, reflux (81%). 
Scheme 4.17. Reintroduction of the 2’,3’-O-isopropilydene moiety on 104 
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Further studies are being carried out to run the last two reactions in one step, that it to perform nucleoside 
phosphorylation under conditions that preserve acid-labile moieties. The use of POCl3 in 
trimethylphosphate (TMP) at 0°C over a limited time147 and procedures requiring anhydrous H3PO4, 
tributylamine and catalytic n-butylimidazole in a DMF-CH3CH2NO2 mixture
148, if necessary under microwave 
radiations149, have already been tested and have produced very encouraging results. 
However, none of these controlled conditions has yet allowed to obtain 95 directly from 102. 
4.2.3.4. Synthesis of N2-acyl-2’,3’-O-isopropylideneguanylic acids (96-97) 
The already exploited synthetic route to obtain N2-acyl-2’,3’-O-isopropylideneguanylic acids (see 4.2.2) was 
chosen again because of its simplicity and good yields, with no need for specific improvements. The 
retrosynthetic strategy for the corresponding guanylic acids includes the formation of a new amide bond as 
the key step and allows to operate on 2’,3’-O-diprotected guanosine, thus eliminating the introduction and 
removal of protecting groups at position 5’ (Scheme 4.18). 
 
Scheme 4.18. Retrosynthetic analysis of N2-acylguanylic acids 
The results of molecular modeling (see 4.2.1) oriented the choice of the R residue. The butyryl residue 
matched the requirements for one of the less favorable poses. On the other hand, the undecanoyl moiety 
was added as the most promising candidate. The first molecule was selected as a negative control for 
GPR17 binding assays, while the second one as the potential best ligand. 
Since the 2’,3’-O-isopropylidene ring is compatible with the conditions requested for acylation, this reaction 
was performed on the corresponding protected guanosine (98) as starting material (Scheme 4.19). The 
already reported N-acylation strategy was used again, starting with the transient protection of N2H, O6 and 
OH5’ with excess TMSCl (almost 7:1) and pyridine in dry CH2Cl2. Since reactions performed with large 
amounts of catalyst are usually complete after a relatively short time and TLC monitoring is hampered by 
acid-labile protecting groups, a 3 h time was always selected before adding either an acyl chloride or an 
anhydride. Due to the low stability of trimethylsilyl groups and the acidity of silica gel, CH2Cl2 had to be 
saturated with NH3 in TLC control to deactivate the plate during elution. Although the moderately stable 
TMS moieties should be removed by a mild acidic workup, 1H NMR analysis of the crude showed a mixture 
of still protected, partially silylated and unprotected intermediates. Treatment with 1 M HCl was thus 
necessary in all cases prior to flash column chromatography. 
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Reagents and conditions (yield): a) i) TMSCl, Py, CH2Cl2; ii) RCOX (X = OCO(CH2)2CH3 for 105 and Cl for 106); 
iii) 1 M HCl, THF (62-63%). 
Scheme 4.19. N2-Acylation of 98 
The usual protocol was followed to provide guanylic acid 107 after semi-preparative HPLC, with the 
concomitant removal of the 2’,3’-O-isopropylidene moiety (Scheme 4.20). 
 
Reagents and conditions (yield): a) i) TEP, 50°C; ii) POCl3, H2O, 0°C; iii) H2O, 6 M NaOH (to pH 2); iv) 70°C 
(75%). 
Scheme 4.20. Phosphorylation of 105 
Treatment with 2,2-dimethoxypropane (2,2-DMP) and p-TsOH·H2O in a 4:1 acetone-DMF mixture once 
again allowed to reinsert the 2’,3’-O-isopropilydene moiety on 107 (Scheme 4.21). After purifying the crude 
by semi-preparative HPLC, 96 was finally obtained in 30% yield. 
 
Reagents and conditions (yield): a) 2,2-DMP, p-TsOH·H2O, acetone/DMF, reflux (30%). 
Scheme 4.21. Reintroduction of the 2’,3’-O-isopropilydene moiety on 107 
To date, the synthetic sequence toward 97 has not been completed yet. N2-Undecanoyl intermediate 106 
will be phosphorylated on OH5’ and subjected to 2’,3’-O-isopropylidene reinsertion presumably by the same 
protocols exploited to convert 105 into 107 and then 96. 
The synthesized guanylic and inosinic acids (94-97) will be tested as potential ligands of GPR17 by Surface 
Plasmon Resonance (SPR).150 
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5 ǀ CONCLUSIONS 
The first part of this PhD Thesis described the chemoenzymatic synthesis of 6-substituted purine 
ribonucleosides catalyzed by a purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNP). 
Starting from the results reported in Adv. Synth. Catal. 2012, 354, 96-104 and J. Chromatogr. B 2014, 968, 
79-86, the following goals were achieved: 
 AhPNP was successfully exploited to catalyze the “one-pot, one-enzyme” regio- and stereoselective 
transfer of β-D-ribose from a proper sugar donor (7-methylguanosine iodide) to a library of 6-
substituted purine acceptors, resulting in the “in batch” synthesis of twenty-four ribonucleosides. 
The conversions of the investigated transglycosylations allowed a preliminary assessment of the 
substrate specificity of AhPNP toward 6-modified purines. All results confirmed a broad tolerance 
and therefore highlighted the potential of AhPNP as biocatalyst, providing the necessary information 
to undertake the preparative synthesis of 6-modified purine nucleosides; 
 AhPNP was immobilized in a stainless steel column resulting in a stable and active bioreactor 
(AhPNP-IMER, Immobilized Enzyme Reactor) that, upon on-line connection to a semi-preparative 
HPLC system, was used to run transglycosylation reactions in a flow mode. In such a set-up, 
biotransformation, on-line monitoring and product purification occurred in a single integrated 
platform, thus assisting the straightforward preparation of five nucleoside analogues at a mg scale in 
moderate to high yield (52-89%). 
These results were described in Curr. Org. Chem. 2015, 19, 2220-2225 and Adv. Synth. Catal. 2015, 357, 
2520-2528, respectively. 
As a step forward, AhPNP was applied to the chemoenzymatic synthesis of sugar-modified purine 
nucleosides. In this frame, preliminary studies were performed as follows: 
 the synthesis of arabinosyladenine was performed to explore the feasibility of a “one-pot, one-
enzyme” chemoenzymatic approach toward arabinonucleosides. However, the necessary β-D-
arabinose donor (7-methylarabinosylguanine iodide) was not phosphorolyzed by the catalyst and the 
application of the process already exploited for the synthesis of 6-substituted purine ribonucleosides 
starting from 7-methylguanosine iodide was not feasible in this case; 
 the alternative “one-pot, two-enzyme” strategy was applied by coupling AhPNP-IMER with an 
analogous bioreactor based on a uridine phosphorylase from Clostridium perfringens (CpUP), 
covalently immobilized in a monolith column. The on-line apparatus of integrated synthesis and 
reaction monitoring obtained by connecting CpUP-IMER and AhPNP-IMER in series was tested in the 
synthesis of adenosine, 2’-deoxyadenosine and arabinosyladenine from uridine, 2’-deoxyuridine and 
arabinosyluracyl as sugar donors, respectively. The corresponding nucleobases were transformed 
into the products in almost 90% conversion over 1 h for the ribosyl and 2’-deoxyribosyl derivatives. 
On the contrary, a 20% conversion was registered for arabinosyladenine after 5 h. Scale-up to a semi-
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preparative synthesis is being developed (G. Cattaneo, M. Rabuffetti, G. Speranza, T. Kupfer, B. 
Peters, G. Massolini, D. Ubiali, E. Calleri Submitted 2017). 
In the second part of this PhD Thesis, the PNP from Mycobacterium tuberculosis (MtPNP) was selected as a 
target to develop potential inhibitors:  
 a new LC-ESI-MS/MS method was set up to evaluate the inhibition activity of 8-substituted purine 
ribonucleosides toward MtPNP and the selectivity against the microbial enzyme with respect to the 
corresponding human one (HsPNP). The enzymatic assay, based on the phosphorolysis of inosine, 
proved to be very convenient in terms of time (15’ for plate processing and 2’ for LC-MS analysis), as 
well as target amount, and was validated according to FDA guidelines. A series of seven 8-substituted 
purine ribonucleosides were screened, together with Acyclovir and Formycin A as positive and 
negative control, respectively. The library did not exert any significant effect up to 1 mM, with 8-
bromoguanosine and 8-methylaminoguanosine being the only exceptions at 500 mM as weak 
inhibitors. 
A complete description of the analytical protocol was published in Anal. Chim. Acta 2016, 943, 89-97. 
The third and last part of this PhD Thesis was dedicated to the chemical synthesis of 8- and N2-substituted 
inosinic and guanylic acids as potential ligands of the human GPR17 receptor. Starting from studies aided 
by molecular modeling on a homology model of the protein target, the following goal was achieved: 
 a small library of 8- and N2-substituted derivatives of inosinic and guanylic acids were synthesized 
either by direct phosphorylation of 8-methylaminoinosine, previously prepared in the context of 
inhibition assays regarding MtPNP, or by proper alkylation/acylation of guanosine, followed by the 
introduction of a phosphate group in position 5’. Owing to the scarce nucleophilicity of the exocyclic 
NH2 group in the synthesis of the N
2-octyl derivative, the 2-position of the purine ring was activated 
as a bromo derivative, whose displacement with the proper amine afforded the desired 
functionalization. On the contrary, N2-acylations were carried out through a procedure involving the 
temporary protection of guanosine by silylation, nitrogen functionalization with a proper acyl 
chloride or anhydride and deprotection. An additional 2’,3’-O-isopropylidene group was inserted 
after the phosporylation step in all N2-functionalized nucleotides. Binding assays on GPR17 will be 
carried out. 
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6 ǀ APPENDIX 
6.1. Mechanisms of selected reactions 
6.1.1. Carbonyl thionation with P4S10 and Lawesson’s reagent 
Tetraphosphorus decasulfide (P4S10) and Lawesson’s reagent (2,4-bis(p-methoxyphenyl)-1,3-
dithiadiphosphetane-2,4-disulfide) are useful reagents for the direct conversion of compounds containing 
carbonyl moieties (ketones, aldehydes, lactones, esters, amides and carboxylic acids) to the corresponding 
thiocarbonyl derivatives in generally good yields, as well as of alcohols to thiols (Scheme 6.1). 
 
Scheme 6.1. Carbonyl thionation with P4S10 and Lawesson’s reagent 
Thionation using P4S10 is conducted in refluxing solvents such as benzene, toluene, 1,4-dioxane, xylene, 
THF, pyridine, CH3CN and CS2 and only seldom in CH2Cl2 or Et2O at lower temperatures (usually 0°C). A base 
is often added (e.g. NaHCO3, Na2CO3, Na2SO3, TEA, Al2O3, …). 
The generally accepted Wittig-type mechanism for thionation of carbonyl compounds by P4S10 (108) 
(Scheme 6.2) consists of an initial thermal decomposition to the active dithiophosphine ylide P2S5 (109), 
which cycloadds to the carbonyl substrate and evolves to a thiaoxaphosphetane (110). The final step, which 
is rate-determining, is a cycloreversion to the thiocarbonyl product (112) and the oxathiophosphine ylide 
(111) of the initial reagent. Apart from the high stability of a new P=O bond, the driving force of the whole 
process is the capacity of 111 to form trimers, instead of performing a second thionation hampered by a 
higher energy barrier.151 
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Scheme 6.2. Wittig-type mechanism of carbonyl thionation with P4S10 
Hydroxyl groups are the most reactive moieties, followed by amides, ketones, aldehydes and esters. 
Lawesson’s reagent was extensively studied by the Lawesson research group as a very convenient 
alternative to P4S10 introduced in the 1950s.
152 As its reactivity is not very high, an excess is often required 
in dry hydrocarbon solvents (benzene, toluene, xylene, …) under heating, to obtain products in clean, fast 
and efficient reactions in terms of yield. Yields and manipulation are higher and easier, respectively, than 
P2S5, with no significant by-product formation. 
The thionation mechanism is almost identical to the previous one (Scheme 6.3). 
 
Scheme 6.3. Wittig-type mechanism of carbonyl thionation with Lawesson’s reagent 
Since the formation of the four-membered intermediate is concerted, no zwitterions are involved, but 
strong electrostatic interactions able to stabilize the carbonyl-ylide encounter pair (113) are essential to 
promote the second step, as computationally demonstrated by Legnani et al..153 
6.1.2. 8-Oxygenation of 8-bromopurine nucleosides 
Due to their electrophilic nature, 8-bromopurine nucleosides are prone to reactions with a large number of 
nucleophiles ranging from mild (amines) to quite strong (alkoxydes, sulfides, …). 
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In the case of carboxylate ions sources (Scheme 6.4), a 2-imidazolyl-type ester can be obtained at high 
temperatures in the presence of the analogous acid. The intermediate ester is significantly sensitive to acid- 
and base-catalyzed hydrolysis, not requiring harsh conditions. Like imine decomposition, this reaction is 
usually carried out in situ during the final work-up by a mildly acidic or basic wash. It is therefore possible to 
perform 8-oxygenation of 8-bromohypoxanthine nucleosides in a single step. 
 
Scheme 6.4. 8-Oxygenation of 8-bromopurine nucleosides with a carboxylate salt 
The first step is a bromide displacement by the carboxylate ion, whose already low nucleophilicity is made 
even scarcer by the presence of the acid. Quite high temperatures are thus necessary (often > 100°C). The 
resulting 2-imidazolyl-type ester undergoes a mild hydrolysis in acidic conditions by the same mechanism 
which leads to the analogous reaction of enol esters (Scheme 6.5).154 
 
Scheme 6.5. Mechanism of the acid-catalyzed hydrolysis of 2-imidazolyl esters of purine derivatives 
After an initial regioselective hydration of 114 aided by the ability of N7 to be protonated, the intermediate 
O-acylhemiacetal 115 undergoes a cyclic six-membered transposition leading to the release of product 117 
and the carboxylic acid corresponding to the initial ester (116). The formation of an intramolecular 
hydrogen bond between OH and the carbonyl moiety is likely to stabilize the transition state and promote 
the electron flow. 
6.1.3. Negishi cross-coupling 
As a reaction involving an organozinc compound, an organic halide or triflate and either Ni or Pd as catalyst, 
the Negishi coupling is able to generate new Csp
3-Csp
3 or Csp
3-Csp
2 bonds. Depending on a choice which seems 
to be totally empirical or based on the ease of access, organozinc reagents such as RZnY can be used (Y = 
halide or organic moiety) (Scheme 6.6).155 
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Scheme 6.6. Negishi cross-coupling catalyzed by a Pd or Ni catalyst 
Due to these very mild conditions, substrates and reagents bearing sensitive moieties (halides, esters, 
alcohols, amines, carboxylic acids, …) can be involved in this kind of reaction with almost no need for 
protective groups. 
All cross-couplings (Suzuki, Miyaura, Negishi, Stille, Sonogashira, …) evolve through the same three steps 
(Scheme 6.7): an oxidative addition of the substrate containing a leaving group to the metal catalyst, the 
inter- or intramolecular transfer of an organic group toward the counterpart (organometals in general) by 
transmetalation and a final reductive elimination to form the new C-C bond. Pd, Ni and Cu are by far 
preferred over other metals, while the nature of the transfer agent depends on the reaction itself. For the 
Negishi cross-coupling reaction, a catalyst such as [Pd(PPh3)4] is usually chosen. 
 
Scheme 6.7. Catalytic cycle of the Negishi cross-coupling 
Although this general mechanism is widely accepted, each step may present specific features different from 
other cross-couplings, depending on reaction conditions. Before the oxidative addition, a preactivation step 
must occur in order to either reduce PdII (usually provided as salt) to Pd0 or dissociate at least two ligands 
from the precatalyst (118), already in the lowest oxidation state, to form a [Pd0(PPh3)x] complex (usually x = 
2). The active catalyst 119 then undergoes an oxidative addition with 120 to form a square planar triflate or 
halide PdII complex (121). The step may occur by a concerted mechanism or, more probably, a SN1-like 
stepwise one. The subsequent transmetalation strongly depends on the organozinc species, which can 
either be a diorgano or a monoorganohalide compound. Prior to the C-C bond formation, the diorganozinc 
intermediate 122 (trans isomer) must isomerize to the corresponding cis complex 123.156 Experimental data 
suggest that such an interconvertion may not occur directly, but rather via retrotransmetalation.157 The last 
reductive elimination affords product R-R’ (124) through a cyclic three-member transition state and 
regenerates the Pd0 active catalyst. 
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6.1.4. Bromination by Sandmeyer-type reaction 
The exocyclic N2H2 moiety of arylamines can be converted into a bromine group by treatment with TMSBr 
and t-BuONO in CH2Br2, between -10 and 5-10°C, following the Sandmeyer-type
158 procedure reported by 
Francom and Robins145 (Scheme 6.8). 
 
Scheme 6.8. Sandmeyer-type bromination of primary arylamines 
A classic Sandmeyer reaction requires two steps, the first of which involves the formation of a diazonium 
salt by reaction of the amine with a source of HNO2 to be formed in situ (usually NaNO2 coupled with HCl, 
AcOH or HBF4). Excess KBr must be added as brominating agent, together with a Cu
IBr-CuIIBr2 catalytic 
mixture. CH3CN is frequently the solvent of choice. In this Thesis, t-BuONO was selected as a good nitrosyl 
cation source to form the key aryldiazonium salt, TMSBr as bromine source and CH2Br2 as a compatible 
solvent which may also participate in the mechanism as halogen donor. It is worth pointing out that this 
choice allows a one-pot process and prevents the use of any Cu catalyst. 
The reaction mechanism is reported in Scheme 6.9. 
 
Scheme 6.9. Mechanism of a Sandmeyer-type bromination on a primary arylamine 
6.1.5. Phosphorylation of N2-alkyl- and N2-acylguanosines with POCl3/TEP 
A phosphate group can be inserted on the primary hydroxyl group of N2-alkyl- and N2-acylguanosines using 
the protocol described by Ikemoto et al..146 This procedure allows the direct phosphorylation of 5’-
unprotected ribonucleosides to their respective phosphates, through POCl3 as phosphorylating agent in the 
presence of a trialkylphosphate as solvent. Trimethyl- and triethylphosphate (TMP and TEP, respectively) 
may be selected. Furthermore, additions of H2O accelerate the reaction. The general protocol, compatible 
with variably substituted substrates, proceeds through four steps (Scheme 6.10). 
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Scheme 6.10. Phosphorylation of N2-alkyl- and N2-acylguanosines with POCl3/TEP 
Before adding any phosphorylating agent, a binary nucleoside-TEP complex (125) must be formed at 50°C 
to properly promote the subsequent steps. The case of guanosine (55) is represented in Scheme 6.11. 
 
Scheme 6.11. Formation of the 55-TEP complex 
125 was extensively studied and showed not only higher selectivity but also more excellent reactivity 
toward POCl3 than 55 itself. This behavior is caused by an internal activation exerted by the phosphate unit 
bridging OH5’ to N7. From various analytical data (IR spectra, XRD analysis, 13C-NMR and dipolar diphase 
determination), 125 was argued to be formed by the interaction of TEP with the high-anti conformer of 55, 
disfavored in the equilibrium with its anti form. A hydrogen bond involves the first complexation site (OH5’) 
and the P=O oxygen in TEP, whereas a charge-transfer interaction likely relocates electron density from N7 
to the P atom. A significant partial charge is thus generated on the hydroxyl moiety and increases its 
nucleophilicity. 
The conditions studied to optimize each step can be applied to 2’-3’-O-isopropilydeneribonucleosides 126 
(Scheme 6.12). 
 
Scheme 6.12. Mechanism of the phosphorylation of 2’,3’-O-isopropilydeneribonucleosides 
First of all, due to the incomplete formation of the 126-TEP complex at < 30°C, preheating at 40-50°C is 
necessary at the beginning of the reaction. As determined from the analysis of various trialkylphosphates, 
the overall rate diminishes with larger substituent sizes, probably because steric hindrance hampers the 
complex formation. The next step is the sequential addition of POCl3 and H2O. A reduction of the chloride 
amount from 3 to 1.5 equivalents underlines improved reactivity and selectivity of the complex if compared 
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to the free nucleoside. In addition, the presence of a little less than ¼ of H2O for each POCl3 equivalent 
markedly promotes the reaction, according to a curve characterized by an optimum point. The nucleophilic 
attack by OH5’ on POCl3 forms a dichlorophosphate intermediate (127) releasing one HCl equivalent. 
Product 128 results from the addition of concentrated NaOH until pH 2 and subsequent heating at 70°C, 
which hydrolyzes the intermediate to the final phosphate ester. It is worth noting that low pH and H2O 
synergistically promote the removal of the acid-labile 2’,3’-O-isopropylidene in situ. 
  
  
 
6.2. General synthetic schemes 
6.2.1. General scheme of the synthesis of 7-methylpurine and 7-methylguanine nucleoside iodides (64-67) 
 
6.2.2. General scheme of the synthesis of 6-substituted purines and adenines (2-10, 12-22, 26) 
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6.2.3. General scheme of the synthesis of 6-substituted inosines and adenosines (28-36, 38-50) 
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6.2.4. General scheme of the synthesis of 6-O-methylguanosine (58) 
 
6.2.5. General scheme of the synthesis of arabinosylguanine (59) 
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6.2.6. General scheme of the synthesis of 8-substituted inosines (69-78) 
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6.2.7. General scheme of the synthesis of 8-bromoguanosine and 8-bromoadenosine (79, 80) 
 
6.2.8. General scheme of the synthesis of 8-methylaminoinosinic acid (94) 
 
6.2.9. General scheme of the synthesis of N2-butyryl-2’,3’-O-isopropylideneguanylic acid (96) 
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6.2.10. General scheme of the synthesis of N2-n-octyl-2’,3’-O-isopropylideneguanylic acid (95) 
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6.3. Semi-preparative chromatograms, 
substituted ribonucleosides synthesized by 
The following chromatograms and 1
Adv. Synth. Catal. 2015, 357, 2520-2528
6.3.1. Semi-preparative chromatograms
6.3.1.1. N6-Butyladenosine (31) 
6.3.1.2. N6-Cyclohexyladenosine (32
6.3.1.3. N6-Hydroxyethyladenosine (
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1H-NMR, 13C-NMR and UV
AhPNP-IMER 
H-NMR, 13C-NMR and UV-Vis spectra are adapted with permission from 
.110 
 
) 
34) 
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6.3.1.4. 6-Chloroinosine (49) 
6.3.1.5. 6-O-Methylguanosine (58) 
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6.3.2. 1H-NMR and 13C-NMR spectra 
9.3.2.1. N6-Butyladenosine (31) (CD3OD) 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
ppm
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6.3.2.2. N6-Cyclohexyladenosine (32) (CD3OD) 
 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
ppm
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6.3.2.3. N6-Hydroxyethyladenosine (34) (DMSO-d6) 
 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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6.3.2.4. 6-Chloroinosine (49) (DMSO-d6) 
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6.3.2.5. 6-O-Methylguanosine (58) (DMSO-d6) 
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6.3.3. Uv-Vis spectra 
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7 ǀ EXPERIMENTAL SECTION 
7.1. Materials and methods 
Solvents and reagents 
All solvents and reagents were purchased from Sigma-Aldrich, VWR International, Fluorochem, Fluka, Herk-
Schuchardt, Merk, Carlo Erba reagents and Baker Analyzed reagents, and were used without further 
purification. CH2Cl2, acetone and CH3CN (dried over CaCl2), MeOH, EtOH and i-PrOH (dried over CaO), n-
BuOH (dried over K2CO3), THF (dried over LiAlH4) and N,N-DMA (dried over CaH) were distilled before use. 
All other solvents were of HPLC grade. 
Recombinant PNP from Aeromonas hydrophila, PNP from Mycobacterium tuberculosis, human PNP, and UP 
from Clostridium perfringens 
Recombinant purine nucleoside phosphorylase from Aeromonas hydrophila and uridine phosphorylase 
from Clostridium perfringens prepared by Gnosis S.p.A. (Desio, MB, Italy).10c Recombinant human purine 
nucleoside phosphorylase and the one from Mycobacterium tuberculosis were overexpressed and purified 
as previously described.75b, 159 
Specific activities toward inosine were 39 IU·mg-1 for AhPNP (stock solution 21.5 mg·mL-1), 0.57 IU·mg-1 for 
HsPNP (stock solution 0.4 mg·mL-1) and 0.10 IU·mg-1 for MtPNP (stock solution 1.5 mg·mL-1). Specific activity 
of CpUP toward 2’-deoxyuridine was 68 IU·mg-1 for AhPNP (stock solution 7.0 mg·mL-1). pH measurements 
were performed with a 718 Stat Titrino pHmeter from Metrohm (Herisau, Switzerland).10c 
Analytical and flash column chromatography 
Analytical TLC was performed on silica gel F254 precoated aluminum sheets (0.2 mm layer, Merck); 
components were detected under an UV lamp (λ 254 nm) and by spraying with a CeSO4/(NH4)6Mo7O24·4H2O 
solution or a 5% w/v ninhydrin solution in EtOH, followed by heating at 150°. 
Silica gel 60, 40–63 μm (Merck, Darmstadt, Germany), was used for flash column chromatography. 
Amberlite® resin XAD-4 was purchased from Sigma-Aldrich. 
NMR spectroscopy 
1H, 13C and 31P NMR spectra were recorded at 400.13, 100.61 and 161.98 Hz, respectively, on a Bruker 
AVANCE 400 spectrometer equipped with a TOPSPIN software package (Bruker, Karlsruhe, Germany) at 300 
K, unless stated otherwise. 1H and 13C chemical shifts (δ) are given in parts per million and were referenced 
to the solvent signals (δH 7.26 - δC 77.16, δH 3.31 - δC 49.00, δH 2.50 - δC 39.52 and δH 4.79 ppm from 
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
112 
tetramethylsilane (TMS) for CDCl3, CD3OD, DMSO-d6 and D2O respectively). 
31P chemical shifts are referred 
to 85% H3PO4 as external standard (δP 0.00 ppm). 
1H signals were assigned with the aid of 1H-1H correlation spectroscopy (1H-1H COSY). 13C NMR signal 
multiplicities were based on APT (attached proton test) spectra. 13C NMR signals were assigned with the aid 
of 1H-13C correlation experiments (heteronuclear multiple quantum correlation spectroscopy, HMQC, and 
heteronuclear multiple bond correlation spectroscopy, HMBC). 
Mass spectrometry 
Electrospray ionization mass spectra (ESI-MS or ESI-Q-Tof-MS) were recorded on a Thermo Finnigan LCQ 
Advantage spectrometer (Hemel Hempstead, Hertfordshire, U.K.) and Micromass Q-Tof micro mass 
spectrometer (Waters, Milford, Massachussets, U.S.A.), respectively. 
UV-Vis spectroscopy 
UV-Vis measurements were performed on a Jasco V-360 spectrophotometer. 
Analytical and semi-preparative HPLC for chemical synthesis 
Analytical and semi-preparative HPLC were performed using an Amersham pharmacia biotech (P900) 
chromatographer equipped with a UV-Vis detector. Conditions were as follows: column, Jupiter® 10u 
Proteo 90A (10 µm, 250 x 4.6 mm (analytical HPLC) and 250 x 10.0 mm (semi-preparative HPLC), 
Phenomenex); flow rate, 0.5 mL·min-1 (analytical HPLC) and 5 mL·min-1 (semi-preparative HPLC); λ, 226 and 
250 nm. Elution methods are reported in each paragraph describing the preparation of the corresponding 
product. HPLC tR is alwas referred to analytical conditions (flow rate: 0.5 mL·min
-1). 
Analytical HPLC for enzyme-catalyzed batch synthesis 
HPLC analysis to monitor the progress of transglycosylation reactions and to check the purity of compounds 
was performed using a Merck Hitachi L-7000 La-Chrom liquid chromatographer equipped with a UV-Vis 
detector, an autosampler (injection volume: 20 μL) and a column oven (temperature: 40 °C). Conditions 
were as follows: column, Kromasil C18 (5 µm particles, 250 x 4.6 mm, Supelco); flow rate, 1 mL·min
-1; λ, 260 
nm; eluent, 10 mM K2HPO4 buffer pH 4.5 or 3.2 (A) and MeOH (B). Elution methods are reported in each 
paragraph describing the preparation of the corresponding product. 
Immobilized Enzyme Reactor apparatus 
Enzyme immobilization and flow biotransformations were performed by two HPLC modular systems 
(system 1 and 2) interfaced by a 6-way switching valve (V) and used in two different settings (analytical and 
semi-preparative set-up). 
System 1 consisted of an Agilent HP-1100 pump (Palo Alto, CA, USA), directly connected to the 
bioreactor(s) (AhPNP-IMER or/and CpUP-IMER) and to a 6-way switching valve (V) containing a loop (5 and 
2 μL or 1.4 mL for analytical or semi-preparative purposes, respectively). In the semi-preparative setting, a 
3-way junction (Y) was inserted between the reactor(s) and V. 
System 2 consisted of an Agilent HP-1100 pump (Palo Alto, CA, USA) connected through V to a 
chromatographic column (Gemini® RP-18, 5 μm, 250 × 4.6 mm Phenomenex equipped with an RP-18 
precolumn (analytical HPLC) or Lichrocart Lichrosphere® RP-18, 10 μm, 300 × 10 mm, Phenomenex (for 
semi-preparative HPLC)) and a UV-Vis detector (λ 260 nm). The systems were controlled by an HPLC 
ChemStation (Revision A.04.01). 
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7.2. Synthesis of structurally modified nucleobases and nucleosides 
7.2.1. Synthesis of 6-substituted purines and guanines (2-10, 12-24) 
7.2.1.1. 6-Chloropurine (23) 
C5H3ClN4; MW 154.56 
 
11 (1.00 g, 7.35 mmol) was suspended in freshly dry N,N-DMA (2.50 mL) under inert atmosphere. The 
mixture was cooled to 0°C, POCl3 (25.00 mL, 268.21 mmol) was added dropwise in 1 h and the resulting 
yellow suspension was allowed to warm to RT and then refluxed for 4 h. 
The solvent was evaporated under reduced pressure and the resulting brown oil was diluted with H2O (30 
mL). The solution was cooled to 0°C and pH was adjusted to 9 with 33% aqueous NH4OH. After removing 
the solvent under reduced pressure, the pale yellow crude was recrystallized from H2O twice and freeze-
dried to get 23 as a pale yellow powder (1.01 g, 6.53 mmol). 
Yield: 89% 
Rf: 0.47 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.94 (br s, 1H, N
9H), 8.75 (s, 1H, H2), 8.70 (s, 1H, H8). 
MS (ESI+): m/z calcd for [C5H3ClN4]
+: 154.00; found: 155.1 [M+H]+, 177.0 [M+Na]+. 
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7.2.1.2. 6-Thiopurine (17) 
C5H4N4S; MW 152.18 
 
P2S5 (9.80 g, 44.09 mmol) was added to a suspension of 11 (1.00 g, 7.35 mmol) in pyridine (30 mL) under 
inert atmosphere and the resulting orange mixture was refluxed overnight. 
The solvent was evaporated under reduced pressure and the obtained oil was diluted with H2O (100 mL). 
The mixture was heated at 90°C, KOH was added until complete dissolution of the oil and the resulting 
solution was treated with activated charcoal. The suspension was filtered on celite and AcOH was added to 
the hot solution to precipitate a yellow powder, which was washed with few cold H2O and dried under 
reduced pressure. The filtrate solution was concentrated to half its volume, freeze-dried and diluted with 
H2O (100 mL). The resulting precipitate was filtered, washed with few cold H2O and recrystallized from 
absolute EtOH. 
The two solids were reunited to get 17 as a pale yellow powder (894 mg, 5.87 mmol). 
Yield: 80% 
Rf: 0.77 (EtOH-H2O, 7:3) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.31 (br s, 1H, N
9H), 8.37 (s, 1H, H8), 8.19 (s, 1H, H2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 171.4 (C
6), 151.1 (C4), 145.2 (C8), 145.0 (C2), 129.0 (C5). 
MS (ESI+): m/z calcd for [C5H4N4S]
+: 152.02; found: 153.4 [M+H]+, 175.4 [M+Na]+, 327.2 [2M+Na]+. 
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7.2.1.3. N6-Methyladenine (2) 
C6H7N5; MW 149.15 
 
40% aqueous CH3NH2 (0.10 mL, 1.16 mmol) was added to a suspension of 23 (154 mg, 1.00 mmol) and TEA 
(0.15 mL, 1.08 mmol) in n-BuOH (2.5 mL) under inert atmosphere. The resulting yellow suspension was 
refluxed for 2 h, during which time it became a light brown solution. 
It was then cooled to RT to precipitate 2 as a pale yellow crystalline solid, which was filtered, washed with 
few cold H2O and dried under reduced pressure (96 mg, 0.64 mmol). 
Yield: 64% 
Rf: 0.59 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.83 (br s, 1H, N
9H), 8.20 (s, 1H, H2), 8.08 (s, 1H, H8), 7.56 (br s, 1H, 
N6H), 2.96 (br s, 3H, NHCH3). 
MS (ESI+): m/z calcd for [C6H7N5]
+: 149.07; found: 149.6 [M]+, 150.3 [M+H]+, 172.2 [M+Na]+, 321.1 
[2M+Na]+. 
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7.2.1.4. N6-Ethyladenine (3) 
C7H9N5; MW 163.18 
 
70% aqueous CH3CH2NH2 (1.30 mL, 16.35 mmol) was added to a suspension of 23 (134 mg, 0.87 mmol) in 
EtOH (1.7 mL) under inert atmosphere. The resulting pale brown mixture was refluxed for 24 h, during 
which time it turned to a dark brown solution. 
The solvent was removed under reduced pressure and the resulting brown crude was purified by flash 
column chromatography (CH2Cl2-MeOH, 9.3:0.7) to get 3 as a white powder (111 mg, 0.68 mmol). 
Yield: 78% 
Rf: 0.68 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.81 (br s, 1H, N
9H), 8.17 (s, 1H, H2), 8.08 (s, 1H, H8), 7.57 (br s, 1H, 
N6H), 3.52 (br s, 1H, NHCH2) 1.18 (t, J = 7.1 Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C7H9N5]
+: 163.09; found: 164.2 [M+H]+, 186.1 [M+Na]+, 349.2 [2M+Na]+. 
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7.2.1.5. N6,N6-Dimethyladenine (9) 
C7H9N5; MW 163.18 
 
A 2.0M Me2NH solution in THF (5.00 mL, 10.00 mmol) was added to a suspension of 23 (155 mg, 1.00 
mmol) in EtOH (6.0 mL). The resulting yellow mixture was refluxed for 17 h, becoming a brown solution. 
The solvent was removed under reduced pressure and the brown crude was suspended in CH2Cl2 to 
separate the product from the exceeding amount of Me2NH, then Et2O was added to cause the 
precipitation of a pale yellow solid, which was filtered and purified by flash column chromatography 
(CH2Cl2-MeOH, 9.6:0.4) to get 9 as a very pale yellow powder (66 mg, 0.40 mmol). 
Yield: 40% 
Rf: 0.41 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.20 (s, 1H, H
2), 8.01 (s, 1H, H8), 3.53 (br s, 6H, N(CH3)2). 
HRMS (ESI-Q-Tof+): m/z calcd for [C7H9N5]
+: 163.09; found: 164.1285 [M+H]+, 186.1132 [M+Na]+. 
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7.2.1.6. General procedure for the synthesis of N6-alkyl- and N6,N6-dialkyladenines 4, 6, 8 and 10 
 
The appropriate amine (10.00 mmol) was added to a suspension of 23 (100 mg, 0.65 mmol) in EtOH (2.0 
mL) under inert atmosphere. In the case of 4 and 10, TEA (0.11 mL, 0.79 mmol) was also added. The 
resulting mixture was refluxed and monitored by TLC (CH2Cl2-MeOH, 9:1) until consumption of the starting 
reagent (between 15 and 36 h). 
10: The formed precipitate was filtered and dried under high vacuum. 
4: After removing the solvent under reduced pressure, the product was purified by flash column 
chromatography (CH2Cl2 saturated with NH3-MeOH, 9.4:0.6). 
6 and 8: The solvent was removed under reduced pressure. H2O (3.0 mL) was added and the solution was 
neutralized with 2 M HCl, then the solvent was removed under reduced pressure and the crude was 
purified by semi-preparative HPLC. 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 97 0 
2 - 18 4 97 → 0 0 → 100 
18 - 30 3 0 100 
    
AAAAAAAAAAAA  
7.2.1.6.1. N6-i-Propyladenine (4) 
C8H11N5; MW 177.21 
 
Brown powder (93 mg, 0.52 mmol). 
Yield: 81% 
Rf: 0.73 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.86 (br s, 1H, N
9H), 8.16 (br s, 1H, H2), 8.07 (s, 1H, H8), 7.34 (br d, J 
= 7.1 Hz, 1H, N6H), 4.45 (br, 1H, NHCH), 1.22 (d, J = 6.5 Hz, 6H, CH(CH3)2). 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.24 (br s, 1H, H
2), 8.07 (s, 1H, H8), 4.47 (br s, 1H, NHCH), 1.34 (d, J = 
6.5 Hz, 6H, CH(CH3)2). 
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MS (ESI+): m/z calcd for [C8H11N5]
+: 177.10; found: 178.3 [M+H]+, 200.3 [M+Na]+, 377.3 [2M+Na]+. 
7.2.1.6.2. N6-Cyclohexyladenine (6) 
C11H15N5; MW 217.27 
 
Pale yellow powder (110 mg, 0.51 mmol). 
Yield: 78% 
Rf: 0.67 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
HPLC tR: 36.0’ (100% B) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.83 (br s, 1H, N
9H), 8.16 (s, 1H, H2), 8.07 (s, 1H, H8), 7.33 (br s, 1H, 
N6H), 4.05 (br s, 1H, Ha), 1.90 (v br d, J = 5.0 Hz, 2H, Hb), 1.75 (br dd, J = 8.9, 3.2 Hz, 2H, Hc), 1.62 (br d, J = 
12.7 Hz, 1H, Hd), 1.45-1.08 (m, 5H, Hb, Hc). 
MS (ESI+): m/z calcd for [C11H15N5]
+: 217.13; found: 218.3 [M+H]+, 869.3 [4M+H]+. 
7.2.1.6.3. N6-Hydroxyethyladenine (8) 
C7H9N5O; MW 179.18 
 
White powder (100 mg, 0.56 mmol). 
Yield: 86% 
Rf: 0.22 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
HPLC tR: 24.1’ (63.3% B) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.78 (v br s, 1H, N
9H), 8.18 (s, 1H, H2), 8.10 (s, 1H, H8), 7.43 (br s, 
1H, N6H), 4.81 (br s, 1H, OH), 3.67-3.49 (m, 4H, CH2CH2). 
MS (ESI+): m/z calcd for [C7H9N5O]
+: 179.08; found: 180.2 [M+H]+, 716.3 [4M]+. 
  
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
120 
7.2.1.6.4. N6,N6-Bis-Hydroxyethyladenine (10) 
C9H13N5O2; MW 223.23 
 
Very pale yellow powder (90 mg, 0.40 mmol). 
Yield: 62% 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.17 (s, 1H, H
2), 8.09 (s, 1H, H8), 4.76 (v br s, 2H, OH), 4.49-3.77 (m, 
4H, CH2CH2OH), 3.68 (br t, J = 6.0 Hz, 4H, CH2CH2OH). 
MS (ESI+): m/z calcd for [C9H13N5O2]
+: 223.11; found: 224.3 [M+H]+, 246.2 [M+Na]+, 469.2 [2M+Na]+. 
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7.2.1.7. General procedure for the synthesis of N6-alkyladenines 5 and 7 
 
The appropriate amine (3.00 mmol) was added to a suspension of 23 (155 mg, 1.00 mmol) in EtOH (5.9 mL) 
under inert atmosphere. The resulting mixture was refluxed and monitored by TLC (CH2Cl2-MeOH, 9:1) until 
consumption of the starting reagent (5 h). 
The solvent was removed under reduced pressure, then the crude was suspended in H2O, filtered, washed 
with few cold H2O and dried under reduced pressure. 
7.2.1.7.1. N6-n-Butyladenine (5) 
C9H13N5; MW 191.23 
 
White powder (153 mg, 0.80 mmol). 
Yield: 80% 
Rf: 0.63 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.24 (s, 1H, H
2), 8.08 (s, 1H, H8), 3.69-3.55 (br s, 2H, NHCH2), 1.71 (dt, J 
= 14.8, 7.5 Hz, 2H, CH2CH2CH3), 1.50 (dq, J = 14.6, 7.3 Hz, 2H, CH2CH3), 1.01 (t, J = 7.4 Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C9H13N5]
+: 191.12; found: 192.2 [M+H]+, 214.2 [M+Na]+, 405.1 [2M+Na]+. 
7.2.1.7.2. N6-(2-Phenyl)ethyladenine (7) 
C13H13N5; MW 239.28 
 
Very pale yellow powder (211 mg, 0.88 mmol). 
Yield: 88% 
Rf: 0.66 (CH2Cl2 saturated with NH3-MeOH, 6:1) 
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1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.69 (br, 1H, N
9H), 8.21 (br s, 1H, H2), 8.09 (s, 1H, H8), 7.63 (br s, 
1H, N6H), 7.34-7.15 (m, 5H, C6H5), 3.73 (br s, 2H, NHCH2), 2.93 (t, J = 7.5 Hz, 2H, CH2C6H5). 
13C NMR (DMSO-d6, 400 MHz): δ (ppm) 154.5 (C
6), 152.9 (C2), 150.9 (C4), 140.1 (Ca), 139.4 (C8), 129.1, 128.8, 
126.5 (Cb, C
c
, C
d), 118.4 (C5), 41.8 (NHCH2), 35.6 (CH2C6H5). 
MS (ESI+): m/z calcd for [C13H13N5]
+: 239.12; found: 240.3 [M+H]+, 262.3 [M+Na]+, 501.2 [2M+Na]+. 
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7.2.1.8. General procedure for the synthesis of 6-alkoxypurines 12, 13 and 15 
 
Na (60 mg, 2.61 mmol) was dissolved in the appropriate dry alcohol (2.00 mL) under inert atmosphere. 2 
(100 mg, 0.65 mmol) was added and the resulting suspension was refluxed and monitored by TLC (CH2Cl2-
MeOH, 9:1) until consumption of the starting reagent (15 h). 
The solvent was removed under reduced pressure and the product was purified by semi-preparative HPLC. 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 97 3 
2 - 18 4 97 → 0 3 → 100 
18 - 30 3 0 100 
    
AAAAAAAAAAAA  
7.2.1.8.1. 6-Methoxypurine (12) 
C6H6N4O; MW 150.14 
Na
MeOH
reflux
N
N
N
Cl
N
H
23
N
N
N
O
N
H
12  
White powder (72 mg, 0.48 mmol). 
Yield: 73% 
Rf: 0.38 (CH2Cl2-MeOH, 9:1) 
HPLC tR: 25.2’ (72.6% B) 
1H NMR (DMSO-d6, 400 MHz): 13.42 (br s, 1H, N
9H), 8.50 (s, 1H, H2), 8.37 (s, 1H, H8), 4.09 (s, 3H, OCH3). 
MS (ESI+): m/z calcd for [C6H6N4O]
+: 150.05; found: 151.0 [M+H]+, 172.9 [M+Na]+. 
7.2.1.8.2. 6-Ethoxypurine (13) 
C7H8N4O; MW 164.16 
 
Ochre powder (90 mg, 0.55 mmol). 
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
124 
Yield: 84% 
Rf: 0.42 (CH2Cl2-MeOH, 9:1) 
HPLC tR: 28.0’ (79.2% B) 
1H NMR (DMSO-d6, 400 MHz): 8.32 (s, 1H, H
2), 8.12 (s, 1H, H8), 4.54 (q, J = 7.1 Hz, 2H, OCH2), 1.40 (t, J = 7.1 
Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C7H8N4O]
+: 164.07; found: 165.0 [M+H]+, 187.0 [M+Na]+, 350.9 [2M+Na]+. 
7.2.1.8.3. 6-n-Butoxypurine (15) 
C9H12N4O; MW 192.22 
 
Pale yellow powder (62 mg, 0.32 mmol). 
Yield: 50% 
Rf: 0.44 (CH2Cl2-MeOH, 9:1) 
HPLC tR: 43.1’ (92.5% B) 
1H NMR (DMSO-d6, 400 MHz): 8.26 (s, 1H, H
2), 8.02 (s, 1H, H8), 4.48 (t, J = 6.7 Hz, 2H, OCH2), 1.77 (quin, J = 
7.1 Hz, 2H, CH2CH2CH3), 1.46 (sext, J = 7.4 Hz, 2H, CH2CH3), 0.95 (t, J = 7.4 Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C9H12N4O]
+: 192.10; found: 215.0 [M+Na]+, 385.1 [2M+H]+, 406.9 [2M+Na]+, 769.1 
[4M+H]+. 
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7.2.1.9. 6-i-Propoxypurine (14) 
C8H10N4O; MW 178.19 
 
A 60% NaH dispersion in mineral oil (180 mg, 4.50 mmol) was added to dry i-PrOH (7.5 mL) portionwise in 3 
h under inert atmosphere, forming a yellow suspension. 23 (133 mg, 0.86 mmol) was added and the 
resulting mixture was refluxed for 15 h. 
The solvent was removed under reduced pressure and the light brown crude was purified by flash column 
chromatography (CH2Cl2 saturated with NH3-MeOH, 9.4:0.6) to obtain 14 as a pale yellow powder (149 mg, 
0.84 mmol). 
Yield: 97% 
 
Na (109 mg, 4.74 mmol) was dissolved in dry i-PrOH (7.3 mL) under inert atmosphere and 23 (132 mg, 0.85 
mmol) was added to the white suspension. The resulting mixture was refluxed for 13 h. 
The solvent was removed under reduced pressure, the crude was dissolved in H2O (3.0 mL) and extracted 
with Et2O (7x3 mL). The reunited organic phases were dried over Na2SO4 and evaporated under reduced 
pressure to obtain 14 as a pale yellow powder (24 mg, 0.13 mmol). 
Yield: 16% 
Rf: 0.49 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.50 (s, 1H, H
2), 8.29 (s, 1H, H8), 5.69 (hept, J = 6.2 Hz, 1H, OCH), 1.48 
(d, J = 6.2 Hz, 6H, CH(CH3)2). 
MS (ESI+): m/z calcd for [C8H10N4O]
+: 178.09; found: 179.0 [M+H]+, 201.2 [M+Na]+, 379.2 [2M+Na]+. 
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7.2.1.10. 6-(2-Phenyl)ethoxypurine (16) 
C13H12N4O; MW 240.26 
 
Na (101 mg, 4.39 mmol) was added portionwise to a solution of PhCH2CH2OH (0.50 mL, 4.17 mmol) in dry 
THF (3.0 mL) under inert atmosphere, forming an orange suspension which was stirred at RT for 15 h. 23 
(154 mg, 1.00 mmol) was added and the suspension was refluxed for 16 h. 
The solvent was removed under reduced pressure and the resulting brown crude was purified by flash 
column chromatography (CH2Cl2-MeOH, 9.4:0.6) to get 16 as a white powder (180 mg, 0.75 mmol). 
Yield: 75% 
Rf: 0.53 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.50 (s, 1H, H
2), 8.30 (s, 1H, H8), 7.37-7.18 (m, 5H, C6H5), 4.84 (t, J = 7.0 
Hz, 2H, OCH2), 3.21 (t, J = 7.0 Hz, 2H, CH2C6H5). 
MS (ESI+): m/z calcd for [C13H12N4O]
+: 240.10; found: 241.4 [M+H]+, 263.4 [M+Na]+, 503.3 [2M+Na]+. 
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7.2.1.11. General procedure for the synthesis of 6-alkylthiopurines 18 and 19 
 
A suspension of 17 (100 mg, 0.66 mmol) in 1 M aqueous NaOH (1.7 mL) was stirred at RT for 30’, until 
almost complete dissolution of the starting reagent, and the appropriate alkyl halide (0.80 mmol for 18 and 
1.20 mmol for 19) was added dropwise. The mixture was stirred at RT and monitored by TLC (CH2Cl2-MeOH, 
9:1) until consumption of the starting reagent (between 2 and 15 h). 
The solution was either acidified to pH 5 with AcOH (for 18) or neutralized with 2 M HCl (for 19) to 
precipitate the product, which was filtered, washed with few precipitation solvent and dried under high 
vacuum. 
7.2.1.11.1. 6-Methylthiopurine (18) 
C6H6N4S; MW 166.20 
 
Pale brown powder (65 mg, 0.39 mmol). 
Yield: 59% 
Rf: 0.50 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.66 (s, 1H, H
2), 8.37 (s, 1H, H8), 2.66 (s, 3H, SCH3). 
MS (ESI+): m/z calcd for [C6H6N4S]
+: 166.03; found: 167.4 [M+H]+, 189.2 [M+Na]+, 355.2 [2M+Na]+. 
7.2.1.11.2. 6-Ethylthiopurine (19) 
C7H8N4S; MW 180.23 
 
White powder (87 mg, 0.48 mmol). 
Yield: 73% 
Rf: 0.53 (CH2Cl2-MeOH, 9:1) 
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1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.49 (s, 1H, H
2), 8.11 (s, 1H, H8), 3.29 (q, J = 7.3 Hz, 2H, SCH2), 1.33 (t, 
J = 7.3 Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C7H8N4S]
+: 180.05; found: 181.3 [M+H]+, 203.2 [M+Na]+, 383.5 [2M+Na]+. 
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7.2.1.12. General procedure for the synthesis of 6-alkylthiopurines 20 and 21 
 
The appropriate thiol (9.80 mmol for 20 and 2.80 mmol for 21) was dissolved in 1 M aqueous NaOH (1.7 
mL) and the resulting solution was stirred at RT for 30’. 23 (100 mg, 0.65 mmol) was added, then the 
suspension was stirred at 10°C below the boiling point of the thiol and monitored by TLC (CH2Cl2-MeOH, 
9:1) until consumption of the starting reagent (between 15 and 48 h). 
The solution was neutralized with 2 M HCl to precipitate the product, which was filtered, washed with few 
cold H2O and dried under high vacuum 
7.2.1.12.1. 6-i-Propylthiopurine (20) 
C8H10N4S; MW 194.26 
 
White powder (107 mg, 0.55 mmol). 
Yield: 85% 
Rf: 0.56 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.47 (br, 1H, N
9H), 8.69 (s, 1H, H2), 8.42 (s, 1H, H8), 4.31 (sept, J = 
6.8 Hz Hz, 1H, SCH), 1.44 (d, J = 6.8 Hz, 6H, CH(CH3)2). 
MS (ESI+): m/z calcd for [C8H10N4S]
+: 194.06; found: 195.1 [M+H]+, 217.1 [M+Na]+, 410.9 [2M+Na]+. 
7.2.1.12.2. 6-n-Butylthiopurine (21) 
C9H12N4S; MW 208.28 
 
Yellow solid (67 mg, 0.32 mmol). 
Yield: 50% 
Rf: 0.54 (CH2Cl2-MeOH, 9:1) 
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1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.56 (s, 1H, H
2), 8.22 (s, 1H, H8), 3.33 (t, J = 7.3 Hz, 2H, SCH2), 1.68 
(quin, J = 7.4 Hz, 2H, CH2CH2CH3), 1.44 (sext, J = 7.4 Hz, 2H, CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, CH3). 
MS (ESI+): m/z calcd for [C9H12N4S]
+: 208.08; found: 209.0 [M+H]+, 231.1 [M+Na]+. 
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7.2.1.13. 6-(2-Phenyl)ethylthiopurine (22) 
C13H12N4S; MW 256.33 
 
17 (152 mg, 1.00 mmol) and K2CO3 (155 mg, 1.12 mmol) were suspended in dry DMF (1.0 mL) and the 
resulting mixture was stirred at RT for 30’. PhCH2CH2I (0.20 mL, 1.38 mmol) was then added dropwise. 
After stirring at RT for 1 h 30‘, H2O (3.0 mL) was added and the solution was neutralized with 2 M HCl at 0°C 
to precipitate 22 as a very pale yellow powder, which was filtered, washed with few cold H2O and dried 
under high vacuum (169 mg, 0.66 mmol). 
Yield: 66% 
 
PhCH2CH2Br (0.19 mL, 1.39 mmol) was added to a suspension of 17 (100 mg, 0.66 mmol) in 1 M aqueous 
NaOH (1.7 mL) under inert atmosphere. The resulting mixture was stirred at RT overnight. 
The solution was neutralized with 1 M HCl to precipitate a solid, which was filtered, washed with few cold 
H2O and with very few cold MeOH and dried under vacuum to get 22 as a white powder (20 mg, 0.08 
mmol). 
Yield: 12% 
Rf: 0.57 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.72 (s, 1H, H
2), 8.43 (s, 1H, H8), 7.36-7.19 (m, 5H, C6H5), 3.62 (t, J = 
7.6 Hz, 2H, SCH2), 3.04 (t, J = 7.5 Hz, 2H, CH2C6H5). 
MS (ESI+): m/z calcd for [C13H12N4S]
+: 256.08; found: 279.2 [M+Na]+. 
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7.2.1.14. 2-Amino-6-methoxypurine (26) 
C6H7N5O; MW 165.15 
 
Na (69 mg, 3.00 mmol) was dissolved in dry MeOH (1.83 mL) under inert atmosphere and 25 (102 mg, 0.60 
mmol) was added to the mixture, forming a yellow suspension which was refluxed for 24 h. 
The resulting mixture was evaporated under reduced pressure and purified by flash column 
chromatography (CH2Cl2-MeOH, 9.7:0.3) to get 26 as a white powder (93 mg, 0.56 mmol). 
Yield: 94% 
Na (69 mg, 3.00 mmol) was dissolved in dry MeOH (1.83 mL) under inert atmosphere and 6-chloroguanine 
(102 mg, 0.60 mmol) was added to the mixture, forming a yellow suspension which was refluxed for 24 h. 
The resulting mixture was diluted with MeOH (0.5 mL), NH4Cl (161 mg, 3.01 mmol) was added and the 
suspension was stirred at RT for 30’. The solvent was evaporated under reduced pressure, H2O was added 
(3.0 mL) and the resulting suspension was neutralized with 2 M NaOH to precipitate Z as a white powder, 
which was filtered, washed with few cold H2O and dried under reduced pressure (69 mg, 0.42 mmol). 
Yield: 70% 
Rf: 0.38 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.19 (v br s, 1H, N
9H), 8.06 (s, 1H, H8), 6.61 (br s, 2H, N2H2), 3.99 (s, 
3H, OCH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 160.4 (C
6), 159.7 (C2), 155.3 (C4), 139.5 (C8), 111.7 (C5), 53.9 (OCH3). 
MS (ESI+): m/z calcd for [C6H7N5O]
+: 165.07; found: 166.2 [M+H]+, 188.2 [M+Na]+, 331.1 [2M+H]+, 353.2 
[2M+Na]+. 
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7.2.2. Synthesis of 6-substituted inosines and guanosines (28-36, 38-48, 58) 
7.2.2.1. General procedure for the synthesis of 2’,3’,5’-tri-O-acetylinosine (51) and guanosine (56) 
 
Ac2O (13.20 mL, 139.64 mmol) and TEA (20.41 mL, 146.43 mmol) were added dropwise to a suspension of 
37 (10.73 g, 40.00 mmol for 51) or 55 (11.33 g, 40.00 mmol for 56) and DMAP (347 mg, 2.84 mmol) in 
CH3CN (380 mL) under inert atmosphere. The mixture was stirred at RT for 2 h, during which time it became 
a transparent solution. 
The solvent was removed under reduced pressure and the resulting white crude was treated with i-PrOH 
(100 mL) to precipitate the product, which was filtered, washed with few cold i-PrOH and dried under 
reduced pressure. 
7.2.2.1.1. 2’,3’,5’-Tri-O-acetylinosine (51) 
C16H18N4O8; MW 394.34 
 
White powder (15.06 g, 38.19 mmol). 
Yield: 95% 
Rf: 0.71 (CH2Cl2-MeOH, 12:1) or 0.63 (CH2Cl2-MeOH, 9:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.91 (br s, 1H, N
1H), 8.21 (s, 1H, H2), 8.02 (s, 1H, H8), 6.18 (d, J = 5.3 Hz, 
1H, H1’), 5.89 (t, J = 5.4 Hz, 1H, H2’), 5.62 (t, J = 5.0 Hz, 1H, H3’), 4.50-4.47 (m, 1H, H4’), 4.46 (dd, J = 8.3, 3.4 
Hz, 1H, H5’a), 4.40 (dd, J = 12.6, 4.9 Hz, 1H, H5’b), 2.17 (s, 3H, CH3CO), 2.16 (s, 3H, CH3CO), 2.12 (s, 3H, 
CH3CO). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 171.2, 170.6, 170.4 (CH3CO), 157.6 (C
6), 149.1 (C4), 147.5 (C2), 138.7 
(C8), 125.9 (C5), 86.7 (C1’), 80.6 (C4’), 73.3 (C2’), 71.1 (C3’), 63.9 (C5’), 21.6, 21.5, 21.3 (CH3CO). 
MS (ESI+): m/z calcd for [C16H18N4O8]
+: 394.11; found: 417.1 [M+Na]+, 811.2 [2M+Na]+, 1204.9 [3M+Na]+. 
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7.2.2.1.2. 2’,3’,5’-Tri-O-acetylguanosine (56) 
C16H19N5O8; MW 409.35 
 
White powder (15.39 g, 37.60 mmol). 
Yield: 94% 
Rf: 0.45 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.78 (br s, 1H, N
1H), 7.93 (s, 1H, H8), 6.56 (br s, 2H, N2H2), 5.99 (d, J 
= 6.2 Hz, 1H, H1’), 5.79 (t, J = 6.0 Hz, 1H, H2’), 5.50 (dd, J = 5.9, 4.1 Hz, 1H, H3’), 4.38 (dd, J = 11.3, 3.7 Hz, 1H, 
H5’a), 4.32 (dd, J = 8.8, 4.6 Hz, 1H, H4’), 4.26 (dd, J = 11.2, 5.6 Hz, 1H, H5’b), 2.12 (s, 3H, CH3CO), 2.05 (s, 3H, 
CH3CO), 2.04 (s, 3H, CH3CO). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 170.4, 169.8, 169.6 (CH3CO), 156.6 (C
6), 153.8 (C2), 151.1 (C4), 135.6 
(C8), 116.9 (C5), 84.5 (C1’), 79.5 (C4’), 72.1 (C2’), 70.3 (C3’), 63.0 (C5’), 20.4, 20.3, 20.1 (CH3CO). 
MS (ESI+): m/z calcd for [C16H19N5O8]
+: 409.12; found: 410.1 [M+H]+, 432.2 [M+Na]+, 841.1 [2M+Na]+, 1249.8 
[3M+Na]+, 1659.5 [4M+Na]+. 
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7.2.2.2. 6-Chloro-2’,3’,5’-tri-O-acetylinosine (52) 
C16H17ClN4O7; MW 412.78 
 
Under inert atmosphere, a solution of SOCl2 (1.40 mL, 19.19 mmol) and dry DMF (0.8 mL) in dry CH2Cl2 (35 
mL) was added dropwise to one of 51 (1.40 g, 3.55 mmol) in dry CH2Cl2 (92 mL) at 0°C. The resulting 
colourless mixture was refluxed for 16 h. 
The resulting light yellow solution was washed with saturated aqueous NaHCO3 (3x40 mL) until no more 
CO2 evolution was observed, brine (2x50 mL) and H2O (2x50 mL) and dried over Na2SO4. After removing the 
solvent under reduced pressure, the oil crude was filtered on silica (CH2Cl2-MeOH, 6:1) to get 52 as a very 
dense yellow oil (1.44 g, 3.49 mmol). 
Yield: 98% 
Rf: 0.71 (CH2Cl2-MeOH, 12:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.80 (s, 1H, H2
8), 8.31 (s, 1H, H8), 6.26 (d, J = 5.2 Hz, 1H, H1’), 5.97 (t, J = 
5.3 Hz, 1H, H2’), 5.67 (t, J = 5.0 Hz, 1H, H3’), 4.51 (dd, J = 7.3, 3.9 Hz, 1H, H5’a), 4.46 (d, J = 3.2 Hz, 1H, H4’), 4.41 
(dd, J = 12.1, 4.2 Hz, 1H, H5’b), 2.18 (s, 3H, CH3CO), 2.15 (s, 3H, CH3CO), 2.11 (s, 3H, CH3CO). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 170.1, 169.5, 169.3 (CH3CO), 152.1 (C
2, C6), 151.2 (C4), 134.9 (C8), 
132.2 (C5), 86.8 (C1’), 80.4 (C4’), 73.0 (C2’), 70.3 (C3’), 62.8 (C5’), 20.6, 20.4, 20.3 (CH3CO). 
MS (ESI+): m/z calcd for [C16H17ClN4O7]
+: 412.08; found: 413.5 [M+H]+, 435.2 [M+Na]+, 825.1 [2M+H]+, 846.8 
[2M+Na]+. 
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7.2.2.3. 6-Chloroinosine (49) 
C10H11ClN4O4; MW 286.67 
 
33% aqueous NH4OH (16.6 mL, 140.66 mmol) was added to a solution of 52 (2.00 g, 4.85 mmol) in MeOH 
(60 mL). The resulting yellow mixture was stirred at RT, monitored by TLC (CH2Cl2-MeOH, 9:1) until 
consumption of the starting reagent and complete formation of the product (1 h 30’) and quenched by 
neutralization with 6 M HCl at 0°C. 
After filtering the insoluble crystalline residue, the solvent was removed under reduced pressure and the 
resulting white crude was purified by flash column chromatography (CH2Cl2-MeOH, 9.3:0.7) to obtain 49 as 
a very pale yellow powder (960 mg, 3.35 mmol). 
Yield: 69% 
Rf: 0.35 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.96 (s, 1H, H
8), 8.83 (s, 1H, H2), 6.05 (d, J = 5.2 Hz, 1H, H1’), 5.58 (d, J 
= 5.8 Hz, 1H, OH2’), 5.26 (d, J = 5.2 Hz, 1H, OH3’), 5.10 (t, J = 5.4 Hz, 1H, OH5’), 4.60 (dd, J = 10.5, 5.3 Hz, 1H, 
H2’), 4.20 (dd, J = 9.2, 4.7 Hz, 1H, H
3’), 4.00 (q, J = 3.9 Hz, 1H, H
4’), 3.72 (dt, J = 12.0, 4.6 Hz, 1H, H
5’a), 3.59 
(ddd, J = 11.9, 5.4, 4.1 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 152.2 (C
2), 152.1 (C6), 149.8 (C4), 146.2 (C8), 131.9 (C5), 88.7 (C1’), 
86.2 (C4’), 74.4 (C2’), 70.5 (C3’), 61.5 (C5’). 
MS (ESI+): m/z calcd for [C10H11ClN4O4]
+: 286.05; found: 287.1 [M+H]+, 309.2 [M+Na]+. 
UV-Vis (CH3OH): λmax = 265 nm. 
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7.2.2.4. 6-Thio-2’,3’,5’-tri-O-acetylinosine (53) 
C16H18N4O7S; MW 410.40 
 
51 (1.97 g, 5.00 mmol) was dissolved in pyridine (10.0 mL) under inert atmosphere and Lawesson’s reagent 
(4.04 g, 9.99 mmol) was added. The solution was refluxed for 7 h. 
The solvent was concentrated under reduced pressure to half its volume, then the resulting solution was 
washed with saturated aqueous NaHCO3 (2x5 mL) and extracted with CH2Cl2 (3x15 mL). The reunited 
organic phases were washed with 1 M HCl (2x5 mL), dried over Na2SO4 and evaporated under reduced 
pressure. Further volatiles were removed with a mechanic pump to obtain 53 as a brown-yellow solid (1.58 
g, 3.85 mmol). 
Yield: 77% 
Rf: 0.39 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.90 (s, 1H, N
6H), 8.51 (s, 1H, H8), 8.25 (d, J = 3.4 Hz, 1H, H2), 6.22 
(d, J = 5.5 Hz, 1H, H1’), 5.91 (t, J = 5.7 Hz, 1H, H2’), 5.55 (dd, J = 5.8, 4.9 Hz, 1H, H3’), 4.44-4.36 (m, 2H, H4’, 
H5’a), 4.27 (dd, J = 12.8, 6.5 Hz, 1H, H
5’b), 2.12 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 176.8 (C
6), 170.5, 169.9, 169.7 (CH3CO), 146.0 (C
2), 144.1 (C4), 142.2 
(C8), 136.2 (C5), 86.2 (C1’), 80.2 (C4’), 72.8 (C2’), 70.4 (C3’), 63.2 (C5’), 21.0, 20.8, 20.6 (CH3CO). 
MS (ESI+): m/z calcd for [C16H18N4O7S]
+: 410.09; found: 433.3 [M+Na]+, 843.3 [2M+Na]+. 
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7.2.2.5. 6-Thioinosine (43) 
C10H12N4O4S; MW 284.29 
 
28% aqueous NH4OH (1.26 mL, 9.06 mmol) was added to a solution of 53 (143 mg, 0.35 mmol) in MeOH 
(7.0 mL). The resulting mixture was stirred at RT for 15 h. 
After neutralization with 2 M AcOH, the solvent was removed under reduced pressure and 43 was 
recrystallized from Et2O as a yellow powder (74 mg, 0.26 mmol). 
Yield: 74% 
 
Under inert atmosphere, 53 (1.25 g, 3.05 mmol) was dissolved in MeOH (60 mL) and a 25% NaOMe solution 
in MeOH (3.10 mL, 13.56 mmol) was added. The resulting solution was stirred at RT for 2 h. 
After quenching by adding NH4Cl (193 mg, 3.61 mmol), the light yellow precipitate was filtered and 
repeatedly washed with acetone. The solvent from the filtered solution was removed under reduced 
pressure to obtainproduct 43 as a light brown solid (503 mg, 1.77 mmol). 
Yield: 58% 
Rf: 0.84 (EtOH-H2O, 7:3) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.80 (s, 1H, N
1H), 8.55 (s, 1H, H8), 8.23 (s, 1H, H2), 5.90 (d, J = 5.5 
Hz, 1H, H1’), 5.53 (d, J = 5.8 Hz, 1H, OH2’), 5.22 (d, J = 4.5 Hz, 1H, OH3’), 5.07 (d, J = 4.4 Hz, 1H, OH5’), 4.48 (ps 
q, J = 5.2 Hz, 1H, H2’), 4.15 (d, J = 4.0 Hz, 1H, H3’), 3.96 (ps q, J = 3.8 Hz, 1H, H4’), 3.67 (dt, J = 11.8, 4.6 Hz, 1H, 
H5’), 3.57 (ddd, J = 11.8, 5.1, 4.4 Hz, 1H, H5’). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 176.5 (C
6), 145.7 (C2), 144.4 (C4), 141.7 (C8), 135.9 (C5), 88.0 (C1’), 
86.1 (C4’), 74.7 (C2’), 70.6 (C3’), 61.6 (C5’). 
MS (ESI+): m/z calcd for [C10H12N4O4S]
+: 284.06; found: 307.0170 [M+Na]+. 
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7.2.2.6. General procedure for the synthesis of N6-alkyl- and N6,N6-dialkyladenosines (28, 29, 30, 31, 32, 
33, 34, 35, 36) 
 
The appropriate amine or amine solution (1.50 mmol for 28, 29, 31, 32, 33, 34 and 36, 10.00 mmol for 30 
and 5.00 mmol for 35) and TEA (0.14 mL, 1.00 mmol) were added to a suspension of 49 (143 mg, 0.50 
mmol) in EtOH (3.5 mL) under inert atmosphere. The resulting mixture was refluxed and monitored by TLC 
(CH2Cl2-MeOH, 9:1) until consumption of the starting reagent (between 2 and 55 h). 
28, 30, 32 and 35: The solvent was removed under reduced pressure and the resulting crude was purified 
by flash column chromatography (CH2Cl2-MeOH, 8.9:1.1 for 28, 9.1:0.9 for 30, 9.3:0.7 for 32 and 35). 
29, 31, 33, 34 and 36: The mixture was stored at 4°C overnight, then the resulting precipitate was filtered, 
washed with very few cold EtOH and dried under reduced pressure. 
7.2.2.6.1. N6-Methyladenosine (28) 
C11H15N5O4; MW 281.27 
 
White powder (116 mg, 0.41 mmol). 
Yield: 82% 
Rf: 0.22 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.34 (s, 1H, H
8), 8.23 (br s, 1H, H2), 7.81 (br s, 1H, N6H), 5.88 (d, J = 
6.2 Hz, 1H, H1’), 5.45-5.39 (m, 2H, OH2’, OH5’), 5.17 (d, J = 4.6 Hz, 1H, OH3’), 4.61 (dd, J = 11.3, 6.1 Hz, 1H, 
H2’), 4.14 (dd, J = 7.8, 4.7 Hz, 1H, H3’), 3.96 (br q, J = 3.3 Hz, 1H, H4’), 3.68 (dt, J = 12.0, 4.1 Hz, 1H, H5’a), 3.55 
(ddd, J = 11.8, 7.6, 3.9 Hz, 1H, H5’b), 2.96 (br s, 1H, NHCH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.2 (C
6), 152.5 (C2), 148.1 (C4), 139.7 (C8), 119.9 (C5), 88.0 (C1’), 
86.0 (C4’), 73.6 (C2’), 70.7 (C3’), 61.7 (C5’), 27.1 (CH3). 
MS (ESI+): m/z calcd for [C11H15N5O4]
+: 281.11; found: 282.0 [M+H]+, 303.9 [M+Na]+, 584.8 [2M+Na]+. 
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7.2.2.6.2. N6-Ethyladenosine (29) 
C12H17N5O4; MW 295.29 
 
White powder (124 mg, 0.42 mmol). 
Yield: 84% 
Rf: 0.27 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.34 (s, 1H, H
8), 8.20 (br s, 1H, H2), 7.86 (br s, 1H, N6H), 5.88 (d, J = 
6.2 Hz, 1H, H1’), 5.46-5.39 (m, 2H, OH2’, OH5’), 5.17 (d, J = 4.6 Hz, 1H, OH3’), 4.61 (dd, J = 11.3, 6.0 Hz, 1H, 
H2’), 4.14 (dd, J = 7.7, 4.6 Hz, 1H, H3’), 3.96 (br q, J = 3.1 Hz, 1H, H3’), 3.67 (dt, J = 12.0, 4.0 Hz, 1H, H5’a), 3.60-
3.44 (m, 2H, H5’b, NHCH2), 1.17 (t, J = 7.1 Hz, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.0 (C
6), 152.8 (C2), 148.7 (C4), 140.1 (C8), 120.2 (C5), 88.4 (C1’), 
86.4 (C4’), 73.9 (C2’), 71.1 (C3’), 62.1 (C5’), 35.0 (NHCH2), 15.3 (CH3). 
MS (ESI+): m/z calcd for [C12H17N5O4]
+: 295.13; found: 296.1 [M+H]+, 318.0 [M+Na]+, 591.4 [2M+H]+, 612.8 
[2M+Na]+. 
7.2.2.6.3. N6-i-Propyladenosine (30) 
C13H19N5O4; MW 309.32 
 
White powder (146 mg, 0.47 mmol). 
Yield: 94% 
Rf: 0.32 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.34 (s, 1H, H
8), 8.20 (br s, 1H, H2), 7.61 (br d, J = 7.9 Hz, 1H, N6H), 
5.89 (d, J = 6.2 Hz, 1H, H1’), 5.46-5.38 (m, 2H, OH2’, OH5’), 5.17 (br d, J = 4.1 Hz, 1H, OH4’), 4.62 (dd, J = 10.6, 
5.4 Hz, 1H, H2’), 4.47 (br s, 1H, NHCH), 4.16 (br dd, J = 6.9, 3.7 Hz, 1H, H3’), 3.98 (q, J = 3.3 Hz, 1H, H
4’), 3.69 
(dt, J = 11.9, 3.7 Hz, 1H, H5’a), 3.61-3.52 (m, 1H, H5’b), 1.23 (d, J = 6.5 Hz, 6H, CH(CH3)2). 
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13C NMR (DMSO-d6, 100 MHz): δ (ppm) 154.5 (C
6), 152.8 (C2), 148.9 (C4), 140.0 (C8), 120.1 (C5), 88.5 (C1’), 
86.4 (C4’), 74.0 (C2’), 71.1 (C3’), 62.2 (C5’), 41.8 (NHCH), 22.8 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C13H19N5O4]
+: 309.14; found: 310.2 [M+H]+, 332.2 [M+Na]+, 641.0 [2M+Na]+. 
7.2.2.6.4. N6-n-Butyladenosine (31) 
C14H21N5O4; MW 323.35 
 
White powder (115 mg, 0.36 mmol). 
Yield: 71% 
Rf: 0.33 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.26 (s, 1H, H
8), 8.23 (br s, 1H, H2), 5.97 (d, J = 6.4 Hz, 1H, H1’), 4.76 (dd, 
J = 6.1, 5.5 Hz, 1H, H2’), 4.34 (dd, J = 5.0, 2.4 Hz, 1H, H3’), 4.19 (br q, J = 2.4 Hz, 1H, H4’), 3.91 (dd, J = 12.6, 2.3 
Hz, 1H, H5’a), 3.76 (dd, J = 12.6, 2.5 Hz, 1H, H5’b), 3.62 (br s, 1H, NHCH2), 1.70 (quint, J = 7.3 Hz, 2H, 
CH2CH2CH3), 1.48 (sest, J = 7.4 Hz, 2H, CH2CH3), 1.00 (t, J = 7.4 Hz, 3H, CH3). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.34 (s, 1H, H
8), 8.21 (br s, 1H, H2), 7.90 (br s, 1H, N6H), 5.88 (d, J = 
6.1 Hz, 1H, H1’), 5.49-5.41(m, 2H, OH2’, OH5’), 5.20 (d, J = 4.4 Hz, 1H, OH3’), 4.62 (dd, J = 11.1, 5.6 Hz, 1H, H2’), 
4.15 (br dd, J = 7.2, 4.2 Hz, 1H, H3’), 3.97 (br d, J = 2.7 Hz, 1H, H4’), 3.73-3.63 (dt, J = 11.8, 3.6 Hz, 1H, H5’a), 
3.55 (ddd, J = 11.6, 7.6, 3.7 Hz, 1H, H5‘b), 3.52-3.40 (m, 1H, NHCH2), 1.58 (ps quint, J = 7.3 Hz, 2H, 
CH2CH2CH3), 1.33 (dq, J = 14.3, 7.1 Hz, 2H, CH2CH3), 0.90 (t, J = 7.3 Hz, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.8 (C
6), 153.5 (C2), 149.3 (C4), 140.7 (C8), 120.9 (C5), 89.1 (C1’), 
87.0 (C4’), 74.6 (C2’), 71.8 (C3’), 62.8 (C5’), 39.7 (NHCH2), 32.3 (CH2CH2CH3), 20.7 (CH2CH3), 14.9 (CH3). 
MS (ESI+): m/z calcd for [C14H21N5O4]
+: 323.16; found: 324.5 [M+H]+, 668.9 [2M+Na]+. 
UV-Vis (CH3OH): λmax = 271 nm. 
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7.2.2.6.5. N6-Cyclohexyladenosine (32) 
C16H23N5O4; MW 349.38 
 
White powder (139 mg, 0.40 mmol). 
Yield: 79% 
Rf: 0.47 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.27 (s, 1H, H
8), 8.22 (s, 1H, H2), 5.97 (d, J = 6.4 Hz, 1H, H1’), 4.76 (dd, J 
= 6.3, 5.3 Hz, 1H, H2’), 4.34 (dd, J = 5.1, 2.5 Hz, 1H, H3’), 4.19 (q, J = 2.5 Hz, 1H, H4’), 4.14 (v br s, 1H, Ha), 3.91 
(dd, J = 12.6, 2.4 Hz, 1H, H5’a), 3.76 (dd, J = 12.6, 2.6 Hz, 1H, H5’b), 2.12-2.02 (m, 2H, Hb), 1.89-1.80 (m, 2H, 
Hc), 1.75-1.66 (m, 1H, Hd), 1.56-1.25 (m, 5H, Hb, Hc). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 154.1 (C
6), 152.2 (C2), 147.7 (C4), 139.9 (C8), 119.8 (C5), 89.9 (C1’), 86.8 
(C4’), 74.1 (C2’), 71.3 (C3’), 62.1 (C5’), 49.3 (Ca), 32.5 (Cb), 25.3 (Cd), 24.6 (Cc). 
MS (ESI+): m/z calcd for [C16H23N5O4]
+: 349.18; found: 350.3 [M+H]+, 372.3 [M+Na]+. 
UV-Vis (CH3OH): λmax = 272 nm. 
7.2.2.6.6. N6-(2-Phenyl)ethyladenosine (33) 
C18H21N5O4; MW 371.39 
 
White powder (121 mg, 0.33 mmol). 
Yield: 65% 
Rf: 0.53 (CH2Cl2-MeOH, 10:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.36 (br s, 1H, H
8), 8.25 (br s, 1H, H2), 7.95 (br s, 1H, N6H), 7.34-7.17 
(m, 5H, C6H5), 5.89 (d, J = 6.1 Hz, 1H, H
1’), 5.45 (d, J = 6.1 Hz, 1H, OH2’), 5.41 (dd, J = 7.1, 4.6 Hz, 1H, OH5’), 
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5.19 (d, J = 4.5 Hz, 1H, OH3’), 4.62 (dd, J = 11.1, 5.8 Hz, 1H, H2’), 4.15 (dd, J = 7.6, 4.5 Hz, 1H, H3’), 3.97 (br 
dd, J = 6.4, 3.3 Hz, 1H, H4’), 3.80-3.64 (m, 3H, NHCH2, H
5’a), 3.61-3.51 (ddd, J = 11.8, 7.5, 3.9 Hz, 1H, H5’b), 
2.93 (t, J = 7.5 Hz, 2H, CH2C6H5). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.0 (C
6), 152.9 (C2), 148.8 (C4), 140.2 (C8), 140.0 (Ca), 129.1, 128.8 
(Cb, Cc), 126.5 (Cd), 120.3 (C5), 88.4 (C1’), 86.4 (C4’), 74.0 (C2’), 71.1 (C3’), 62.1 (C5’), 41.8 (NHCH2), 35.5 
(CH2C6H5). 
MS (ESI+): m/z calcd for [C18H21N5O4]
+: 371.16; found: 372.3 [M+H]+, 394.3 [M+Na]+, 765.3 [2M+Na]+. 
7.2.2.6.7. N6-Hydroxyethyladenosine (34) 
C12H17N5O5; MW 311.29 
 
White powder (129 mg, 0.41 mmol). 
Yield: 83% 
Rf: 0.18 (CH2Cl2-MeOH, 7:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.36 (s, 1H, H
8), 8.22 (s, 1H, H2), 7.69 (br s, 1H, N6H), 5.89 (d, J = 6.1 
Hz, 1H, H1’), 5.50-5.35 (m, 2H, OH2’, OH5’), 5.19 (br s, 1H, OH3’), 4.76 (br s, 1H, CH2CH2OH), 4.61 (br dd, J = 
8.6, 5.2 Hz, 1H, H2’), 4.15 (br s, 1H, H3’), 3.97 (q, J = 3.3 Hz, 1H, H
4’), 3.68 (br dt, J = 12.0, 3.2 Hz, 1H, H5’a), 
3.63-3.51 (m, 5H, H5’b, NHCH2CH2OH). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.3 (C
6), 152.8 (C2), 148.9 (C4), 140.2 (C8), 120.3 (C5), 88.4 (C1’), 
86.4 (C4’), 74.0 (C2’), 71.1 (C3’), 62.1 (C5’), 60.2 (CH2OH), 43.0 (NHCH2). 
MS (ESI+): m/z calcd for [C12H17N5O5]
+: 311.12; found: 312.3 [M+H]+, 334.3 [M+Na]+, 645.2 [2M+Na]+. 
UV-Vis (CH3OH): λmax = 262 nm. 
7.2.2.6.8. N6,N6-Dimethyladenosine (35) 
C12H17N5O4; MW 295.29 
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White powder (102 mg, 0.35 mmol). 
Yield: 69% 
Rf: 0.51 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.22 (s, 1H, H
8), 8.20 (s, 1H, H2), 5.97 (d, J = 6.4 Hz, 1H, H1’), 4.76 (dd, J 
= 6.0, 5.4 Hz, 1H, H2’), 4.34 (dd, J = 5.0, 2.4 Hz, 1H, H3’), 4.19 (br dd, J = 4.5, 2.5 Hz, 1H, H4’), 3.90 (dd, J = 12.5, 
2.2 Hz, 1H, H5’a), 3.76 (dd, J = 12.5, 2.2 Hz, 1H, H5’b), 3.53 (br s, 6H, N(CH3)2). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 154.9 (C
6), 151.3 (C2), 149.3 (C4), 138.8 (C8), 120.6 (C5), 89.8 (C1’), 86.7 
(C4’), 73.9 (C2’), 71.3 (C3’), 62.1 (C5’), 37.6 (N(CH3)2).  
MS (ESI+): m/z calcd for [C12H17N5O4]
+: 295.13; found: 296.2 [M+H]+, 318.3 [M+Na]+, 613.4 [2M+Na]+. 
7.2.2.6.9. N6,N6-Bis-Hydroxyethyladenosine (36) 
C14H21N5O6; MW 355.35 
 
White powder (165 mg, 0.46 mmol). 
Yield: 93% 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.38 (s, 1H, H
8), 8.21 (s, 1H, H2), 5.91 (d, J = 6.0 Hz, 1H, H1’), 5.44 (d, J 
= 6.2 Hz, 1H, OH2’), 5.36 (dd, J = 6.8, 4.7 Hz, 1H, OH5’), 5.17 (d, J = 4.7 Hz, 1H, OH3’), 4.79 (br t, J = 5.2 Hz, 2H, 
N(CH2CH2OH)2), 4.59 (dd, J = 11.2, 5.9 Hz, 1H, H
2’), 4.37-4.19 (br s, 2H, Ha), 4.15 (dd, J = 8.1, 4.7 Hz, 1H, H3’), 
3.97 (br q, J = 3.3 Hz, 1H, H4’), 3.92-3.76 (br, 2H, Ha), 3.74-3.62 (m, 5H, Hb, H5‘b), 3.56 (ddd, J = 11.7, 7.3, 3.9 
Hz, 1H, H5‘b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 154.3 (C
6), 152.1 (C2), 150.4 (C4), 139.4 (C8), 120.0 (C5), 88.3 (C1’), 
86.2 (C4’), 73.9 (C2’), 71.0 (C3’), 62.0 (C5’), 60.6, 58.9 (Cb), 52.8, 52.6 (Ca). 
MS (ESI+): m/z calcd for [C14H21N5O6]
+: 355.15; found: 356.2 [M+H]+, 378.3 [M+Na]+, 733.2 [2M+Na]+. 
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7.2.2.7. General procedure for the synthesis of 6-alkoxyinosines 38, 39 and 42 
 
Na (69 mg, 3.00 mmol) was dissolved in the appropriate dry alcohol (3.00 mL) (for 38 and 39) or in a 
solution of it (3.00 mmol) in dry THF (4.0 mL) (for 42) under inert atmosphere. A solution of 52 (206 mg, 
0.50 mmol) in the same dry alcohol (3.00 mL) or in dry THF (2.0 mL) was added, respectively, and the 
resulting mixture was refluxed and monitored by TLC (CH2Cl2-MeOH, 9:1) until consumption of the starting 
reagent and complete formation of the product (between 1 and 6 h). 
NH4Cl (160 mg, 3.00 mmol) was added, the suspension was stirred at RT for 15’, filtered to eliminate the 
residue solid and the solvent was removed under reduced pressure. 
38 and 42: The product was purified by flash column chromatography (CH2Cl2-MeOH, 9.1:0.9 for 38 and 
9.4:0.6 for 42). 
39: The crude residue was suspended in acetone and filtered. The operation was repeated twice after 
evaporation of the filtrate. 
7.2.2.7.1. 6-Methoxyinosine (38) 
C11H14N4O5; MW 282.25 
 
Light brown powder (128 mg, 0.45 mmol). 
Yield: 91% 
Rf: 0.33 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.56 (s, 1H, H
8), 8.54 (s, 1H, H2), 6.10 (d, J = 5.9 Hz, 1H, H1’), 4.76 (t, J = 
5.5 Hz, 1H, H2’), 4.38 (dd, J = 5.1, 3.2 Hz, 1H, H
3’), 4.22-4.18 (m, 4H, H4’, OCH3), 3.91 (dd, J =12.4, 2.8 Hz, 1H, 
H5’a), 3.79 (dd, J = 12.4, 3.1 Hz, 1H, H5’b). 
1H NMR (CD3OD, 100 MHz): δ (ppm) 161.0 (C
6), 151.8 (C2), 151.1 (C4), 142.5 (C8), 121.4 (C5), 89.6 (C1’), 86.5 
(C4’), 74.3 (C2’), 70.9 (C3’), 61.8 (C5’), 53.5 (OCH3). 
MS (ESI+): m/z calcd for [C11H14N4O5]
+: 282.10; found: 305.3 [M+Na]+, 587.2 [2M+Na]+. 
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7.2.2.7.2. 6-Ethoxyinosine (39) 
C12H16N4O5; MW 296.28 
 
Ochre powder (148 mg, 0.50 mmol). 
Yield: quantitative 
Rf: 0.38 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.53 (s, 1H, H
8), 8.51 (s, 1H, H2), 6.09 (d, J = 6.0 Hz, 1H, H1’), 4.76 (t, J = 
5.5 Hz, 1H, H2’), 4.69 (q, J = 7.1 Hz, 2H, OCH2), 4.37 (dd, J = 5.2, 3.1 Hz, 1H, H
3’), 4.19 (q, J = 3.0 Hz, 1H, H4’), 
3.91 (dd, J = 12.4, 2.8 Hz, 1H, H5’a), 3.79 (dd, J = 12.4, 3.0 Hz, 1H, H5’b), 1.51 (t, J = 7.1 Hz, 3H, CH2CH3). 
1H NMR (CD3OD, 100 MHz): δ (ppm) 160.8 (C
6), 151.8 (C2), 151.2 (C4), 142.4 (C8), 121.5 (C5), 89.7 (C1’), 86.5 
(C4’), 74.3 (C2’), 71.0 (C3’), 63.1 (OCH2), 61.8 (C
5’), 13.3 (CH3). 
MS (ESI+): m/z calcd for [C12H16N4O5]
+: 296.11; found: 319.2 [M+Na]+, 615.1 [2M+Na]+. 
7.2.2.7.3. 6-(2-Phenyl)ethoxyinosine (42) 
C18H20N4O5; MW 372.38 
 
White solid (54 mg, 0.15 mmol). 
Yield: 29% 
Rf: 0.48 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.63 (s, 1H, H
8), 8.55 (s, 1H, H2), 7.38-7.17 (m, 5H, C6H5), 6.02 (d, J = 
5.7 Hz, 1H, H1’), 5.52 (br d, J = 5.7 Hz, 1H, OH2’), 5.24 (br d, J = 4.4 Hz, 1H, OH3’), 5.16 (t, J = 5.4 Hz, 1H, OH5’), 
4.78 (t, J = 6.9 Hz, 1H, OCH2), 4.61 (dd, J = 10.3, 5.1 Hz, 1H, H
2’), 4.20 (br d, J = 3.7 Hz, 1H, H3’), 4.00 (br dd, J 
= 3.5, 3.6 Hz, 1H, H4’), 3.71 (dt, J = 11.4, 4.1 Hz, 1H, H5’a), 3.59 (br ddd, J = 11.9, 5.4, 4.2 Hz, 1H, H5’b), 3.15 (t, 
J = 6.9 Hz, 2H, CH2C6H5). 
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13C NMR (DMSO-d6, 100 MHz): δ (ppm) 160.5 (C
6), 152.4 (C4), 152.1 (C2), 142.9 (C8), 138.5, 129.4, 128.8, 
126.8 (C6H5), 121.6 (C
5), 88.3 (C1’), 86.2 (C4’), 74.3 (C2’), 70.8 (C3’), 67.5 (OCH2), 61.8 (C
5’), 35.0 (CH2C6H5). 
MS (ESI+): m/z calcd for [C18H20N4O5]
+: 372.14; found: 373.0 [M+H]+, 395.2 [M+Na]+, 767.1 [2M+Na]+. 
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7.2.2.8. 6-i-Propoxyinosine (40) 
C13H18N4O5; MW 310.31 
 
A 60% NaH dispersion in mineral oil (100 mg, 2.50 mmol) was added to dry i-PrOH (10.0 mL) portionwise in 
2 h at 50°C, under inert atmosphere. 49 (143 mg, 0.50 mmol) was added and the resulting suspension was 
refluxed for 4 h. 
After treatment with NH4Cl (134 mg, 2.51 mmol), the mixture was stirred at RT for 15’ and the solvent was 
removed under reduced pressure. The crude was purified by flash column chromatography (CH2Cl2-MeOH, 
9.2:0.8) to obtain 40 as a pale yellow powder (50 mg, 0.16 mmol). 
Yield: 32% 
Rf: 0.36 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.52 (s, 1H, H
8), 8.50 (s, 1H, H2), 6.08 (d, J = 6.0 Hz, 1H, H1’), 5.70 (sept, 
J = 6.2 Hz, 1H, OCH), 4.75 (t, J = 5.5 Hz, 1H, H2’), 4.37 (dd, J = 5.0, 3.2 Hz, 1H, H3’), 4.19 (q, J = 2.9 Hz, 1H, H4’), 
3.91 (dd, J = 12.4, 2.7 Hz, 1H, H5’a), 3.79 (dd, J = 12.4, 3.0 Hz, 1H, H5’b), 1.48 (d, J = 6.2 Hz, 6H, CH(CH3)2). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 160.4 (C
6), 151.8 (C2), 151.2 (C4), 142.3 (C8), 121.7 (C5), 89.7 (C1’), 86.5 
(C4’), 74.3 (C2’), 71.0 (C3’), 70.5 (OCH2), 61.8 (C
5’), 20.8 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C13H18N4O5]
+: 310.13; found: 311.0 [M+H]+, 333.2 [M+Na]+, 643.1 [2M+Na]+. 
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7.2.2.9. 6-n-Butoxyinosine (41) 
C14H20N4O5; MW 324.33 
 
Na (79 mg, 3.44 mmol) was dissolved in dry n-BuOH (3.00 mL) under inert atmosphere and a solution of 52 
(235 mg, 0.57 mmol) in dry n-BuOH (3.00 mL) was added. The resulting mixture was refluxed for 6 h. 
NH4Cl (193 mg, 3.61 mmol) was added, the suspension was stirred at RT for 15’, filtered to eliminate the 
residue solid and the solvent was removed under reduced pressure. The crude residue was suspended in 
acetone and filtered. The operation was repeated twice to obtain 41 as an ochre solid (159 mg, 0.49 mmol) 
after removing the solvent of the filtrate solution under reduced pressure. 
Yield: 86% 
 
Under inert atmosphere, Na (23 mg, 1.00 mmol) was dissolved in dry n-BuOH (1.0 mL) and the resulting 
solution was added to a one of 49 (143 mg, 0.50 mmol) in dry DMSO (1.2 mL). The transparent solution 
immediately became a white suspension, which was stirred at RT for 3 h, during which time it became less 
opaque. 
NH4Cl (40 mg, 0.75 mmol) was added and 41 was obtained by flash column cromatography (CH2Cl2-MeOH, 
9.4:0.6) as a solution in DMSO. It was then diluted in water and lyophilized to get a pale grey solid (96 mg, 
0.30 mmol). 
Yield: 59% 
Rf: 0.41 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.62 (s, 1H, H
8), 8.53 (s, 1H, H2), 6.00 (d, J = 5.7 Hz, 1H, H1’), 5.49 (d, J 
= 6.0 Hz, 1H, OH2’), 5.22 (d, J = 4.9 Hz, 1H, OH3’), 5.14 (t, J = 5.6 Hz, 1H, OH5’), 4.64-4.53 (m, 3H, H2’, OCH2), 
4.18 (dd, J = 8.6, 4.6 Hz, 1H, H3’), 3.98 (q, J = 3.7 Hz, 1H, H4’), 3.70 (dt, J = 11.8, 4.5 Hz, 1H, H5’a), 3.58 (ddd, J = 
12.0, 6.1, 4.2, 1H, H5’b), 1.80 (quin, J = 7.1 Hz, 2H, CH2CH2CH3), 1.46 (sext, J = 7.4 Hz, 2H, CH2CH3), 0.95 (t, J = 
7.4 Hz, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 160.7 (C
6), 152.3 (C4), 152.1 (C2), 142.8 (C8), 121.6 (C5), 88.3 (C1’), 
86.2 (C4’), 74.2 (C2’), 70.8 (C3’), 66.8 (OCH2), 61.8 (C
5’), 30.9 (CH2CH2CH3), 19.1 (CH2CH3), 14.1 (CH3). 
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MS (ESI+): m/z calcd for [C14H20N4O5]
+: 324.14; found: 325.2 [M+H]+, 347.3 [M+Na]+, 647.7 [2M]+, 671.2 
[2M+Na]+, 972.5 [3M]+, 973.6 [3M+H]+. 
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7.2.2.10. General procedure for the synthesis of 6-alkylthioinosines 45, 46 and 47 
 
The appropriate thiol (7.80 mmol for 45 and 2.50 mmol for 46 and 47) was added to a suspension of 
Na2CO3 (318 mg, 3.00 mmol) in EtOH (5.0 mL) and the resulting mixture was stirred at RT for 30’. 49 (143 
mg, 0.50 mmol) was added and the suspension was stirred at 30 °C for 48 h (for 45) or refluxed for 15 h (for 
46 and 47). 
After removing the solvent under reduced pressure, the product was purified by flash chromatography 
(AcOEt-n-hexane,1:1 for 45 and CH2Cl2-MeOH, 9.3:0.7 for 46 and 9.5:0.5 for 47). 
7.2.2.10.1. 6-Ethylthioinosine (45) 
C12H16N4O4S; MW 312.34 
 
White powder (104 mg, 0.33 mmol). 
Yield: 67% 
Rf: 0.45 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.74 (s, 1H, H
2), 8.71 (s, 1H, H8), 6.00 (d, J = 5.6 Hz, 1H, H1’), 5.53 (d, J 
= 5.9 Hz, 1H, OH2’), 5.24 (d, J = 5.0 Hz, 1H, OH3’), 5.12 (t, J = 5.6 Hz, 1H, OH5’), 4.61 (dd, J = 10.9, 5.5 Hz, 1H, 
H2’), 4.18 (dd, J = 8.7, 4.7 Hz, 1H, H3’), 3.98 (q, J = 3.8 Hz, 1H, H4’), 3.69 (dt, J = 11.9, 4.6 Hz, 1H, H5’a), 3.57 
(ddd, J = 11.9, 6.0, 4.1 Hz, 1H, H5’b), 3.36 (q, J = 7.3 Hz, 2H, SCH2), 1.37 (t, J = 7.3 Hz, 3H, CH3). 
1H NMR (DMSO-d6, 100 MHz): δ (ppm) 160.4 (C
6), 152.0 (C2), 148.6 (C4), 143.9 (C8), 131.7 (C5), 88.2 (C1’), 
86.2 (C4’), 74.2 (C2’), 70.7 (C3’), 61.7 (C5’), 22.9 (SCH2), 15.4 (CH3). 
HRMS (ESI-Q-Tof+): m/z calcd for [C12H16N4O4S]
+: 312.0892; found: 335.1109 [M+Na]+. 
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7.2.2.10.2. 6-i-Propylthioinosine (46) 
C13H18N4O4S; MW 326.37 
 
White powder (96 mg, 0.29 mmol). 
Yield: 59% 
Rf: 0.48 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.69 (s, 1H, H
2), 8.59 (s, 1H, H8), 6.09 (d, J = 5.8 Hz, 1H, H1’), 4.75 (t, J = 
5.4 Hz, 1H, H2’), 4.46-4.35 (m, 2H, H3’, SCH), 4.18 (dd, J = 5.9, 2.9 Hz, 1H, H4’), 3.91 (dd, J = 12.4, 2.7 Hz, 1H, 
H5’a), 3.79 (dd, J = 12.4, 3.0 Hz, 1H, H5’b), 1.51 (d, J = 6.8 Hz, 6H, CH(CH3)2). 
1H NMR (CD3OD, 100 MHz): δ (ppm) 161.8 (C
6), 151.3 (C2), 147.7 (C4), 143.0 (C8), 131.2 (C5), 89.5 (C1’), 86.4 
(C4’), 74.3 (C2’), 70.9 (C3’), 61.7 (C5’), 34.1 (SCH), 22.1 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C13H18N4O4S]
+: 326.10; found: 349.2 [M+Na]+, 675.2 [2M+Na]+ 
7.2.2.10.3. 6-n-Butylthioinosine (47) 
C14H20N4O4S; MW 340.40 
 
Pale ochre powder (150 mg, 0.44 mmol). 
Yield: 88% 
Rf: 0.47 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.74 (s, 1H, H
2), 8.70 (s, 1H, H8), 5.99 (d, J = 5.6 Hz, 1H, H1’), 5.53 (d, J 
= 5.9 Hz, 1H, OH2’), 5.24 (d, J = 5.0 Hz, 1H, OH3’), 5.12 (t, J = 5.5 Hz, 1H, OH5’), 4.60 (dd, J = 10.9, 5.6 Hz, 1H, 
H2’), 4.18 (dd, J = 8.7, 4.8 Hz, 1H, H3’), 3.98 (q, J = 3.8 Hz, 1H, H4’), 3.69 (dt, J = 11.9, 4.6 Hz, 1H, H5’a), 3.57 
(ddd, J = 12.0, 6.0, 4.1 Hz, 1H, H5’b), 3.37 (t, J = 7.3 Hz, 2H, SCH2), 1.70 (quin, J = 7.4 Hz, 2H, CH2CH2CH3), 1.45 
(sext, J = 7.4 Hz, 2H, CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, CH3). 
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1H NMR (DMSO-d6, 100 MHz): δ (ppm) 160.5 (C
6), 152.0 (C2), 148.6 (C4), 143.9 (C8), 131.7 (C5), 88.2 (C1’), 
86.2 (C4’), 74.2 (C2’), 70.7 (C3’), 61.7 (C5’), 31.7 (CH2CH2CH3), 28.0 (SCH2), 21.9 (CH2CH3), 14.0 (CH3). 
HRMS (ESI-Q-Tof+): m/z calcd for [C14H20N4O4S]
+: 340.1205; found: 363.1116 [M+Na]+. 
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7.2.2.11. 6-(2-Phenyl)ethylthioinosine (48) 
C18H20N4O4S; MW 388.44 
 
43 (143 mg, 0.50 mmol) and K2CO3 (83 mg, 0.60 mmol) were suspended in dry DMF (1.0 mL) and the 
resulting mixture was stirred at RT for 30’, then PhCH2CH2Br (0.14 mL, 1.00 mmol) was added. The mixture 
was stirred at RT for 1 h. 
The solution was diluted with a CH2Cl2-MeOH, 8:2 mixture and filtered on silica, then the solvent was 
removed under reduced pressure. The resulting crude was suspended in MeOH to precipitate 48 as a 
brown powder, which was filtered, washed with few cold precipitation solvent and dried under vacuum (92 
mg, 0.24 mmol). 
Yield: 47% 
Rf: 0.51 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.78 (s, 1H, H
2), 8.71 (s, 1H, H8), 7.39-7.18 (m, 5H, C6H5), 6.01 (d, J = 
5.5 Hz, 1H, H1’), 5.53 (d, J = 5.9 Hz, 1H, OH2’), 5.24 (d, J = 4.9 Hz, 1H, OH3’), 5.12 (t, J = 5.4 Hz, 1H, OH5’), 4.61 
(dd, J = 10.7, 5.4 Hz, 1H, H2’), 4.19 (dd, J = 8.3, 4.3 Hz, 1H, H3’), 3.98 (br dd, J = 7.3, 3.7 Hz, 1H, H4’), 3.70 (dt, J 
= 12.0, 4.3 Hz, 1H, H5’a), 3.66-3.54 (m, 3H, H5’b, SCH2), 3.04 (t, J = 7.5 Hz, 2H, CH2C6H5). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 160.2 (C
6), 152.1 (C2), 148.7 (C4), 143.7 (C8), 140.5, 129.1, 128.9, 
126.9 (C6H5), 131.7 (C
5), 88.2 (C1’), 86.2 (C4’), 74.2 (C2’), 70.7 (C3’), 61.7 (C5’), 35.6 (CH2C6H5), 29.7 (SCH2). 
HRMS (ESI-Q-Tof+): m/z calcd for [C18H20N4O4S]
+: 388.1205; found: 411.1547 [M+Na]+. 
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7.2.2.12. 6-Methyl-2’,3’,5’-tri-O-acetylinosine (54) 
C17H20N4O7; MW 392.36 
 
Under inert atmosphere, a 2.0 M solution of Me2Zn in toluene (1.6 mL, 3.2 mmol) was diluted in dry THF 
(5.0 mL) and a solution of 52 (233 mg, 0.56 mmol) in dry THF (2.0 mL) was added to it dropwise at 0°C. The 
formation of a light yellow solid was immediately observed. Pd(PPh3)4 (104 mg, 0.09 mmol) was added and 
the resulting brown suspension was stirred at 55°C for 10 h, then at RT for 5 days. 
After adding NH4Cl (626 mg, 11.70 mmol) and filtering the brown precipitate, the solvent was removed 
under reduced pressure to get a brown crude, which was purified by flash column chromatography (AcOEt-
n-hexane, 7.5:2.5) to obtain 54 as a yellow oil (179 mg, 0.46 mmol). 
Yield: 81% 
Rf: 0.33 (AcOEt-n-hexane, 7.5:2.5) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.84 (s, 1H, H
8), 8.61 (s, 1H, H2), 6.35 (d, J = 5.0 Hz, 1H, H1’), 6.12 (ps t, J = 
5.4 Hz, 1H, H2’), 5.77 (ps t, J = 5.3 Hz, 1H, H3’), 4.52-4.49 (m, 1H’, H5’a), 4.47 (q, J = 4.0 Hz, 1H, H4’), 4.40 (dd, 
1H, J = 12.9, 5.6 Hz, H5’b), 2.85 (s, 3H, CH3), 2.17 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 2.07 (s, 3H, CH3CO). 
MS (ESI+): m/z calcd for [C17H20N4O7]
+: 392.13; found: 393.3 [M+H]+, 415.3 [M+Na]+, 807.2 [2M+Na]+. 
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7.2.2.13. 6-Methylinosine (50) 
C11H14N4O4; MW 266.25 
 
54 (166 mg, 0.42 mmol) was dissolved in MeOH (6.0 mL) under inert atmosphere and 33% aqueous NH4OH 
(0.6 mL, 5.03 mmol) was added. The yellow solution was stirred at RT for 2 h 30’. 
After removing the solvent under reduced pressure, the resulting crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9:1) to obtain 50 as a white solid (74 mg, 0.28 mmol). 
Yield: 66% 
Rf: 0.46 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.80 (s, 1H, H
2), 8.76 (s, 1H, H8), 6.02 (d, J = 5.7 Hz, 1H, H1’), 5.52 (d, J 
= 6.0 Hz, 1H, OH2’), 5.23 (d, J = 5.0 Hz, 1H, OH3’), 5.12 (t, J = 5.6 Hz, 1H, OH5’), 4.63 (dd, J = 11.0, 5.7 Hz, 1H, 
H2’), 4.19 (dd, J = 8.6, 4.8 Hz, 1H, H3’), 3.98 (q, J = 3.8 Hz, 1H, H4’), 3.70 (dt, J = 11.9, 4.6 Hz, 1H, H5’a), 3.58 
(ddd, J =11.9, 6.0, 4.1 Hz, 1H, H5’b), 2.74 (s, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 158.8 (C
6), 152.1 (C2), 150.5 (C4), 144.5 (C8), 133.4 (C5), 88.1 (C1’), 
86.1 (C4’), 74.1 (C2’), 70.8 (C3’), 61.8 (C5’), 19.6 (CH3). 
MS (ESI+): m/z calcd for [C11H14N4O4]
+: 266.10; found: 267.3 [M+H]+, 289.2 [M+Na]+. 
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7.2.2.14. 6-Chloro-2’,3’,5’-tri-O-acetylguanosine (57) 
C16H18ClN5O7; MW 427.80 
 
Under inert atmosphere, 56 (10.23 g, 24.99 mmol), N,N-DMA (3.16 mL, 24.93 mmol) and Et4NCl (8.29 g, 
50.03 mmol), pre-dried in vacuo over P2O5 at 80°C for 1 day, were dissolved in dry CH3CN (50 mL). After 
stirring the mixture for 2’, POCl3 (13.7 mL, 146.98 mmol) was added dropwise and the resulting solution 
was refluxed and monitored by TLC (CH2Cl2-MeOH, 9.5:0.5) until complete disappearance of the reagent 
(35‘). 
The solvent was removed under reduced pressure and the resulting yellow foam was dissolved in CHCl3 
(150 mL) and stirred vigorously with crushed ice for 15’. The layers were separated and the aqueous phase 
was extracted with CHCl3 (4x50 mL). The combined organic phases were washed with cold H2O (3x60 mL), 
5% aqueous NaHCO3 until neutralization (3x50 mL) and brine (2x50 mL), dried over Na2SO4, filtered and 
concentrated to half its starting volume. i-PrOH (60 mL) was added and the solution was slowly 
concentrated under reduced pressure to 40 mL, then stored at 4 °C overnight. The formed precipitate was 
filtered, washed with cold i-PrOH and recrystallized from i-PrOH to obtain 57 (8.10 g, 18.93 mmol) as white 
crystals. 
Yield: 76% 
Rf: 0.45 (CH2Cl2-MeOH, 9.5:0.5) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.89 (s, 1H, H
8), 6.02 (d, J = 4.9 Hz, 1H, H1’), 5.97 (t, J = 5.1 Hz, 1H, H2’), 
5.76 (t, J = 4.97 Hz, 1H, H3’), 5.25 (br s, 2H, N2H2), 4.50-4.43 (m, 2H, H
4’, H5’a), 4.42-4.36 (m, 1H, H5’b), 2.16 (s, 
3H, CH3CO), 2.12 (s, 3H, CH3CO), 2.10 (s, 3H, CH3CO). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 170.4, 169.5, 169.3 (CH3CO), 159.1 (C
2), 153.1 (C4), 152.0 (C6), 140.7 
(C8), 125.9 (C5), 86.7 (C1’), 80.1 (C4’), 72.8 (C2’), 70.5 (C3’), 62.9 (C5’), 20.7, 20.5, 20.4 (CH3CO). 
MS (ESI+): m/z calcd for [C16H18ClN5O7]
+: 427.09; found: 428.2 [M+H]+, 450.4 [M+Na]+. 
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7.2.2.15. 6-O-Methylguanosine (58) 
C11H15N5O5; MW 297.27 
 
Na (35 mg, 1.52 mmol) was dissolved in MeOH (1.50 mL) under inert atmosphere and 57 (128 mg, 0.30 
mmol) was added. The resulting transparent solution was stirred at RT for 23 h. 
The solvent was removed under reduced pressure and the crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9.1:0.9) to obtain 58 as a white powder (51 mg, 0.17 mmol). 
Yield: 57% 
Rf: 0.32 (CH2Cl2-MeOH, 9:1) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 8.04 (s, 1H, H
8), 5.87 (d, J = 6.4 Hz, 1H, H1’), 4.74 (dd, J = 6.2, 5.3 Hz, 1H, 
H2’), 4.33 (dd, J = 5.2, 2.6 Hz, 1H, H3’), 4.16 (q, J = 2.5 Hz, 1H, H4’), 4.08 (s, 3H, OCH3), 3.90 (dd, J = 12.4, 2.5 
Hz, 1H, H5’a), 3.76 (dd, J = 12.4, 2.7 Hz, 1H, H5’b). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 161.4 (C
6), 160.0 (C2), 153.6 (C4), 139.2 (C8), 114.4 (C5), 87.7 (C1’), 85.9 
(C4’), 73.6 (C2’), 70.9 (C3’), 61.9 (C5’), 54.2 (CH3). 
HRMS (ESI-Q-Tof+): m/z calcd for [C11H15N5O5]
+: 297.107; found: 320.177 [M+Na]+, 617.370 [2M+Na]+. 
UV-Vis (CH3OH): λmax = 286 nm. 
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7.2.3. Synthesis of arabinosylguanine (59) 
7.2.3.1. 3’,5’-O-Tetra-i-propyldisiloxanylguanosine (60) 
C22H39N5O6Si2; MW 525.75 
 
TIPDSCl2 (1.28 mL, 4.00 mmol) was added dropwise to a stirred suspension of 55 (1.13 g, 3.99 mmol) and 
imidazole (654 mg, 9.61 mmol) in dry DMF (11.8 mL) under inert atmosphere. The resulting mixture was 
stirred for 2 h 30’ at RT, becoming a colourless solution. 
Cold H2O (15 mL) was added to the solution to precipitate 60 as a white powder, which was filtered, 
washed several times with cold H2O and dried under reduced pressure (2.06 g, 3.92 mmol). 
Yield: 98% 
Rf: 0.34 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.64 (br s, 1H, N
1H), 7.76 (s, 1H, H8), 6.50 (br s, 2H, N2H2), 5.68 (br 
d, J = 1.7 Hz, 1H, H1’), 5.62 (d, J = 5.1 Hz, 1H, OH2’), 4.35 (dd, J = 8.0, 5.1 Hz, 1H, H3’), 4.26 (td, J = 5.1, 1.7 Hz, 
1H, H2’), 4.09 (dd, J = 12.8, 3.2 Hz, 1H, H5’a), 3.99 (dt, J = 8.0, 2.9 Hz, 1H, H4’), 3.93 (dd, J = 12.7, 2.7 Hz, 1H, 
H5’b), 1.10-0.92 (m, 28H, CH(CH3)2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 157.1 (C
6), 154.3 (C4), 151.0 (C2), 134.6 (C8), 117.2 (C5), 88.3 (C1’), 
81.5 (C4’), 74.3 (C2’), 70.1 (C3’), 61.2 (C5’), 17.8, 17.7, 17.6, 17.42, 17.35, 17.32, 17.27 (CH(CH3)2), 13.2, 12.9, 
12.8, 12.5 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C22H39N5O6Si2]
+: 525.24; found: 526.7 [M+H]+, 548.8 [M+Na]+, 1051.7 [2M+H]+, 
1073.8 [2M+Na]+. 
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7.2.3.2. 2’-O-Trifluoromethanesulfonyl-3’,5’-O-tetra-i-propyldisiloxanylguanosine (61) 
C23H38F3N5O8SSi2; MW 657.81 
 
60 (314 mg, 0.60 mmol), TEA (96 μL, 0.69 mmol) and DMAP (85 mg, 0.70 mmol) were suspended in dry 
CH2Cl2 (3.9 mL) under inert atmosphere. The mixture was stirred at RT for 10’ to form an opalescent 
colourless solution, which was cooled to 0°C, and TfCl (94 μL, 0.88 mmol) was added dropwise. The 
resulting yellow transparent solution was allowed to warm to RT and stirred for 3 h at RT. 
The mixture was diluted with H2O (3.0 mL), then the organic phase was separated from the aqueous one 
and washed with 1 M HCl (2x5 mL). Both aqueous phases were extracted with CH2Cl2 (2x10 mL). The 
reunited organic phases were evaporated under reduced pressure and the resulting yellow crude was 
purified by flash column chromatography (CH2Cl2-MeOH, 9.5:0.5) to get 61 as a white solid (273 mg, 0.42 
mmol). 
Yield: 69% 
Rf: 0.55 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.75 (br s, 1H, N
1H), 7.81 (s, 1H, H8), 6.34 (br s, 2H, N2H2), 6.13 (d, J 
= 1.2 Hz, 1H, H1’), 5.94 (d, J = 5.0 Hz, 1H, H2’), 4.77 (dd, J = 8.9, 5.1 Hz, 1H, H3’), 4.10 (dd, J = 9.3, 4.0 Hz, 1H, 
H5’a), 4.04-3.95 (m, 2H, H4’, H5’b), 1.26-0.92 (m, 28H, CH(CH3)2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 157.0 (C
6), 154.4 (C2), 151.0 (C4), 135.5 (C8), 117.0 (q, J = 319.8 Hz, 
CF3), 116.9 (C
5), 89.2 (C2’), 84.8 (C1’), 81.2 (C4’), 68.9 (C3’), 60.5 (C5’), 17.7, 17.6, 17.5, 17.4, 17.3, 17.18, 17.16 
(CH(CH3)2), 13.1, 12.8, 12.7, 12.6 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C23H38F3N5O8SSi2]
+: 657.19; found: 658.6 [M+H]+, 680.6 [2M+Na]+, 1315.2 [2M+H]+, 
1337.3 [2M+Na]+. 
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7.2.3.3. 2’-O-Acetyl-3’,5’-O-tetra-i-propyldisiloxanylarabinosylguanine (62) 
C24H41N5O7Si2; MW 567.78 
 
61 (323 mg, 0.49 mmol) was dissolved in dry DMF (4.5 mL) under inert atmosphere, then CsOAc (941 mg, 
4.90 mmol) was added and the resulting pale yellow suspension was stirred at RT for 24 h, during which 
time it became dark orange. 
After filtering the colourless precipitate, the brown solution was diluted with AcOEt (30 mL) and washed 
with H2O (3x10 mL) until a colourless aqueous phase was obtained. The organic phase was dried over 
Na2SO4 and concentrated under reduced pressure. The pale orange crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9.4:0.6) to obtain 62 as a very pale yellow solid (154 mg, 0.27 mmol). 
Yield: 55% 
Rf: 0.53 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.65 (br s, 1H, N
1H), 7.66 (s, 1H, H8), 6.50 (br s, 2H, N2H2), 6.17 (d, J 
= 6.7 Hz, 1H, H1’), 5.55 (br dd, J = 7.8, 7.0 Hz, 1H, H
2’), 4.57 (t, J = 8.3 Hz, 1H, H3’), 4.09 (dd, J = 13.3, 4.0 Hz, 
1H, H5’a), 3.99-3.92 (m, 2H, H4’, H5’b), 1.75 (s, 3H, COCH3), 1.16-0.91 (m, 28H, CH(CH3)2). 
1H NMR (CD3OD, 400 MHz): δ (ppm) 7.87 (s, 1H, H
8), 6.28 (d, J = 6.3 Hz, 1H, H1’), 5.62 (dd, J = 8.0, 6.4 Hz, 1H, 
H2’), 4.67 (t, J = 8.4 Hz, 1H, H3’), 4.18 (dd, J = 13.2, 2.8 Hz, 1H, H5’a), 4.13 (dd, J = 13.2, 2.9 Hz, 1H, H5’b), 3.99 
(dt, J = 8.6, 2.8 Hz, 1H, H4’), 1.82 (s, 3H, COCH3), 1.22-0.97 (m, 28H, CH(CH3)2). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 169.7 (COCH3), 157.9 (C
6), 154.1 (C2), 151.5 (C4), 136.0 (C8), 115.9 (C5), 
80.5 (C1’), 80.2 (C4’), 76.1 (C2’), 71.4 (C3’), 60.5 (C5’), 18.8 (COCH3), 16.50, 16.48, 16.4, 16.02, 15.97, 15.9 
(CH(CH3)2), 13.3, 12.83, 12.81, 12.3 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C24H41N5O7Si2]
+: 567.25; found: 568.4 [M+H]+, 590.7 [M+Na]+, 1133.6 [2M-H]+, 
1157.5 [2M+Na]+. 
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7.2.3.4. 3’,5’-O-Tetra-i-propyldisiloxanylarabinosylguanine (63) 
C22H39N5O6Si2; MW 525.75 
 
33% aqueous NH4OH (1.04 mL, 8.81 mmol) was added dropwise to a solution of 62 (149 mg, 0.26 mmol) in 
a 5:2 MeOH/1,4-dioxane mixture (2.40 mL). A white precipitate was immediately formed. The resulting 
suspension was stirred at RT for 24 h, during which time it became a yellow solution. 
The solvent was removed under reduced pressure and 63 was isolated from the resulting dark yellow crude 
by flash column chromatography (CH2Cl2-MeOH, 9:1) as a pale yellow solid (109 mg, 0.21 mmol). 
Yield: 80% 
Rf: 0.32 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.59 (br s, 1H, N
1H), 7.61 (s, 1H, H8), 6.46 (br s, 2H, N2H2), 5.96 (d, J 
= 6.5 Hz, 1H, H1’), 5.79 (d, J = 5.9 Hz, 1H, OH2’), 4.43 (dd, J = 13.3, 6.7 Hz, 1H, H2’), 4.31 (t, J = 7.8 Hz, 1H, H3’), 
3.98 (dd, J = 12.8, 3.7 Hz, 1H, H5’a), 3.92 (dd, J = 12.8, 2.5 Hz, 1H, H5’b), 3.78-3.72 (m, 1H, H4’), 1.21-1.05 (m, 
28H, CH(CH3)2). 
1H NMR (CD3OD, 400 MHz): δ (ppm) 7.85 (br s, 1H, H
8), 6.13 (d, J = 5.6 Hz, 1H, H1’), 4.47 (t, J = 6.2 Hz, 1H, 
H2’), 4.43 (t, J = 6.9 Hz, 1H, H3’), 4.10 (dd, J = 12.7, 3.3 Hz, 1H, H5’a), 4.04 (dd, J = 12.7, 4.2 Hz, 1H, H5’b), 3.85 
(dt, J = 7.3, 3.8 Hz, 1H, H4’), 1.21-0.87 (m, 28H, CH(CH3)2). 
13C NMR (CD3OD, 100 MHz): δ (ppm) 158.0 (C
6), 154.0 (C2), 151.7 (C4), 137.4 (C8), 115.7 (C5), 82.5 (C1’), 81.0 
(C4’), 75.7 (C2’, C3’), 61.6 (C5’), 16.54, 16.50, 16.4, 16.13, 16.08, 16.0 (CH(CH3)2), 13.4, 13.0, 12.9, 12.4 
(CH(CH3)2). 
MS (ESI+): m/z calcd for [C22H39N5O6Si2]
+: 525.24; found: 526.5 [M+H]+, 548.6 [M+Na]+, 1051.3 [2M+H]+, 
1073.5 [2M+Na]+. 
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7.2.3.5. Arabinosylguanine (59) 
C10H13N5O5; MW 283.24 
 
TBAF·3H2O (48 mg, 152 μmol) was added to a solution of 63 (38 mg, 72 μmol) in THF (0.53 mL). The 
resulting yellow opaque solution was stirred at RT for 30’ to precipitate a light grey glass. 
The solvent was removed under reduced pressure and the brown crude was purified by semi-preparative 
HPLC to get 59 as a white powder (13.6 mg, 48 μmol). 
Yield: 67% 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 97 3 
2 - 18 4 97 → 0 3 → 100 
18 - 20 1 0 100 
    
AAAAAAAAAAAA  
HPLC tR: 19.8’ (39.4% B) 
Rf: 0.83 (EtOH-H2O, 7:3) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.59 (br s, 1H, N
1H), 7.76 (s, 1H, H8), 6.50 (br s, 2H, N2H2), 6.02 (d, J 
= 4.6 Hz, 1H, H1’), 5.62 (br d, J = 5.1 Hz, 1H, OH2’), 5.50 (d, J = 4.0 Hz, 1H, OH3’), 5.06 (br t, J = 4.5 Hz, 1H, 
OH5’), 4.07 (dd, J = 7.9, 4.0 Hz, 1H, H3’), 4.03 (dd, J = 9.3, 4.7 Hz, 1H, H2’), 3.74 (dd, J = 8.9, 4.4 Hz, 1H, H4’), 
3.65 (dd, J = 11.7, 4.3 Hz, 1H, H5’a), 3.59 (dd, J = 11.7, 5.3 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 157.3 (C
6), 154.1 (C2), 151.5 (C4), 137.3 (C8), 116.3 (C5), 84.7 (C4’), 
83.8 (C1’), 75.9 (C2’), 75.8 (C3’), 61.4 (C5’). 
MS (ESI+): m/z calcd for [C10H13N5O5]
+: 283.09; found: 284.17 [M+H]+, 306.17 [M+Na]+, 589.17 [2M+Na]+, 
1155.0 [4M+Na]+. 
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7.2.4. Synthesis of 7-methylpurine and 7-methylguanine nucleoside iodides (64-67) 
7.2.4.1. 7-Methylinosine iodide (64) 
C11H15IN4O5; MW 410.17 
 
CH3I (1.80 mL, 28.91 mmol) was added dropwise to a solution of 37 (805 mg, 3.00 mmol) in dry DMSO (8.7 
mL) under inert atmosphere. The resulting colourless solution was protected from light exposure and 
stirred at RT for 24 h, during which time the solution slowly turned to dark red and then brown. The 
disappearance of the substrate was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.80). 
The solution was cooled to 0°C and diluted with CHCl3 (75 mL) to precipitate a dark orange syrup. The 
supernatant was discarded and the syrup was ground in acetone to precipitate 64 as a white powder, which 
was filtered, washed with few cold acetone, dried under reduced pressure and stored at -20°C (825 mg, 
2.01 mmol). 
Yield: 67% 
Rf: 0.23 (EtOH-H2O, 4:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.50 (br s, 1H, N
1H), 9.68 (s, 1H, H8), 8.46 (s, 1H, H2), 6.03 (d, J = 3.1 
Hz, 1H, H1’), 5.80 (br d, J = 4.9 Hz, 1H, OH2’), 5.34 (br d, J = 5.4 Hz, 1H, OH3’), 5.16 (br t, J = 4.8 Hz, 1H, OH5’), 
4.43 (dd, J = 7.7, 4.5 Hz, 1H, H2’), 4.17 (dd, J = 10.1, 5.2 Hz, 1H, H3’), 4.13 (s, 3H, CH3), 4.06 (dt, J = 6.2, 3.3 Hz, 
1H, H4’), 3.78 (dd, J = 12.3, 3.1 Hz, 1H, H5’a), 3.65 (dd, J = 12.3, 3.6 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 153.5 (C
6), 150.6 (C2), 146.3 (C4), 139.4 (C8), 116.1 (C5), 90.7 (C1’), 
86.3 (C4’), 75.0 (C2’), 69.4 (C3’), 60.6 (C5’), 36.6 (CH3). 
MS (ESI+): m/z calcd for [C11H15N4O5]
+: 283.10; found: 283.0 [M]+, 305.1 [M-H+Na]+, 565.3 [2M-H]+. 
MS (ESI-): m/z calcd for [I]-: 126.91; found: 127.2 [I]-. 
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7.2.4.2. 7-Methylguanosine iodide (65) 
C11H16IN5O5; MW 425.18 
 
CH3I (0.13 mL, 2.09 mmol) was added dropwise to a suspension of 55 (200 mg, 0.71 mmol) at 30°C in a dry 
3:1 DMF/DMSO mixture (2.0 mL) under inert atmosphere. The resulting colourless solution was protected 
from light exposure and stirred at 30°C for 4 h, during which time the solution slowly turned to brown. The 
disappearance of the substrate was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.79). 
The solution was diluted with H2O (50 mL) and freeze-dried twice to get a very dense brown oil. Acetone 
(20 mL) was added, the resulting mixture was cooled to 0°C and sonicated to get 65 as a white powder, 
which was filtered, washed with few cold acetone, dried under reduced pressure and stored at -20°C (263 
mg, 0.62 mmol). 
Yield: 87% 
Rf: 0.18 (EtOH-H2O, 4:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 11.74 (br s, 1H, N
1H), 9.35 (s, 1H, H8), 7.22 (br s, 2H, N2H2), 5.84 (d, J 
= 3.9 Hz, 1H, H1’), 5.64 (br d, J = 5.1 Hz, 1H, OH2’), 5.33 (d, J = 5.4 Hz, 1H, OH3’), 5.12 (t, J = 5.1 Hz, 1H, OH5’), 
4.37 (dd, J = 8.5, 4.3 Hz, 1H, H2’), 4.16 (dd, J = 10.0, 5.1 Hz, 1H, H3’), 4.05-3.97 (m, 4H, H4’, CH3), 3.72 (dt, J = 
11.8, 3.9 Hz, 1H, H5’a), 3.61 (dt, J = 9.0, 4.3 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.1 (C
2), 153.8 (C6), 149.7 (C4), 136.8 (C8), 108.1 (C5), 89.2 (C1’), 
86.2 (C4’), 74.7 (C2’), 69.8 (C3’), 60.9 (C5’), 36.3 (CH3). 
MS (ESI+): m/z calcd for [C11H16N5O5]
+: 298.11; found: 297.5 [M-H]+, 298.1 [M]+, 595.2 [2M-H]+, 894.3 [3M-
2H]+. 
MS (ESI-): m/z calcd for [I]-: 126.91; found: 127.2 [I]-. 
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7.2.4.3. 7-Methyl-2’-deoxyguanosine iodide (66) 
C11H16IN5O4; MW 409.18 
 
CH3I (0.26 mL, 4.18 mmol) was added to a solution of 68 (160 mg, 0.60 mmol) in dry DMSO (1.20 mL) under 
inert atmosphere. The resulting colourless mixture was protected from light exposure and stirred at 20°C 
for 3 h 30’, during which time it turned brown-red. More CH3I (37 μL, 0.59 mmol) was added and the 
mixture was stirred at 20°C for 1 h. Throughout the reaction, the disappearance of the substrate was 
monitored by TLC (EtOH-H2O, 4:1; Rf = 0.80). 
Cold CHCl3 (15 mL) was added to precipitate a pale yellow powder and the suspension was decanted at 0°C 
for 2 h. The precipitate was filtered, washed with few cold CHCl3 and dried under reduced pressure to 
obtain 66 as a pale yellow powder, which was stored at -20°C (197 mg, 0.48 mmol). 
Yield: 80% 
Rf: 0.21 (EtOH-H2O, 4:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 11.67 (s, 1H, N
1H), 9.28 (s, 1H, H8), 7.18 (br s, 2H, N2H2), 6.20 (t, J = 
6.0 Hz, 1H, H1’), 5.40 (br s, 1H, OH3’), 4.98 (br s, 1H, OH5’), 4.37 (dd, J = 9.1, 4.6 Hz, 1H, H3’), 4.00 (s, 3H, CH3), 
3.93 (q, J = 3.9 Hz, 1H, H
4’), 3.62 (dd, J = 12.1, 4.2 Hz, 1H, H5’a), 3.57 (dd, J = 12.1, 4.2 Hz, 1H, H5’b), 2.55-2.47 
(m, 1H, H2’a), 2.40 (ddd, J = 13.4, 6.2, 4.8 Hz, 1H, H2’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.0 (C
2), 153.9 (C6), 149.3 (C4), 136.7 (C8), 108.1 (C5), 89.1 (C4’), 
85.8 (C1’), 70.2 (C3’), 61.3 (C5’), 40.5 (C2’), 36.1 (CH3). 
MS (ESI+): m/z calcd for [C11H16N5O4]
+: 282.12; found: 280.8 [M-H]+, 282.1 [M]+, 304.1 [M-H+Na]+, 305.3 
[M+Na]+, 563.0 [2M-H]+, 563.7 [2M]+, 585.5 [2M-2H+Na]+. 
MS (ESI-): m/z calcd for [I]-: 126.91; found: 127.2 [M]-. 
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7.2.4.4. 7-Methylarabinofuranosylguanine iodide (67) 
C11H16IN5O5; MW 425.18 
 
CH3I (0.14 mL, 2.25 mmol) was added to a solution of 59 (100 mg, 0.35 mmol) in a dry 3:1 DMF/DMSO 
mixture (0.96 mL) under inert atmosphere. The resulting colourless mixture was protected from light 
exposure and stirred at RT for 6 h, during which time it turned yellow. The disappearance of the substrate 
was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.83). 
The solution was diluted with H2O (50 mL) and freeze-dried until complete removal of DMSO. The resulting 
pale yellow crude was suspended in dry acetone (2.5 mL), filtered, washed with few cold dry acetone and 
dried under reduced pressure to obtain 67 as an off-white powder, which was stored at -20°C (133 mg, 0.31 
mmol). 
Yield: 89% 
Rf: 0.53 (EtOH-H2O, 7:3) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 11.68 (br s, 1H, N
1H), 9.22 (s, 1H, H8), 7.21 (br s, 2H, N2H2), 6.17 (d, J 
= 4.3 Hz, 1H, H1’), 5.82 (d, J = 5.3 Hz, 1H, OH2’), 5.64 (d, J = 4.3 Hz, 1H, OH3’), 5.04 (t, J = 5.4 Hz, 1H, OH5’), 
4.17 (dd, J = 8.6, 4.4 Hz, 1H, H2’), 4.11 (dd, J = 7.5, 3.7 Hz, 1H, H3’), 4.06 (s, 3H, CH3), 3.90 (dd, J = 8.9, 5.1 Hz, 
1H, H4’), 3.70 (dd, J = 11.5, 5.0 Hz, 1H, H5’a), 3.64 (dd, J = 11.6, 5.4 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.2 (C
2), 153.8 (C6), 149.6 (C4), 137.8 (C8), 107.6 (C5), 86.5 (C4’), 
86.0 (C1’), 75.5 (C2’), 75.4 (C3’), 61.3 (C5’), 36.1 (CH3). 
MS (ESI+): m/z calcd for [C11H16N5O5]
+: 298.11; found: 297.1 [M-H]+, 298.0 [M]+, 319.9 [M-H+Na]+, 594.9 
[2M-H]+, 617.0 [2M-2H+Na]+, 1192.1 [4M]+. 
MS (ESI-): m/z calcd for [I]-: 126.91; found: 127.1 [M]-. 
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7.2.5. Synthesis of 8-substituted inosines, guanosines and adenosines (69-80) 
7.2.5.1. 8-Bromo-2’,3’,5’-tri-O-acetylinosine (81) 
C16H17BrN4O8; MW 473.23 
 
51 (3.40 g, 8.62 mmol) was suspended in 1,4-dioxane (130 mL) under inert atmosphere and decanted 
solutions of Br2 (1.60 mL) in 10% aqueous Na2HPO4 (70 mL) were added at 0, 24, 48, 72, 96 and 120 h, 
during which time the mixture was protected from light exposure and stirred at RT. At 8 days, the resulting 
red solution was decolorized with NaHSO3 and extracted with CH2Cl2 (3x120 mL). The reunited organic 
phases were dried over Na2SO4 and evaporated under reduced pressure, and the resulting crude was 
purified by flash column chromatography (CH2Cl2-MeOH, 9.5:0.5) to obtain 81 as a white powder (3.39 g, 
7.16 mmol). 
Yield: 83% 
Rf: 0.59 (CH2Cl2-MeOH, 9:1) or 0.93 (CH2Cl2-MeOH, 4:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.76 (br s, 1H, N
1H), 8.17 (s, 1H, H2), 6.24 (dd, J = 6.0, 4.8 Hz, 1H, H2’), 
6.12 (d, J = 4.7 Hz, 1H, H1’), 5.79 (t, J = 5.9 Hz, 1H, H3’), 4.51 (dd, J = 11.7, 3.6 Hz, 1H, H5’a), 4.40 (td, J = 5.8, 
3.7 Hz, 1H, H4’), 4.33 (dd, J = 11.7, 6.1 Hz, 1H, H5’b), 2.17 (s, 3H, CH3CO), 2.12 (s, 3H, CH3CO), 2.08 (s, 3H, 
CH3CO). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.5, 169.5, 169.4 (CH3CO), 157.5 (C
6), 149.8 (C4), 145.3 (C2), 126.6 
(C8), 125.8 (C5), 88.8 (C1’), 80.2 (C4’), 72.1 (C2’), 70.3 (C3’), 63.0 (C5’), 20.7, 20.5, 20.4 (CH3CO). 
MS (ESI+): m/z calcd for [C16H17
79BrN4O8]
+: 472.02; found: 237.1 [(79Br)M-(2’,3’,5’-tri-O-acetylribosyl)+Na]+, 
239.0 [(81Br)M-(2’,3’,5’-tri-O-acetylribosyl)+Na]+, 494.9 [(79Br)M+Na]+, 496.9 [(81Br)M+Na]+, 966.7 
[2(79Br)M+Na]+, 968.8 [(79Br)M+(81Br)M+Na]+, 970.8 [2(81Br)M+Na]+. 
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7.2.5.2. General procedure for the synthesis of 8-alkylaminoinosines (70, 71, 72, 73 and 74) 
 
The appropriate amine or amine solution (13.98 mmol for 70, 14.21 mmol for 71, 37.48 mmol for 72, 5.58 
mmol for 73 and 11.95 mmol for 74) was added to a solution of 81 (189 mg, 0.40 mmol) in dry 1,4-dioxane 
(0.90 mL) under inert atmosphere. The resulting mixture was stirred at 80°C and monitored by TLC (CH2Cl2-
MeOH, 4:1 for 70, 71 and 72 and 9:1 for 73) or analytical HPLC (for 74) until complete consumption of the 
starting material and formation of the product (between 1 and 15 days). 
70, 71, 72 and 74: The solvent was removed under reduced pressure and the crude was purified by semi-
preparative HPLC. 
73: The mixture was concentrated under reduced pressure to get a dark orange oil residue. n-Hexane (25 
mL) was added, the two-phase mixture was stirred at RT for 10’ and the upper layer was removed. Et2O (25 
mL) was added to precipitate a very dense brown syrup, which was sonicated to form an ochre powder, 
then the yellow supernatant was discarded. The procedure was repeated four times, until the organic 
phase became colourless and no more amine was detected by TLC (CH2Cl2/MeOH, 9:1). The residue was 
evaporated under reduced pressure and the light orange crude was purified by semi-preparative HPLC. 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 97 3 
2 - 30 7 97 → 0 3 → 100 
30 - 32 0.5 0 100 
    
AAAAAAAAAAAA  
7.2.5.2.1. 8-Methylaminoinosine (70) 
C11H15N5O5; MW 297.27 
 
White powder (96 mg, 0.32 mmol). 
Yield: 81% 
Rf: 0.18 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 17.8’ (48.1% B) 
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1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.08 (br s, 1H, N
1H), 7.82 (s, 1H, H2), 6.81 (q, J = 4.5 Hz, 1H, N8H), 
5.86 (d, J = 7.3 Hz, 1H, H1’), 5.68 (t, J = 4.6 Hz, 1H, OH5’), 5.29 (d, J = 6.5 Hz, 1H, OH2’), 5.13 (d, J = 4.3 Hz, 1H, 
OH3’), 4.57 (dd, J = 12.6, 6.7 Hz, 1H, H2’), 4.13-4.08 (m, 1H, H3’), 3.96 (q, J = 2.3 Hz, 1H, H4’), 3.68-3.62 (m, 2H, 
H5’a, H5’b), 2.84 (d, J = 4.6 Hz, 3H, NHCH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.3 (C
6), 152.2 (C8), 148.5 (C4), 143.1 (C2), 122.6 (C5), 87.4 (C1’), 
86.4 (C4’), 71.7 (C3’), 71.3 (C2’), 62.2 (C5’), 29.8 (NHCH3). 
MS (ESI+): m/z calcd for [C11H15N5O5]
+: 297.11; found: 166.1 [M-ribosyl+H]+, 188.1 [M-ribosyl+Na]+, 298.1 
[M+H]+, 320.1 [M+Na]+, 617.1 [2M+Na]+. 
7.2.5.2.2. 8-Ethylaminoinosine (71) 
C12H17N5O5; MW 311.29 
 
White powder (98 mg, 0.31 mmol). 
Yield: 78% 
Rf: 0.28 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 19.3’ (53.0% B) 
1H NMR (CD3OD, 300 MHz): δ (ppm) 7.84 (s, 1H, H
2), 6.06 (d, J = 7.2 Hz, 1H, H1’), 4.68 (dd, J = 7.6, 5.8 Hz, 1H, 
H2’), 4.27 (dd, J = 5.8, 1.8 Hz, 1H, H3’), 4.10 (br d, J = 1.8 Hz, 1H, H4’), 3.87-3.76 (m, 2H, H5’a, H5’b), 3.42 (ddd, J 
= 14.4, 7.0, 3.7 Hz, 2H, NHCH2), 1.24 (t, J = 7.3 Hz, 3H, CH3).
 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.06 (br s, 1H, N
1H), 7.81 (s, 1H, H2), 6.79 (t, J = 5.3 Hz, 1H, N8H), 
5.88 (d, J = 7.4 Hz, 1H, H1’), 5.64 (br t, J = 4.2 Hz, 1H, OH5’), 5.27 (d, J = 6.3 Hz, 1H, OH2’), 5.12 (br d, J = 3.2 Hz, 
1H, OH3’), 4.57 (q, J = 6.2 Hz, 1H, H2’), 4.15-4.09 (m, 1H, H3’), 3.96 (br q, J = 2.2 Hz, 1H, H4’), 3.69-3.62 (m, 2H, 
H5’a, H5’b), 3.40-3.24 (m, 2H, NHCH2), 1.17 (t, J = 7.2 Hz, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.9 (C
6), 151.1 (C8), 148.0 (C4), 142.6 (C2), 122.2 (C5), 87.1 (C1’), 
86.0 (C4’), 71.2 (C3’), 71.0 (C2’), 61.8 (C5’), 37.5 (NHCH2), 15.1 (CH3). 
MS (ESI+): m/z calcd for [C12H17N5O5]
+: 311.12; found: 180.4 [M-ribosyl+H]+, 202.2 [M-ribosyl+Na]+, 334.2 
[M+Na]+, 645.1 [2M+Na]+. 
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7.2.5.2.3. 8-i-Propylaminoinosine (72) 
C13H19N5O5; MW 325.32 
 
White powder (23 mg, 0.07 mmol). 
Yield: 18% 
Rf: 0.32 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 19.1’ (52.2% B) 
1H NMR (CD3OD, 300 MHz): δ (ppm) 7.83 (s, 1H, H
2), 6.06 (d, J = 7.7 Hz, 1H, H1’), 4.67 (dd, J = 7.2, 5.7 Hz, 1H, 
H2’), 4.26 (dd, J = 5.8, 1.8 Hz, 1H, H3’), 4.18-4.06 (m, 2H, NHCH, H4’), 3.87-3.76 (m, 2H, H5’a, H5’b), 1.24 (d, J = 
6.7 Hz, 6H, CH(CH3)2). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.01 (br s, 1H, N
1H), 7.81 (s, 1H, H2), 6.59 (d, J = 7.6 Hz, 1H, N8H), 
5.89 (d, J = 7.4 Hz, 1H, H1’), 5.63 (br s, 1H, OH5’), 5.48-4.96 (m, 2H, OH2’, OH3’), 4.54 (dd, J = 7.1, 5.8 Hz, 1H, 
H2’), 4.12 (dd, J = 5.5, 2.0 Hz, 1H, H3’), 4.07-3.97 (m, 1H, NHCH), 3.95 (br q, J = 2.1 Hz, 1H, H4’), 3.71-3.61 (m, 
2H, H5’a, H5’b), 1.20 (d, J = 3.5 Hz, 3H, CH(CH3)2), 1.18 (d, J = 3.4 Hz, 3H, CH(CH3)2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.9 (C
6), 150.5 (C8), 147.9 (C4), 142.5 (C2), 122.2 (C5), 87.0 (C1’), 
86.0 (C4’), 71.2 (C3’), 70.9 (C2’), 61.8 (C5’), 44.4 (NHCH), 23.1, 22.8 (CH(CH3)2). 
MS (ESI+): m/z calcd for [C13H19N5O5]
+: 325.14; found: 326.0 [M+H]+, 348.2 [M+Na]+, 673.1 [2M+Na]+. 
7.2.5.2.5. 8-Benzylaminoinosine (73) 
C17H19N5O5; MW 373.36 
 
White powder (123 mg, 0.33 mmol). 
Yield: 83% 
Rf: 0.13 (CH2Cl2-MeOH, 9:1) 
HPLC tR: 21.6’ (60.8% B) 
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1H NMR (CD3OD, 400 MHz): δ (ppm) 7.86 (s, 1H, H
2), 7.43-7.19 (m, 5H, C6H5), 6.12 (d, J = 7.5 Hz, 1H, H
1’), 
4.74 (dd, J = 7.5, 5.6 Hz, 1H, H2’), 4.68 (d, J = 15.3 Hz, 1H, NHCHa), 4.59 (d, J = 15.3 Hz, 1H, NHCHb), 4.29 (dd, 
J = 5.6, 2.0 Hz, 1H, H3’), 4.14 (br q, J = 2.0 Hz, 1H, H4’), 3.82 (dd, J = 11.8, 2.3 Hz, 1H, H5’a), 3.78 (dd, J = 11.8, 
1.9 Hz, 1H, H5’b). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.05 (br s, 1H, N
1H), 7.82 (s, 1H, H2), 7.50 (br t, J = 5.8 Hz, 1H, N8H), 
7.39-7.20 (m, 5H, C6H5), 5.93 (d, J = 7.4 Hz, 1H, H
1’), 5.69 (br s, 1H, OH5’), 5.47-5.05 (m, 2H, OH2’, OH3’), 4.64 
(br t, J = 6.1 Hz, 1H, H2’), 4.59-4.46 (m, 2H, NHCH2), 4.14 (br d, J = 4.3 Hz, 1H, H
3’), 4.00 (br s, 1H, H4’), 3.66 
(br s, 2H, H5’a, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.9 (C
6), 151.0 (C8), 148.1 (C4), 142.7 (C2), 140.5 (Ca), 128.6, 127.5, 
127.1 (Cb, Cc, Cd), 122.1 (C5), 87.1 (C1’), 86.2 (C4’), 71.4 (C3’), 71.2 (C2’), 61.9 (C5’), 45.7 (NHCH2). 
MS (ESI+): m/z calcd for [C17H19N5O5]
+: 373.14; found: 396.3 [M+Na]+, 769.3 [2M+Na]+. 
7.2.5.2.4. 8-N,N-Dimethylaminoinosine (74) 
C12H17N5O5; MW 311.29 
 
White powder (109 mg, 0.35 mmol). 
Yield: 87% 
Rf: 0.54 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 18.4’ (50.0% B) 
1H NMR (CD3OD, 400 MHz): δ (ppm) 7.97 (s, 1H, H
2), 5.91 (d, J = 6.9 Hz, 1H, H1’), 5.11 (br dd, J = 6.6, 5.7 Hz, 
1H, H2’), 4.38 (dd, J = 5.4, 2.6 Hz, 1H, H3’), 4.11 (dd, J = 6.2, 3.2 Hz, 1H, H4’), 3.86 (dd, J = 12.3, 3.1 Hz, 1H, 
H5’a), 3.75 (dd, J = 12.3, 3.8 Hz, 1H, H5’b), 2.99 (s, 6H, N(CH3)2). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 11.90 (v br s, 1H, N
1H), 7.97 (s, 1H, H2), 5.68 (d, J = 6.7 Hz, 1H, H1’), 
5.61-5.07 (m, 2H, OH), 5.06-4.84 (br s, 1H, OH), 5.01 (t, J = 6.0 Hz, 1H, H2’), 4.16 (dd, J = 5.3, 3.0 Hz, 1H, H3’), 
3.90 (dd, J = 7.7, 4.7 Hz, 1H, H4’), 3.66 (dd, J = 11.9, 4.6 Hz, 1H, H5’a), 3.52 (dd, J = 11.9, 5.0 Hz, 1H, H5’b), 2.84 
(s, 6H, N(CH3)2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.2 (C
6), 156.1 (C8), 148.2 (C4), 144.5 (C2), 122.7 (C5), 88.8 (C1’), 
86.2 (C4’), 71.4 (C2’), 71.1 (C3’), 62.5 (C5’), 43.3 (N(CH3)2). 
MS (ESI+): m/z calcd for [C12H17N5O5]
+: 311.12; found: 180.1 [M-ribosyl+H]+, 201.9 [M-ribosyl+Na]+, 267.0 
[M-N(CH3)2-H]
+, 297.1 [M-CH3]
+, 334.0 [M+Na]+, 645.0 [2M+Na]+. 
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7.2.5.3. 8-Aminoinosine (69) 
C10H13N5O5; MW 283.24 
 
73 (60 mg, 0.16 mmol) and 10% Pd-C (90 mg, 84.6 μmol) were suspended in MeOH (2.50 mL) under inert 
atmosphere. Portions of HCOONH4 were added at 0 h and 24 h (202 mg, 3.20 mmol), 96 h (404 mg, 6.41 
mmol) and 120 h (101 mg, 1.60 mmol) and the resulting mixture was refluxed and monitored by TLC 
(CH2Cl2-MeOH, 4:1). 
At 6 days, the suspension was filtered on celite and evaporated under reduced pressure to get 69 as a very 
pale yellow powder (43 mg, 0.15 mmol). 
Yield: 96% 
Rf: 0.10 (CH2Cl2-MeOH, 8:2) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.04 (br s, 1H, N
1H), 7.79 (s, 1H, H2), 6.50 (br s, 2H, N8H2), 5.85 (d, J 
= 7.3 Hz, 1H, H1’), 5.56 (br s, 1H, OH5’), 5.30 (br s, 1H, OH2’), 5.16 (br s, 1H, OH3’), 4.59 (t, J = 6.4 Hz, 1H, H2’), 
4.12 (dd, J = 5.4, 2.0 Hz, 1H, H3’), 3.94 (br q, J = 2.3 Hz, 1H, H4’), 3.63 (br s, 2H, H5’a, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.4 (C
6), 151.1 (C8), 147.5 (C4), 143.0 (C2), 120.9 (C5), 87.2 (C1’), 
86.2 (C4’), 71.2 (C3’), 71.0 (C2’), 61.8 (C5’). 
MS (ESI+): m/z calcd for [C10H13N5O5]
+: 283.09; found: 284.0 [M+H]+, 306.1 [M+Na]+, 567.0 [2M+H]+, 589.0 
[2M+Na]+. 
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7.2.5.4. General procedure for the synthesis of 8-alkoxyinosines (76, 77) 
 
81 (189 mg, 0.40 mmol) was added to a solution of the appropriate alkoxide, freshly prepared by dissolving 
Na (46 mg, 2.00 mmol) in the corresponding dry alcohol (3.00 mL) under inert atmosphere. The resulting 
mixture was refluxed and monitored by TLC (CH2Cl2-MeOH, 4:1) until complete consumption of the starting 
material and formation of the product (between 2 and 3 h). 
76 and 77: The solvent was removed under reduced pressure and the crude was purified by semi-
preparative HPLC. 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 97 3 
2 - 30 7 97 → 0 3 → 100 
30 - 32 0.5 0 100 
    
AAAAAAAAAAAA  
7.2.5.4.1. 8-Methoxyinosine (76) 
C11H14N4O6; MW 298.25 
 
White powder (104 mg, 0.35 mmol). 
Yield: 87% 
Rf: 0.47 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 17.5’ (47.2% B) 
1H NMR (CD3OD, 300 MHz): δ (ppm) 7.94 (s, 1H, H
2), 5.88 (d, J = 6.8 Hz, 1H, H1’), 4.97-4.82 (m, 1H, H2’), 4.30 
(dd, J = 5.1, 2.6 Hz, 1H, H3’), 4.15 (s, 3H, OCH3), 4.07 (q, J = 2.9 Hz, 1H, H
4’), 3.82 (dd, J = 12.6, 2.9 Hz, 1H, 
H5’a), 3.68 (dd, J = 12.6, 3.8 Hz, 1H, H5’b). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.88 (s, 1H, H
2), 5.68 (d, J = 6.7 Hz, 1H, H1’), 4.84 (dd, J = 6.5, 5.4 Hz, 
1H, H2’), 4.11 (dd, J = 5.1, 2.5 Hz, 1H, H3’), 4.04 (s, 3H, OCH3), 3.90 (dd, J = 6.3, 3.6 Hz, 1H, H
4’), 3.61 (dd, J = 
12.1, 3.8 Hz, 1H, H5’a), 3.48 (dd, J = 12.1, 4.2 Hz, 1H, H5’b). 
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13C NMR (DMSO-d6, 100 MHz): δ (ppm) 161.0 (C
6), 153.3 (C8), 148.3 (C2), 148.0 (C4), 120.2 (C5), 87.3 (C1’), 
86.5 (C4’), 71.8 (C2’), 71.4 (C3’), 62.8 (C5’), 57.2 (OCH3). 
MS (ESI+): m/z calcd for [C11H14N4O6]
+: 298.09; found: 165.0 [M-ribosyl-H]+, 189.1 [M-ribosyl+Na]+, 321.1 
[M+Na]+, 619.1 [2M+Na]+. 
7.2.5.4.2. 8-Ethoxyinosine (77) 
C12H16N4O6; MW 312.28 
 
White powder (93 mg, 0.30 mmol). 
Yield: 74% 
Rf: 0.57 (CH2Cl2-MeOH, 4:1) 
HPLC tR: 19.8’ (54.7% B) 
1H NMR (CD3OD, 300 MHz): δ (ppm) 7.94 (s, 1H, H
2), 5.91 (d, J = 6.6 Hz, 1H, H1’), 4.93-4.81 (m, 1H, H2’), 4.56 
(q, J = 7.1 Hz, 2H, OCH2), 4.32 (dd, J = 5.6, 2.8 Hz, 1H, H
3’), 4.07 (q, J = 3.2 Hz, 1H, H4’), 3.82 (dd, J = 12.3, 3.2 
Hz, 1H, H5’a), 3.69 (dd, J = 12.6, 3.8 Hz, 1H, H5’b), 1.47 (t, J = 7.3 Hz, 3H, CH3). 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.93 (s, 1H, H
2), 5.71 (d, J = 6.4 Hz, 1H, H1’), 4.83 (t, J = 5.8 Hz, 1H, 
H2’), 4.47 (q, J = 7.3 Hz, 2H, OCH2), 4.12 (dd, J = 5.1, 3.2 Hz, 1H, H
3’), 3.88 (dd, J = 7.6, 4.4 Hz, 1H, H4’), 3.61 
(dd, J = 11.9, 4.4 Hz, 1H, H5’a), 3.48 (dd, J = 11.9, 4.8 Hz, 1H, H5’b), 1.39 (t, J = 7.1 Hz, 3H, CH3). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 158.7 (C
6), 153.1 (C8), 147.7 (C4), 146.7 (C2), 120.4 (C5), 87.2 (C1’), 
86.2 (C4’), 71.7 (C2’), 71.2 (C3’), 66.4 (OCH2), 62.6 (C
5’), 14.8 (CH3). 
MS (ESI+): m/z calcd for [C12H16N4O6]
+: 312.11; found: 203.1 [M-ribosyl+Na]+, 335.1 [M+Na]+, 647.1 
[2M+Na]+, 935.3 [3M-H]+. 
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7.2.5.5. 2’,3’,5’-Tri-O-acetyl-8-pxoinosine (82) 
C16H18N4O9; MW 410.34 
 
81 (189 mg, 0.40 mmol) and well-dried NaOAc (98 mg, 1.19 mmol) were dissolved in AcOH (2.40 mL) under 
inert atmosphere and the resulting solution was stirred at 110-125°C for 3 h. 
The mixture was partitioned between CH2Cl2 (20 mL) and H2O (10 mL) and the aqueous phase was 
extracted with CH2Cl2 (2x20 mL). The reunited organic phases were dried over Na2SO4 and evaporated 
under first reduced pressure and then high vacuum. The resulting crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9.4:0.6) to obtain 82 as a white solid (152 mg, 0.37 mmol). 
Yield: 93% 
Rf: 0.49 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 300 MHz): δ (ppm) 11.60 (br m, 2H, N
1H, N7H), 8.02 (s, 1H, H2), 6.00 (t, J = 4.8 Hz, 1H, 
H2’), 5.84 (d, J = 4.5 Hz, 1H, H1’), 5.55 (t, J = 6.0 Hz, 1H, H3’), 4.37 (dd, J = 12.0, 3.6 Hz, 1H H5’a), 4.24 (dd, J = 
9.3, 5.4 Hz, 1H, H4’), 4.11 (dd, J = 12.0, 5.7 Hz, 1H, H5’b), 2.08 (s, 3H, CH3CO), 2.06 (s, 3H, CH3CO), 2.00 (s, 3H, 
CH3CO). 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.48 (v br s, 1H, N
1H), 11.22 (br s, 1H, N7H), 8.04 (s, 1H, H2), 6.21 (br s, 
1H, H2’), 6.12 (br d, J = 2.4 Hz, 1H, H1’), 5.75 (br t, J = 5.0 Hz, 1H, H3’), 4.51 (br d, J = 9.1 Hz, 1H H5’a), 4.41-4.29 
(m, 2H, H4’, H5’b), 2.17 (s, 3H, CH3CO), 2.15 (s, 3H, CH3CO), 2.11 (s, 3H, CH3CO). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 170.7, 169.8, 169.7 (CH3CO), 152.7 (C
8), 152.4 (C6), 145.3 (C4), 144.4 
(C2), 109.2 (C5), 84.3 (C1’), 79.5 (C4’), 71.8 (C2’), 70.8 (C3’), 63.4 (C5’), 20.9, 20.8, 20.6 (CH3CO). 
MS (ESI+): m/z calcd for [C16H18N4O9]
+: 410.11; found: 433.3 [M+Na]+, 842.9 [2M+Na]+. 
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7.2.5.6. 8-Oxoinosine (75) 
C10H12N4O6; MW 284.23 
 
82 (75 mg, 0.18 mmol) was dissolved in 1.8 M NaOH (0.40 mL, 0.72 mmol) and the resulting colourless 
solution was stirred at RT for 15’. 
The mixture was neutralized with KH2PO4, the solvent was removed under reduced pressure and the crude 
was purified by semi-preparative HPLC. The resulting white solid was suspended in dry MeOH, filtered, 
washed with few cold MeOH and dried under reduced pressure to get 75 as a white powder (33 mg, 0.12 
mmol). 
Yield: 65% 
Time (min) Column volumes % A (H2O) % B (MeOH) 
    
0 - 2 0.5 100 0 
2 - 30 7 100 → 0 0 → 100 
30 - 32 0.5 0 100 
    
AAAAAAAAAAAA  
HPLC tR: 8.4’ (16.8% B) 
 
A 25% NaOMe solution in MeOH (0.12 mL, 0.52 mmol) was added to a suspension of 82 (50 mg, 0.12 mmol) 
in dry MeOH (0.38 mL) and the resulting mixture was stirred at RT for 2 h 30’. 
The resulting precipitate was filtered, washed with few cold MeOH and dried under reduced pressure to 
obtain 75 as a white powder (17 mg, 0.06 mmol). 
Yield: 50% 
Rf: 0.12 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 11.47 (v br s, 2H, N
1H, N8H), 7.71 (s, 1H, H2), 6.17 (br s, 1H, OH5’), 
5.65 (d, J = 7.1 Hz, 1H, H1’), 5.29-4.88 (m, 2H, OH2’, OH3’), 4.83 (dd, J = 6.8, 5.3 Hz, 1H, H2’), 4.09 (dd, J = 5.0, 
1.6 Hz, 1H, H3’), 3.88 (br dd, J = 4.5, 2.5 Hz, 1H, H4’), 3.60 (dd, J = 12.2, 2.6 Hz, 1H, H5’a), 3.46 (br d, J = 11.9 
Hz, 1H, H5’b). 
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13C NMR (DMSO-d6, 100 MHz): δ (ppm) 159.6 (C
6), 152.6 (C8), 150.4 (C2), 145.0 (C4), 108.6 (C5), 86.2 (C4’), 
86.1 (C1’), 71.9 (C2’), 71.2 (C3’), 63.2 (C5’). 
MS (ESI+): m/z calcd for [C10H12N4O6]
+: 284.08; found: 284.9 [M+H]+, 307.1 [M+Na]+. 
MS (ESI+): m/z calcd for [C10H12N4O6]
-: 284.08; found: 283.1 [M-H]+, 566.8 [2M-H]-. 
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7.2.5.7. 8-Bromoinosine (78) 
C10H11BrN4O5; MW 347.12 
 
25% NaOMe in MeOH (0.38 mL, 1.66 mmol) was added to a suspension of 81 (189 mg, 0.40 mmol) in dry 
MeOH (1.0 mL) and the resulting solution was stirred at RT for 55’. 
The solvent was removed under reduced pressure, the crude was suspended in H2O (2.0 mL) and the 
mixture was neutralized with 6 M HCl to precipitate 78 as a white powder, which was filtered, washed with 
few cold H2O and dried under reduced pressure (125 mg, 0.36 mmol). 
Yield: 90% 
 
81 (62 mg, 0.13 mmol) was dissolved in 1.0 M NaOH (1.30 mL, 1.30 mmol) and the resulting opalescent 
solution was stirred at RT for 1 h. 
The mixture was diluted with H2O (0.5 mL) and neutralized with NaH2PO4 to precipitate 78 as a white 
powder, which was filtered, washed with few cold H2O and dried under reduced pressure (29 mg, 0.08 
mmol). 
Yield: 64% 
Rf: 0.26 (CH2Cl2-MeOH, 8.1:1.5) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.63 (br s, 1H, N
1H), 8.11 (s, 1H, H2), 5.83 (d, J = 6.3 Hz, 1H, H1’), 
5.50 (br d, J = 4.0 Hz, 1H, OH2’), 5.24 (br s, 1H, OH3’), 5.03 (br t, J = 5.1 Hz, 1H, H2’), 4.94 (br t, J = 5.6 Hz, 1H, 
OH5’), 4.20 (br s, 1H, H3’), 3.93 (dd, J = 8.2, 4.9 Hz, 1H, H4’), 3.66 (dt, J = 10.9, 4.2 Hz, 1H, H5’a), 3.52 (dt, J = 
11.8, 5.7 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.7 (C
6), 149.6 (C4), 146.7 (C2), 126.4 (C8), 125.8 (C5), 91.0 (C1’), 
86.7 (C4’), 71.7 (C2’), 70.9 (C3’), 62.3 (C5’). 
MS (ESI+): m/z calcd for [C10H11
79BrN4O5]
+: 345.99; found: 369.0 [(79Br)M+Na]+, 371.0 [(81Br)M+Na]+, 714.9 
[2(79Br)M+Na]+, 716.9 [(79Br)M+(81Br)M+Na]+, 718.9 [2(
81Br)M+Na]+.  
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7.2.5.8. 8-Bromoguanosine (79) 
C10H12BrN5O5; MW 362.14 
 
NBS (890 mg, 5.00 mmol) was added to a suspension of 55 (1.42 mg, 5.01 mmol) in distilled H2O (9.0 mL) at 
0°C. The resulting white mixture was stirred at 0°C for 1 h, allowed to warm at RT and stirred for 5 h, during 
which time it turned light orange. 
The suspension was filtered and washed once with few cold distilled H2O. The resulting pale pink crude was 
recrystallized from H2O to obtain 79 as white crystals (1.61 g, 4.45 mmol). 
Yield: 89% 
Rf: 0.80 (EtOH-H2O, 4:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.83 (br s, 1H, N
1H), 6.50 (br s, 2H, N2H2), 5.68 (d, J = 6.3 Hz, 1H, 
H1’), 5.45 (d, J = 6.2 Hz, 1H, OH2’), 5.10 (d, J = 5.1 Hz, 1H, OH3’), 5.00 (dd, J = 11.9, 6.1 Hz, 1H, H2’), 4.93 (t, J = 
6.0 Hz, 1H, OH5’), 4.12 (dd, J = 8.6, 5.1 Hz, 1H, H3’), 3.84 (dd, J = 8.6, 5.2 Hz, 1H, H4’), 3.64 (dt, J = 10.6, 5.2 Hz, 
1H, H5’a), 3.50 (dt, J = 12.0, 6.0 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 156.0 (C
2), 154.0 (C6), 152.6 (C4), 121.5 (C8), 118.0 (C5), 90.2 (C1’), 
86.4 (C4’), 71.0 (C3’), 70.8 (C2’), 62.5 (C5’). 
MS (ESI+): m/z calcd for [C10H12
79BrN5O5]
+: 361.00; found: 230.2 [(79Br)M-ribosyl+H]+, 232.3 [(81Br)M-
ribosyl+H]+, 384.0 [(79Br)M+Na]+, 386.0 [(81Br)M+Na]+, 744.8 [2(79Br)M+Na]+, 746.9 [(79Br)M+(81Br)M+Na]+, 
748.9 [2(81Br)M+Na]+. 
  
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
181 
7.2.5.9. 8-Bromoadenosine (80) 
C10H12BrN5O4; MW 346.14 
 
Aliquots of decanted saturated bromine water (9.90 and 5.00 mL) were added at 0 and 24 h, respectively, 
to a suspension of 27 (267 mg, 1.00 mmol) in 0.5 M NaOAc pH 4.0 (6.0 mL) under inert atmosphere. The 
resulting yellow solution was protected from light exposure and stirred at RT, during which time it became 
dark and a white precipitate was formed. 
At 48 h the suspension was decolorized with NaHSO3 and neutralized with 6 M NaOH. The precipitate was 
filtered, washed with few cold H2O and dried under reduced pressure to obtain 80 as a white powder (287 
mg, 0.83 mmol). 
Yield: 83% 
 
Additions of NBS (534 mg, 3.00 mmol) were made at 0’, 24 h and 7 2 h to a suspension of 27 (802 mg, 3.00 
mmol) in distilled H2O (15.0 mmol) under inert atmosphere. The resulting mixture was protected from light 
exposure and stirred at RT, during which time it became brown. 
At 4 days, the suspension was filtered and washed with cold H2O until a clear colourless solution was 
obtained. The pink solid was washed once with cold Et2O, few cold i-PrOH and cold Et2O and dried under 
reduced pressure. The crude was recrystallized from distilled H2O to obtain 80 as brown needles (601 mg, 
1.74 mmol) 
Yield: 58% 
Rf: 0.32 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.13 (s, 1H, H
2), 7.57 (br s, 2H, NH2), 5.84 (d, J = 6.7 Hz, 1H, H
1’), 5.50 
(dd, J = 8.6, 3.8 Hz, 1H, OH5’), 5.46 (d, J = 6.2 Hz, 1H, OH2’), 5.23 (d, J = 4.3 Hz, 1H, OH3’), 5.10 (dd, J = 11.8, 
6.1 Hz, 1H, H2’), 4.20 (br dd, J = 5.5, 4.6 Hz, 1H, H3’), 3.99 (br dd, J = 5.8, 4.1 Hz, 1H, H4’), 3.69 (dt, J = 11.7, 3.5 
Hz, 1H, H5’a), 3.53 (ddd, J = 11.9, 8.6, 3.7 Hz, 1H, H5’b). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 155.6 (C
6), 152.9 (C2), 150.4 (C4), 127.6 (C8), 120.2 (C5), 90.9 (C1’), 
87.2 (C4’), 71.6 (C2’), 71.3 (C3’), 62.6 (C5’). 
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MS (ESI+): m/z calcd for [C10H12
79BrN5O4]
+: 345.01; found: 212.3 [(79Br)M-ribosyl-H]+, 214.1 [(81Br)M-ribosyl-
H]+, 344.1 [(79Br)M-H]+, 346.2 [(81Br)M-H]+, 689.2 [2(79Br)M-H]+, 691.0 [((79Br)M+(81Br)M)-H]+, 693.0 
[2(81Br)M-H]+. 
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7.2.6. Synthesis of 8- and N2-substituted inosinic and guanylic acids (94-97) 
7.2.6.1. 8-Methylaminoinosinic acid (94) 
C11H16N5O8P; MW 377.25 
 
A suspension of 70 (25 mg, 84 μmol) in TEP (278 μL) was stirred at 50°C for 15’. POCl3 (47 μL, 504 μmol) and 
H2O (1.5 μL, 83 μmol) were added at 0°C and the resulting transparent colourless mixture was stirred at 0°C 
for 6 h. The disappearance of the substrate was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.88). After adding 
H2O (556 μL), pH was adjusted to 2 with 6 M NaOH and the resulting solution was stirred at 70°C for 1 h 30’. 
The mixture was neutralized with 6 M NaOH, diluted with H2O (15 mL) and freeze-dried twice. The crude 
was purified by semi-preparative HPLC to get 94 as an off-white powder (24 mg, 64 μmol). 
Yield: 75% 
Time (min) Column volumes % A (H2O/0.1% TFA) % B ((H2O/0.1% TFA)-CH3CN, 4:1) 
    
0 - 32 8 100 → 70 0 → 30 
    
AAAAAAAAAAAA  
Rf: 0.67 (EtOH-H2O, 7:3) 
HPLC tR: 14.9’ (11.5% B) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.12 (br s, 1H, N
1H), 7.83 (s, 1H, H2), 6.27 (br s, 1H, N8H), 5.79 (d, J 
= 6.4 Hz, 1H, H1’), 5.51-5.30 (m, 2H, OH2’, OH3’), 4.68 (br t, J = 5.8 Hz, 1H, H2’), 4.20-4.13 (m, 1H, H3’), 4.09-
3.95 (m, 3H, H4’, H5’a, H5’b), 2.88 (s, 3H, NHCH3). 
1H NMR (D2O, 400 MHz): δ (ppm) 8.15 (s, 1H, H
2), 6.07 (d, J = 7.1 Hz, 1H, H1’), 4.68 (br dd, J = 7.0, 5.9 Hz, 1H, 
H2’), 4.40 (dd, J = 5.6, 2.5 Hz, 1H, H3’), 4.33 (br t, J = 1.8 Hz, 1H ,H4’), 4.14 (br dd, J = 11.4, 7.0 Hz, 1H, H5’a), 
4.12-4.06 (m, 1H, H5’b), 3.11 (s, 3H, NHCH3). 
13C NMR (D2O, 100 MHz): δ (ppm) 153.2 (C
6), 148.9 (C8), 147.1 (C2), 146.8 (C4), 111.4 (C5), 87.8 (C1’), 85.0 (d, 
3
JCP = 8.2 Hz, C
4’), 71.3 (C2’), 70.1 (C3’), 64.6 (br d, 2JCP = 3.0 Hz, C
5’), 29.7 (CH3). 
31P NMR (D2O, 161 MHz): δ (ppm) 0.78. 
MS (ESI+): m/z calcd for [C11H16N5O8P]
+: 377.07; found: 377.2 [M]+, 399.0 [M-H+Na]+, 1507.3 [4M-H]+. 
MS (ESI+): m/z calcd for [C11H16N5O8P]
-: 377.07; found: 376.0 [M-H]-, 753.0 [2M-H]-, 775.1 [2M-2H+Na]-, 
1529.9 [4M-H+Na]+. 
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7.2.6.2. 2’,3’-O-Isopropylideneguanosine (98) 
C13H17N5O5; MW 323.30 
 
2,2-DMP (34.30 mL, 278.94 mmol) and p-TsOH·H2O (6.72 g, 35.33 mmol) were added to a suspension of 55 
(10.00 g, 35.31 mmol) in acetone (250 mL) under inert atmosphere. The resulting mixture was stirred at RT 
for 24 h. 
The solvent was removed under reduced pressure and the resulting foam was suspended in 5% aqueous 
NH4OH (215 mL) to precipitate 98 as a white powder, which was filtered, washed with cold H2O and dried 
under reduced pressure (10.93 g, 33.81 mmol). 
Yield: 96% 
Rf: 0.32 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.55 (br s, 1H, N
1H), 7.92 (s, 1H, H2), 6.52 (br s, 2H, N2H2), 5.93 (d, J 
= 2.8 Hz, 1H, H1’), 5.19 (dd, J = 6.3, 2.8 Hz, 1H, H2’), 5.11 (t, J = 5.4 Hz, 1H, OH5’), 4.97 (dd, J = 6.3, 3.0 Hz, 1H, 
H3’), 4.12 (td, J = 5.1, 3.2 Hz, 1H, H4’), 3.56 (dd, J = 11.2, 4.8 Hz, 1H, H5’a), 3.51 (dd, J = 11.6, 5.2 Hz, 1H, H5’b), 
1.51 (s, 3H, C(CH3)2), 1.31 (s, 3H, C(CH3)2). 
13C NMR (DMSO-d6, 400 MHz): δ (ppm) 157.2 (C
6), 154.2 (C2), 151.2 (C4), 136.3 (C8), 117.2 (C5), 113.5 
(C(CH3)2), 88.9 (C
1’), 87.1 (C4’), 84.0 (C2’), 81.6 (C3’), 62.1 (C5’), 27.5, 25.7 (C(CH3)2). 
MS (ESI+): m/z calcd for [C13H17N5O5]
+: 323.12; found: 345.9 [M+Na]+, 669.0 [2M+Na]+, 991.9 [3M-H+Na]+, 
1315.3 [4M+Na]+. 
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7.2.6.3. 2-Bromo-2’,3’-O-isopropylideneinosine (100) 
C13H15BrN4O5; MW 387.19 
 
TMSBr (3.17 mL, 24.02 mmol) and t-BuONO (5.95 mL, 50.03 mmol) were added dropwise at -10°C to a 
suspension of 98 (646 mg, 2.00 mmol) in CH2Br2 (10.0 mL) under inert atmosphere. The resulting dark 
brown solution was protected from light exposure and allowed to warm to 5-10°C for 7 h under stirring. 
The solution was added dropwise to a 1:1 AcOEt/saturated aqueous NaHCO3 mixture (300 mL) and 
vigorously stirred at 0°C for 10’. After separating the layers, the aqueous one was extracted with AcOEt 
(1x50 mL), then the reunited organic phases were washed with H2O (1x50 mL) and dried over Na2SO4. The 
solvent was removed under reduced pressure and the resulting yellow foam was purified by flash column 
chromatography twice (CH2Cl2-MeOH, 8.8:1.2 and 9.1:0.9) to obtain 100 as a light yellow powder (163 mg, 
0.42 mmol). 
Yield: 21% 
Rf: 0.36 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.37 (br s, 1H, N
1H), 8.30 (s, 1H, H8), 6.05 (d, J = 2.7 Hz, 1H, H1’), 
5.24 (dd, J = 6.2, 2.7 Hz, 1H, H2’), 5.08 (br t, J = 4.8 Hz, 1H, OH5’), 4.92 (dd, J = 6.2, 2.7 Hz, 1H, H3’), 4.22 (td, J 
= 4.8, 2.8 Hz, 1H, H4’), 3.57-3.51 (m, 2H, H5’a, H5’b), 1.54 (s, 3H, C(CH3)2), 1.33 (s, 3H, C(CH3)2). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 157.6 (C
6), 148.2 (C4), 139.2 (C8), 134.6 (C2), 123.9 (C5), 113.6 
(C(CH3)2), 89.9 (C
1’), 87.4 (C4’), 84.3 (C2’), 81.7 (C3’), 61.9 (C5’), 27.5, 25.6 (C(CH3)2. 
MS (ESI+): m/z calcd for [C13H15BrN4O5]
+: 386.02; found: 409.2 [(79Br)M+Na]+, 411.0 [(81Br)M+Na]+, 795.1 
[2(79Br)M+Na]+, 797.1 [(79Br)M+(81Br)M+Na]+, 799.1 [2(81Br)M+Na]+. 
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7.2.6.4. 2’,3’-O-Isopropylidene-5’-O-t-butyldimethylsilylguanosine (99) 
C19H31N5O5Si; MW 437.57 
 
TBDMSCl (1.09 g, 7.23 mmol) and imidazole (950 mg, 13.95 mmol) were added to a suspension of 98 (2.00 
g, 6.19 mmol) in dry DMF (15.0 mL) under inert atmosphere and the resulting mixture was stirred at RT for 
4 h. 
The suspension was diluted with H2O (50 mL) and extracted with AcOEt (1x50 mL), then the reunited 
organic phases were washed with H2O (1x50 mL) and brine (1x50 mL) and evaporated under reduced 
pressure. The resulting crude was purified by flash column chromatography (CH2Cl2-MeOH, 12.5:1.0) to 
obtain 99 as a white powder (2.57 g, 6.95 mmol). 
Yield: 95% 
Rf: 0.54 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.70 (br s, 1H, N
1H), 7.83 (s, 1H, H8), 6.53 (br s, 2H, N2H2), 5.96 (br 
d, J = 1.8 Hz, 1H, H1’), 5.22 (dd, J = 6.1, 1.7 Hz, 1H, H2’), 4.97 (dd, J = 6.1, 3.1 Hz, 1H, H3’), 4.12 (dd, J = 8.5, 5.2 
Hz, 1H, H4’), 3.76-3.66 (m, 2H, H5’a, H5’b), 1.51 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 0.82 (s, 9H, Si(C(CH3)3), -
0.04 (s, 3H, Si(CH3)2), -0.05 (s, 3H, Si(CH3)2). 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.05 (br s, 1H, N
1H), 7.79 (s, 1H, H8), 6.29 (br s, 2H, N2H2), 6.02 (br d, J = 
2.3 Hz, 1H, H1’), 5.19 (br dd, J = 6.0, 2.0 Hz, 1H, H2’), 4.94 (dd, J = 6.2, 2.8 Hz, 1H, H3’), 4.36 (dd, J = 7.0, 4.0 Hz, 
1H, H4’), 3.87 (dd, J = 11.2, 4.0 Hz, 1H, H5’a), 3.80 (dd, J = 11.3, 4.0 Hz, 1H, H5’b), 1.64 (s, 3H, C(CH3)2), 1.43 (s, 
3H, C(CH3)2), 0.90 (s, 9H, Si(C(CH3)3), 0.073 (s, 3H, Si(CH3)2), 0.068 (s, 3H, Si(CH3)2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 159.0 (C
6), 153.6 (C2), 151.3 (C4), 136.4 (C8), 117.4 (C5), 114.1 (C(CH3)2), 
90.3 (C1’), 87.0 (C4’), 84.7 (C2’), 81.2 (C3’), 63.5 (C5’), 27.3, 25.5 (C(CH3)2), 25.9 (Si(C(CH3)3), 18.4 (Si(C(CH3)3), -
5.4, -5.5 (Si(CH3)2). 
MS (ESI+): m/z calcd for [C19H31N5O5Si]
+: 437.21; found: 438.1 [M+H]+, 460.2 [M+Na]+, 897.2 [2M+Na]+, 
1772.4 [4M+H+Na]+. 
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7.2.6.5. 2-Bromo-2’,3’-O-isopropylidene-5’-O-t-butyldimethylsilylinosine (101) 
C19H29BrN4O5Si; MW 501.45 
 
TMSBr (1.20 mL, 9.09 mmol) and t-BuONO (2.40 mL, 20.18 mmol) were added dropwise at -10°C to a 
solution of 99 (438 mg, 1.00 mmol) in CH2Br2 (7.0 mL) under inert atmosphere. The resulting dark brown 
solution was protected from light exposure and stirred at -10°C for 2 h, allowed to warm and stirred at 5-
10°C for 5 h. 
The solution was added dropwise to a 1:1 CH2Cl2/saturated aqueous NaHCO3 mixture (300 mL) and 
vigorously stirred at 0°C for 10’. After separating the layers, the aqueous one was extracted with cold 
CH2Cl2 (1x70 mL), then the reunited organic phases were washed with H2O (2x70 mL) and brine (1x70 mL) 
and dried over Na2SO4. The solvent was removed under reduced pressure and the resulting yellow foamy 
crude was purified by flash column chromatography (CH2Cl2-MeOH, 9.5:0.5) to obtain 101 as a yellow 
crystalline solid (350 mg, 0.70 mmol). 
Yield: 70% 
Rf: 0.56 (CH2Cl2-MeOH, 9:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.85 (br s, 1H, N
1H), 8.10 (s, 1H, H8), 6.15 (d, J = 2.8 Hz, 1H, H1’), 5.06 
(dd, J = 6.1, 2.6 Hz, 1H, H2’), 4.95 (dd, J = 6.1, 2.7 Hz, 1H, H3’), 4.41 (q, J = 3.4 Hz, 1H, H4’), 3.92 (dd, J = 11.4, 
3.4 Hz, 1H, H5’a), 3.83 (dd, J = 11.3, 3.7 Hz, 1H, H5’b), 1.66 (s, 3H, C(CH3)2), 1.42 (s, 3H, C(CH3)2), 0.91 (s, 9H, 
Si(C(CH3)3), 0.094 (s, 3H, Si(CH3)2), 0.089 (s, 3H, Si(CH3)2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 158.9 (C
6), 148.3 (C4), 138.8 (C8), 133.1 (C2), 123.8 (C5), 114.4 (C(CH3)2), 
90.7 (C1’), 87.1 (C4’), 85.2 (C2’), 81.1 (C3’), 63.5 (C5’), 27.3, 25.4 (C(CH3)2), 25.9 (Si(C(CH3)3), 18.4 (Si(C(CH3)3), -
5.4, -5.5 (Si(CH3)2). 
MS (ESI+): m/z calcd for [C19H29
79BrN4O5Si]
+: 500.11; found: 523.0 [(79Br)M+Na]+, 525.1 [(81Br)M+Na]+, 
1023.0 [2(79Br)M+Na]+, 1025.0 [(79Br)M+(81Br)M+Na]+, 1027.0 [2(81Br)M+Na]+. 
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7.2.6.6. N2-n-Octyl-2’,3’-O-isopropylidene-5’-O-t-butyldimethylsilylguanosine (103) 
C27H47N5O5Si; MW 549.78 
 
n-OctNH2 (0.18 mL, 1.09 mmol) was added to a solution of 101 (111 mg, 0.22 mmol) in 2-methoxyethanol 
(2.70 mL) under inert atmosphere. The resulting dark brown solution was protected from light exposure 
and stirred at 85°C for 3 days, during which time it became first yellow and then orange. 
The mixture was diluted with AcOEt (5 mL), washed with 1 M HCl (4x5 mL), saturated aqueous Na2S2O3 (1x5 
mL) and brine (1x5 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and the 
orange oil crude was purified by flash column chromatography (CH2Cl2-MeOH, 9.5:0.5) to obtain 103 as a 
dense yellow foam (84 mg, 0.15 mmol). 
Yield: 69% 
Rf: 0.59 (CH2Cl2-MeOH, 9:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 11.81 (br s, 1H, N
1H), 7.71 (br s, 1H, H8), 6.93 (br s, 1H, N2H), 5.94 (br s, 
1H, H1’), 5.18 (br d, J = 4.3 Hz, 1H, H2’), 4.84 (br dd, J = 5.2, 2.1 Hz, 1H, H3’), 4.27 (br dd, J = 6.8, 4.2 Hz, 1H, 
H4’), 3.78 (br dd, J = 11.1, 3.5 Hz, 1H, H5’a), 3.70 (dd, J = 11.0, 4.6 Hz, 1H, H5’b), 3.32 (br t, J = 5.4 Hz, 2H, CH2
a), 
1.64-1.50 (m, 5H, C(CH3)2, CH2
b), 1.36-1.05 (m, 13H, C(CH3)2, CH2
c, CH2
d, CH2
e, CH2
f, CH2
g), 0.86-0.71 (m, 12H, 
CH3
h, Si(C(CH3)3), -0.04 (s, 3H, Si(CH3)2), -0.05 (s, 3H, Si(CH3)2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 158.1 (C
6), 153.1 (C2), 151.2 (C4), 132.9 (C8), 117.8 (C5), 113.9 (C(CH3)2), 
90.5 (C1’), 87.2 (C4’), 84.6 (C2’), 81.5 (C3’), 63.6 (C5’), 41.6 (Ca), 31.9 (Cb), 31.9, 29.4, 29.3 (Cc, Cd, Ce), 27.2, 25.4 
(C(CH3)2), 27.1 (C
f), 25.9 (SiC(CH3)3), 22.6 (C
g), 18.3 (SiC(CH3)3), 14.1 (C
h), -5.4, -5.5 (Si(CH3)2). 
MS (ESI+): m/z calcd for [C27H47N5O5Si]
+: 549.33; found: 550.2 [M+H]+, 572.3 [M+Na]+, 1121.4 [2M+Na]+. 
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7.2.6.7. N2-n-Octyl-2’,3’-O-isopropylideneguanosine (102) 
C21H33N5O5; MW 435.52 
 
n-OctNH2 (0.41 mL, 2.48 mmol) was added to a solution of 101 (253 mg, 0.50 mmol) in 2-methoxyethanol 
(6.10 mL) under inert atmosphere. The resulting dark brown solution was protected from light exposure 
and stirred at 85°C for 3 days. The mixture was concentrated under reduced pressure and filtered on silica 
(CH2Cl2-MeOH, 8.6:1.4), diluted with AcOEt (10 mL), washed with 2 M HCl (4x5 mL) and dried over Na2SO4. 
The organic phase was concentrated under reduced pressure and the brown oil crude was purified by flash 
column chromatography (CH2Cl2-MeOH, 9.2:0.8) to obtain 102 as a yellow foam (119 mg, 0.27 mmol). 
Yield: 55% 
 
TBAF·3H2O (51 mg, 0.16 mmol) was added to a solution of 103 (74 mg, 0.13 mmol) in THF (1.50 mL) under 
inert atmosphere. The resulting yellow solution was stirred at RT for 6 h, during which time it became pale 
orange and a precipitate was formed. 
The mixture was diluted with CH2Cl2 (3 mL), washed with H2O (2x2 mL) and dried over Na2SO4. The solvent 
was removed under reduced pressure and the yellow oil crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9.2:0.8) to obtain 102 as an off-white powder (34 mg, 0.08 mmol). 
Yield: 60% 
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n-OctNH2 (0.47 mL, 2.84 mmol) was added to a solution of 100 (138 mg, 0.36 mmol) in 2-methoxyethanol 
(4.40 mL) under inert atmosphere. The resulting orange solution was protected from light exposure and 
stirred at 85°C for 8 days. 
The mixture was diluted with AcOEt (10 mL), washed with 2 M HCl (4x5 mL) and dried over Na2SO4. The 
solvent was removed under reduced pressure and the yellow oil crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 9.3:0.7) to obtain 102 as a yellow foam (61 mg, 0.14 mmol). 
Yield: 39% 
Rf: 0.35 (CH2Cl2-MeOH, 9:1) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.62 (br s, 1H N
1H), 7.88 (s, 1H, H8), 6.53 (t, J = 5.4 Hz, 1H, NHCH2), 
5.99 (d, J = 2.8 Hz, 1H, H1’), 5.31 (dd, J = 6.0, 2.8 Hz, 1H, H2’), 4.98 (t, J = 5.6 Hz, 1H, OH5’), 4.91 (dd, J = 6.2, 
3.1 Hz, 1H, H3’), 4.12 (dt, J = 5.3, 2.8 Hz, 1H, H4’), 3.47-3.57 (m, 2H, H5’a, H5’b), 3.31-3.21 (m, 2H, CH2
a), 1.64-
1.50 (m, 2H, CH2
b), 1.53 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 1.24-1.29 (m, 10H, CH2
c, CH2
d, CH2
e, CH2
f, CH2
g), 
0.85 (t, J = 6.8 Hz, 3H, CH3
h). 
13C NMR (DMSO-d6, 100 MHz): δ (ppm) 157.6 (C
6), 153.5 (C2), 151.1 (C4), 137.2 (C8), 117.8 (C5), 113.8 
(C(CH3)2), 89.6 (C
1’), 87.4 (C4’), 84.2 (C2’), 82.2 (C3’), 62.5 (C5’), 41.4 (Ca), 32.1 (Cb), 29.6, 29.51, 29.45 (Cc, Cd, 
Ce), 27.9, 26.0 (C(CH3)2), 27.2 (C
f), 22.9 (Cg), 14.7 (Ch). 
MS (ESI+): m/z calcd for [C21H33N5O5]
+: 435.25; found: 436.08 [M+H]+, 458.30 [M+Na]+, 871.21 [2M]+, 893.15 
[2M+Na]+. 
MS (ESI-Q-Tof+): m/z calcd for [C21H33N5O5]
+: 435.25; found: 458.83 [M+Na]+, 894.18 [2M+H+Na]+. 
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7.2.6.8. N2-n-Octylguanylic acid (104) 
C18H30N5O8P; MW 475.43 
 
A suspension of 102 (30 mg, 69 μmol) in TEP (230 μL) was stirred at 50°C for 15’ under inert atmosphere. 
POCl3 (39 μL, 418 μmol) and H2O (1.4 μL, 78 μmol) were added at 0°C and the resulting mixture was stirred 
at 0°C for 6 h. The disappearance of the substrate was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.87). After 
adding H2O (344 μL), pH was adjusted to 2 with 6 M NaOH and the resulting colourless solution was stirred 
at 70-80°C for 2 h. 
The mixture was neutralized with 6 M NaOH, diluted with H2O (60 mL) and freeze-dried. The resulting crude 
was purified by semi-preparative HPLC to get 104 as a white powder (24 mg, 50 μmol). 
Yield: 73% 
Time (min) Column volumes % A (H2O/0.1% TFA) % B ((H2O/0.1% TFA)-CH3CN, 4:1) 
    
0 - 2 0.5 100 0 
2 - 50 12 60 → 0 40 → 100 
    
AAAAAAAAAAAA  
Rf: 0.74 (EtOH-H2O, 7:3) 
HPLC tR: 17.3’ (55.4% B) 
1H NMR (DMSO-d6, 400 MHz): δ (ppm) 10.52 (br s, 1H, N
1H), 7.90 (s, 1H, H8), 6.50 (br s, 1H, NHCH2), 5.73 
(br d, J = 5.4 Hz, 1H, H1’), 4.53 (br t, J = 4.4 Hz, 1H, H2’), 4.15 (br s, 1H, H3’), 4.07-3.86 (m, 3H, H4’, H5’a, H5’b), 
3.32-3.20 (m, 2H, CH2
a), 1.58-1.46 (br t, J = 5.4 Hz, 2H, CH2
b), 1.38-1.17 (m, 10H, CH2
c, CH2
d, CH2
e, CH2
f, CH2
g), 
0.85 (br t, J = 6.0 Hz, 3H, CH3
h). 
1H NMR (D2O, 400 MHz): δ (ppm) 8.00 (s, 1H, H
8), 5.91 (d, J = 5.6 Hz, 1H, H1’), 4.68 (t, J = 5.4 Hz, 1H, H2’), 
4.42 (t, J = 4.5 Hz, 1H, H3’), 4.22 (br d, J = 2.5 Hz, 1H, H4’), 4.02 (dd, J = 11.7, 4.4 Hz, 1H, H5’a), 3.97 (dd, J = 
12.0, 4.6 Hz, 1H, H5’b), 3.28 (qt, J = 3.4, 6.9 Hz, 2H, CH2
a), 1.55-1.45 (m, 2H, CH2
b), 1.30-1.06 (m, 10H, CH2
c, 
CH2
d, CH2
e, CH2
f, CH2
g), 0.72 (t, J = 6.6 Hz, 3H, CH3
h). 
13C NMR (D2O, 100 MHz): δ (ppm) 158.0 (C
6), 152.6 (C2), 151.7 (C4), 137.0 (C8), 114.6 (C5), 86.9 (C1’), 83.5 (d, 
3
JCP = 7.1 Hz, C
4’), 74.6 (C2’), 70.2 (C3’), 64.8 (br d, 2JCP = 3.2 Hz, C
5’), 41.0 (Ca), 29.0 (Cb), 31.6, 29.1, 28.8 (Cc, Cd, 
Ce), 26.8 (Cf), 22.3 (Cg), 13.6 (Ch). 
31P NMR (D2O, 161 MHz): δ (ppm) 1.44. 
MS (ESI-): m/z calcd for [C18H30N5O8P]
-: 475.18; found: 474.32 [M-H]-, 496.34 [M-2H+Na]-, 949.10 [2M-H]-, 
971.15 [2M-2H+Na]-. 
MS (ESI-Q-Tof+): m/z calcd for [C18H30N5O8P]
+: 475.18; found: 476.29 [M+H]+, 498.27 [M+Na]+. 
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7.2.6.9. N2-n-Octyl-2’,3’-O-isopropilydeneguanylic acid (95) 
C21H34N5O8P; MW 515.50 
 
2,2-DMP (2.14 mL, 17.40 mmol) and p-TsOH·H2O (16 mg, 84.11 μmol) were added to a suspension of 104 
(40 mg, 84.13 μmol) in a dry 8:1 acetone-DMF mixture (2.40 mL) under inert atmosphere and the resulting 
mixture was refluxed for 26 h. 
The suspension was neutralized with saturated aqueous NaHCO3 and freeze-dried. The crude was purified 
by semi-preparative HPLC to obtain 95 as a white solid (35 mg, 68 μmol). 
Yield: 81% 
Time (min) Column volumes % A (H2O) % B (H2O-CH3CN, 4:1) 
    
0 - 2 0.5 95 5 
2 - 50 12 95 → 40 5 → 60 
    
AAAAAAAAAAAA  
Rf: 0.35 (n-BuOH-AcOH-H2O, 4:1:1) 
HPLC tR: 42.8’ (47.5% B) 
1H NMR (D2O, 400 MHz): δ (ppm) 8.01 (s, 1H, H
8), 6.06 (br d, J = 2.0 Hz, 1H, H1’), 5.30 (br dd, J = 5.0, 2.8 Hz, 
1H, H2’), 5.05 (br dd, J = 6.0, 1.9 Hz, 1H, H3’), 4.46 (br dd, J = 6.4, 4.1 Hz, 1H, H4’), 3.91-3.84 (m, 2H, H5’a, H5’b), 
3.29 (ddq, J = 20.3, 13.6, 6.9 Hz, 2H, CH2
a), 1.57 (s, 3H, C(CH3)2), 1.56-1.49 (m, 2H, CH2
b), 1.35 (s, 3H, 
C(CH3)2), 1.31-1.08 (m, 10H, CH2
c, CH2
d, CH2
e, CH2
f, CH2
g), 0.73 (br t, J = 6.7 Hz, 3H, CH3
h). 
13C NMR (D2O, 100 MHz): δ (ppm) 158.9 (C
6), 152.7 (C2), 151.4 (C4), 137.2 (C8), 115.3 (C5), 113.8 (C(CH3)2), 
89.2 (C1’), 85.3 (C4’), 84.4 (C2’), 81.5 (C3’), 64.4 (C5’), 41.1 (Ca), 31.7 (Cb), 26.7, 24.7 (C(CH3)2), 29.2, 28.9, 26.9 
(Cc, Cd, Ce, Cf), 22.4 (Cg), 13.7 (Ch). 
31P NMR (D2O, 161 MHz): δ (ppm) 3.33. 
MS (ESI+): m/z calcd for [C21H34N5O8P]
+: 515.21; found: 538.55 [M+Na]+, 1053.38 [2M+Na]+. 
MS (ESI-): m/z calcd for [C21H34N5O8P]
-: 515.21; found: 514.24 [M-H]-, 1051.07 [2M-2H+Na]-. 
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7.2.6.10. General procedure for the synthesis of N2-acyl-2’,3’-O-isopropylideneguanosines (105 and 106) 
 
TMSCl (2.70 mL, 21.27mmol) was added dropwise to a suspension of 98 (969 mg, 3.00 mmol) in a dry 5:1 
CH2Cl2/pyridine mixture (90.0 mL) under inert atmosphere at 0°C. The resulting mixture was stirred at RT 
for 4 h, becoming more transparent, and the appropriate acylating agent (3.30 mmol) was added dropwise 
over 2’ at 0°C. The reaction was stirred at RT and monitored by TLC (CH2Cl2 saturated with NH3-MeOH, 9:1) 
until complete consumption of the starting material. 
The solution was washed with 1 M HCl (2x60 mL) and saturated aqueous NaHCO3 (2x60 mL) and dried over 
Na2SO4. The solvent was evaporated under reduced pressure, removing residual pyridine by co-evaporation 
with toluene. 
The resulting yellow foam was dissolved in a 1:1 1 M HCl/THF mixture (30 mL) and stirred at RT for 2 h. 
CH2Cl2 (150 mL) was added, the solution was washed with H2O (90 mL) and dried over Na2SO4. After 
removing the solvent under reduced pressure, the resulting crude was purified by flash column 
chromatography (CH2Cl2-MeOH, 20:1 for 105 and 25:1 for 106). 
7.2.6.10.1. N2-Butyryl-2’,3’-O-isopropylideneguanosine (105) 
C17H23N5O6; MW 393.39 
 
White powder (740 mg, 1.88 mmol). 
Yield: 63% 
Rf: 0.29 (CH2Cl2-MeOH, 20:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.28 (br s, 1H, N
1H), 9.82 (br s, 1H, N2H), 8.14 (s, 1H, H8), 5.93 (d, J = 3.0 
Hz, 1H, H1’), 5.19 (dd, J = 6.0, 3.0 Hz, 1H, H2’), 5.15 (dd, J = 6.2, 1.7 Hz, 1H, H3’), 4.39 (q, J = 2.7 Hz, 1H, H4’), 
4.38-4.24 (br s, 1H, OH5’), 4.00 (dd, J = 12.2, 3.0 Hz, 1H, H5’a), 3.82 (dd, J = 12.2, 2.6 Hz, 1H, H5’a), 2.57 (t, J = 
7.4 Hz, 2H, COCH2), 1.76 (hex, J = 7.4 Hz, 2H, CH2CH3), 1.60 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 1.01 (t, J = 
7.4 Hz, 3H, CH3). 
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13C NMR (CDCl3, 100 MHz): δ (ppm) 175.2 (COCH2), 155.1 (C
6), 147.6 (C2), 147.2 (C4), 138.4 (C8), 121.3 (C5), 
114.0 (C(CH3)2), 91.8 (C
1’), 86.3 (C4’), 83.7 (C2’), 81.0 (C3’), 62.3 (C5’), 38.7 (COCH2), 27.1 (C(CH3)2), 25.0 
(C(CH3)2), 18.0 (CH2CH3), 13.3 (CH3). 
MS (ESI+): m/z calcd for [C17H23N5O6]
+: 393.16; found: 394.52 [M+H]+, 416.71 [M+Na]+, 787.38 [2M+H]+, 
809.46 [2M+Na]+. 
7.2.6.10.2. N2-Undecanoyl-2’,3’-O-isopropylideneguanosine (106) 
C24H37N5O6; MW 491.58 
 
Light yellow powder (914 mg, 1.86 mmol). 
Yield: 62% 
Rf: 0.37 (CH2Cl2-MeOH, 20:1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 12.27 (br s, 1H, N
1H), 9.81 (br s, 1H, N2H), 8.07 (s, 1H, H8), 5.91 (d, J = 3.2 
Hz, 1H, H1’), 5.19 (dd, J = 6.0, 3.3 Hz, 1H, H2’), 5.09 (dd, J = 6.0, 1.8 Hz, 1H, H3’), 4.39 (br dd, J = 5.1, 3.0 Hz, 
1H, H4’), 3.96 (dd, J = 12.0, 2.6 Hz, 1H, H5’a), 3.80 (dd, J = 12.1, 2.6 Hz, 1H, H5’a), 2.56 (t, J = 7.5 Hz, 2H, CH2
a), 
1.76-1.64 (m, 2H, CH2
b), 1.59 (s, 3H, C(CH3)2), 1.40-1.21 (m, 17H, CH2
c, CH2
d, CH2
e, CH2
f, CH2
g, CH2
h, CH2
i, 
C(CH3)2), 0.89 (t, J = 6.8 Hz, 3H, CH3
j). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 174.9 (COCH2), 154.0 (C
6), 147.1 (C2), 146.4 (C4), 139.0 (C8), 119.6 (C5), 
113.2 (C(CH3)2), 91.2 (C
1’), 85.9 (C4’), 83.0 (C2’), 80.4 (C3’), 61.4 (C5’), 36.1 (Ca), 30.9, 28.5, 28.4, 28.3, 28.2, 
28.0 (Cc, Cd, Ce, Cf, Cg, Ch), 26.2 (C(CH3)2), 24.2 (C(CH3)2), 23.7 (C
b), 21.6 (Ci), 13.1 (Cj). 
MS (ESI+): m/z calcd for [C24H37N5O6]
+: 491.27; found: 514.59 [M+Na]+, 1005.38 [2M+Na]+. 
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7.2.6.11. N2-Butyrylguanylic acid (107) 
C14H20N5O9P; MW 433.31 
 
A suspension of 105 (54 mg, 137 μmol) in TEP (460 μL) was stirred at 50°C for 30’ under inert atmosphere. 
POCl3 (78 μL, 837 μmol) and H2O (2.8 μL, 156 μmol) were added at 0°C and the resulting mixture was stirred 
at 0°C for 6 h. The disappearance of the substrate was monitored by TLC (EtOH-H2O, 7:3; Rf = 0.84). After 
adding H2O (688 μL), pH was adjusted to 2 with 6 M NaOH and the resulting colourless solution was stirred 
at 70-80°C for 2 h. 
The mixture was neutralized with 6 M NaOH, diluted with H2O (150 mL) and freeze-dried. The resulting 
crude was purified by semi-preparative HPLC to get 107 as a white powder (44 mg, 102 μmol). 
Yield: 75% 
Time (min) Column volumes % A (H2O/0.1% TFA) % B ((H2O/0.1% TFA)-CH3CN, 4:1) 
    
0 - 2 0.5 100 0 
2 - 50 12 60 → 0 40 → 100 
    
AAAAAAAAAAAA  
Rf: 0.72 (EtOH-H2O, 7:3) 
HPLC tR: 16.4’ (52.6% B) 
1H NMR (D2O, 400 MHz): δ (ppm) 8.30 (s, 1H, H
8), 6.04 (d, J = 6.0 Hz, 1H, H1’), 4.88 (t, J = 5.6 Hz, 1H, H2’), 
4.55 (t, J = 4.0 Hz, 1H, H3’), 4.44-4.39 (dt, J = 5.2, 3.1 Hz, 1H, H4’), 4.23-4.13 (m, 2H, H5’a, H5’b), 2.57 (t, J = 7.2 
Hz, 2H, COCH2), 1.76 (hex, J = 7.6 Hz, 2H, CH2CH3), 1.03 (t, J = 7.2 Hz, 3H, CH3). 
13C NMR (D2O, 100 MHz): δ (ppm) 178.2 (COCH2), 157.2 (C
6), 149.4 (C2), 147.6 (C4), 139.8 (C8), 120.0 (C5), 
87.7 (C1’), 84.1 (d, 3JCP = 8.4 Hz, C
4’), 73.7 (C2’), 70.5 (C3’), 64.5 (br d, 2JCP = 4.3 Hz, C
5’), 38.3 (COCH2), 18.0 
(CH2CH3), 12.7 (CH3). 
31P NMR (D2O, 161 MHz): δ (ppm) 1.64. 
MS (ESI-): m/z calcd for [C14H20N5O9P]
-: 433.10; found: 433.61 [M]-, 455.88 [2M+Na]-. 
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7.2.6.12. N2-Butyryl-2’,3’-O-isopropylideneguanylic acid (96) 
C17H24N5O9P; MW 473.37 
 
2,2-DMP (2.95 mL, 23.99 mmol) and p-TsOH·H2O (23 mg, 121 μmol) were added to a suspension of 107 (50 
mg, 115 μmol) in a dry 4:1 acetone-DMF mixture (1.70 mL) under inert atmosphere and the resulting 
mixture was refluxed for 6 h. 
The suspension was neutralized with 3 M NaOH and freeze-dried. The crude was purified by semi-
preparative HPLC to obtain 96 as a white solid (16 mg, 34 μmol). 
Yield: 30% 
Time (min) Column volumes % A (H2O) % B (H2O-CH3CN, 4:1) 
    
0 - 4 1 95 5 
4 - 48 10 95 → 0 5 → 100 
    
AAAAAAAAAAAA  
Rf: 0.26 (n-BuOH-AcOH-H2O, 4:1:1) 
HPLC tR: 51.6’ (23.1% B) 
1H NMR (D2O, 400 MHz): δ (ppm) 8.16 (s, 1H, H
8), 6.10 (d, J = 2.8 Hz, 1H, H1’), 5.33 (dd, J = 6.1, 2.8 Hz, 1H, 
H2’), 5.18 (dd, J = 6.1, 2.1 Hz, 1H, H3’), 4.55 (dd, J = 5.7, 4.4 Hz, 1H, H4’), 3.96 (dt, J = 11.3, 4.6 Hz, 1H, H5’a), 
3.88 (dd, J = 11.3, 5.0 Hz, 1H, H5’b), 2.47 (t, J = 7.4 Hz, 2H, COCH2), 1.64 (hex, J = 7.4 Hz, 2H, CH2CH3), 1.58 (s, 
3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 0.90 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (D2O, 100 MHz): δ (ppm) 178.2 (COCH2), 157.4 (C
6), 151.7 (C2), 147.7 (C4), 142.4 (C8), 114.6 (C5, 
C(CH3)2), 90.9 (C
1’), 85.7 (C4’), 84.1 (C2’), 81.6 (C3’), 64.1 (C5’), 38.4 (Ca), 26.1, 24.3 (C(CH3)2), 18.1 (C
b), 12.7 
(Cc). 
31P NMR (D2O, 161 MHz): δ (ppm) 2.03. 
MS (ESI-): m/z calcd for [C17H24N5O9P]
-: 473.13; found: 473.47 [M]-, 495.36 [M-H+Na]-, 946.56 [2M]-, 967.52 
[2M-2H+Na]-, 1418.19 [3M-H]-. 
  
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
197 
7.2.7. Batch and flow synthesis of ribonucleosides 
7.2.7.1. General procedure for the batch synthesis of 6-substituted purine ribonucleosides catalyzed by 
AhPNP 
N
N
N
X
N
H
+
1-24
NH
N
N
O
N
+
NH2
+ HI
83
65
NH
N
N
O
N
O
HO OH
HO NH2
I
27-50
N
N
N
X
N
O
HO OH
HO
AhPNP
50 mM K2HPO4
buffer pH 7.5/
glycerol (4:1 v/v)
RT  
AhPNP (1.15 IU) was added at 25°C to a solution of 65 (1.0 mM) and 1-24 (1.0 mM) in a 4:1 (v/v) 50 mM 
K2HPO4 buffer pH 7.5/glycerol mixture (20 mL). At fixed times (10’, 30’, 1 h, 3 h, 6 h and 24 h), aliquots (200 
μL) of the reaction mixture were withdrawn, centrifuged on 10 kDa MWCO centrifugal filter devices (12000 
rpm, 25°C) for 2’ and the solution was analyzed by analytical HPLC. 
The formed nucleosides 27-50 were identified by comparison of their retention times in analytical HPLC 
with those of pure samples. 
HPLC method 1: 
Time (min) % A (10 mM K2HPO4 buffer pH 3.2 or 4.5) % B (MeOH) 
   
0 - 20 97 → 35 3 → 65 
20 - 30 35 65 
   
AAAAAAAAAAAA  
HPLC method 2: 
Time (min) % A (10 mM K2HPO4 buffer pH 3.2 or 4.5) % B (MeOH) 
   
0 - 25 97 → 30 3 → 70 
   
AAAAAAAAAAAA  
HPLC method 3: 
Time (min) % A (10 mM K2HPO4 buffer pH 3.2 or 4.5)  % B (MeOH) 
   
0 - 15 97 3 
15 - 25 97 → 50 3 → 50 
   
AAAAAAAAAAAA  
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7.2.7.2. AhPNP-IMER activity assay 
 
A solution of 37 (40 mM) in 0.1 M K2HPO4 buffer pH 7.5 (5 mL) was pumped once through the AhPNP-IMER 
at 37°C, collected, diluted with the analytical HPLC mobile phase (1:10) and analyzed on-line. 
Time (min) % A (H2O) % B (MeOH) 
   
0 - 15  90 10 
   
AAAAAAAAAAAA  
7.2.7.3. General procedure for the flow synthesis of 6-substituted purine ribonucleosides catalyzed by 
AhPNP-IMER 
 
A solution of 5, 6, 8, 23, or 25 (2.5 mM for 5 and 6 and 5 mM for 8, 23 and 25) and 37 (2:1 donor/acceptor 
ratio) in 10 mM K2HPO4 buffer pH 7.5 (10 mL for 5 and 6 and 5 mL for 8, 23 and 25) with DMSO as co-
solvent (5.0 mL for 8 and 23 and 7.5 mL for 5) was recirculated through the AhPNP-IMER at 0.5 mL·min-1 
and 37°C. Each reaction was performed in duplicate and monitored on-line by the analytical HPLC set to 
assess the time necessary to reach the equilibrium (10’ for 8 and 25, 20’ for 5 and 6 and 30’ for 23). 
In all cases, a third reaction was carried out and purified on-line by the semi-preparative HPLC apparatus. 
Analytical scale 
For 27: 
Time (min) % A (H2O) % B (MeOH) 
   
0 - 15 90 10 
   
AAAAAAAAAAAA  
For 31 and 32: 
Time (min) % A (10 mM NH4OAc buffer pH 5.5) % B (MeOH) 
   
0 - 6 90 10 
6 - 15 90 → 60 10 → 40 
   
AAAAAAAAAAAA  
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For 34 and 49: 
Time (min) % A (10 mM NH4OAc buffer pH 5.5) % B (MeOH) 
   
0 - 6 90 10 
6 - 15 90 → 85 10 → 15 
   
AAAAAAAAAAAA  
For 58: 
Time (min) % A (10 mM NH4OAc buffer pH 5.5) % B (MeOH) 
   
0 - 6 90 10 
6 - 15 90 → 80 10 → 20 
   
AAAAAAAAAAAA  
Semi-preparative scale 
For 31 and 32: 
Time (min) % A (10 mM NH4OAc buffer pH 5.5) % B (MeOH) 
   
0 - 30 50 50 
   
AAAAAAAAAAAA  
For 34, 49 and 58: 
Time (min) % A (10 mM NH4OAc buffer pH 5.5) % B (MeOH) 
   
0 - 60 90 10 
   
AAAAAAAAAAAA  
  
Chapter 7 ǀ EXPERIMENTAL SECTION 
  
 
200 
7.2.7.4. General procedure for the batch synthesis of 2’-deoxyadenosine (84) and arabinosyladenine (85) 
catalyzed by AhPNP 
 
AhPNP (0.20 IU for 66 and 2.00 IU for 67) was added at 25°C to a solution of 66 or 67 (1.0 mM) and 1 (1.0 
mM) in a 4:1 (v/v) 50 mM K2HPO4 buffer pH 7.5/glycerol mixture (20 mL). At fixed times (10’, 30’, 1 h, 3 h, 6 
h and 24 h), aliquots (200 μL) of the reaction mixture were withdrawn, centrifuged on 10 kDa MWCO 
centrifugal filter devices (12000 rpm, 25°C) for 2’ and the solution was analyzed by analytical HPLC. 
The formed nucleoside 84 was identified by comparison of its retention time in analytical HPLC with those 
of pure samples. The formation of 85 was not detected. 
For 84: 
Time (min) % A (10 mM K2HPO4 buffer pH 4.5) % B (MeOH) 
   
0 - 15 97 3 
15 - 35 97 → 50 3 → 50 
   
AAAAAAAAAAAA  
For 85: 
Time (min) % A (10 mM K2HPO4 buffer pH 4.5) % B (MeOH) 
   
0 - 20 95 5 
   
AAAAAAAAAAAA  
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7.2.7.5. CpUP-IMER activity assay 
 
A solution of 86 (40 mM) in 0.1 M K2HPO4 buffer pH 7.5 (5 mL) was pumped once through the CpPNP-IMER 
at 37°C, collected, diluted with the analytical HPLC mobile phase (1:10) and analyzed on-line. 
Time (min) % A (H2O) % B (MeOH) 
   
0 - 15  90 10 
   
AAAAAAAAAAAA  
7.2.7.6. General procedure for the flow synthesis of 2’-deoxyadenosine (84), adenosine (27) and 
arabinosyladenine (85) catalyzed by CpUP-IMER/AhPNP-IMER 
 
A solution of 1 (5 mM for 86 and 88 and 1 mM for 89) and 86, 88 or 89 (2:1 donor/acceptor ratio) in 10 mM 
K2HPO4 buffer pH 7.25 (10 mM for 86 and 88 or 2 mM for 89, 10 mL) was recirculated through the 
combined CpUP-IMER and AhPNP-IMER system at 0.5 mL·min-1 and 37°C. Each reaction was performed in 
duplicate and monitored on-line by the analytical HPLC set to assess the time necessary to reach the 
equilibrium. 
For 84 and 27: 
Time (min) % A (10 mM K2HPO4 buffer pH 5.5) % B (MeOH) 
   
0 - 15 95 → 85 5 → 15 
   
AAAAAAAAAAAA  
For 85: 
Time (min) % A (10 mM K2HPO4 buffer pH 4.5) % B (MeOH) 
   
0 - 15 95 → 80 5 → 20 
   
AAAAAAAAAAAA  
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